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vApplications of Cross-Validated Genetic Predictions from Linear Mixed Models and Other
Results in Statistical Genetics
by Joel Andrew MEFFORD
Abstract
In this document I present statistical methods for use in analyses of human genetics. The methods
presented are based on the predictions made by linear mixed models (LMMs). The key result is
that vectors of out-of-sample predictions from an LMM, here named cvBLUPs, may be efficiently
calculated and then used in novel applications. One application is as adjustment covariates in
association studies where they bring control for population structure and boost power as in LMM
analyses, but now in an efficient linear regression framework. An interpretation of cvBLUPs is as
reference-free polygenic risk scores. With this interpretation of cvBLUPs, a method for trans-eQTL
analyses is developed. In this application, eQTLs are identified by gene-based tests of association
between cvBLUPs for expression at possible regulatory genes with actual expression at other, re-
mote genes. Analytic results are shown for the efficient calculation of effect size estimates and
genetic predictions from sparse and multivariate extensions of the linear mixed model. In sim-
ulations, cross-validated predictions (CVPs) from sparse models are shown to boost power even
more than cvBLUPs in association tests for traits with sparse genetic architectures. Finally, the
results of an association study on a multi-phenotype, metabolomic data set are presented.
vi
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1Chapter 1
Introduction
1.1 Methods and applications in statistical genetics
This dissertation represents much of the work I did at the University of California at San Fran-
cisco during my time as a PhD student in the program in Pharmaceutical Science and Pharma-
cogenomics (PSPG). My main interests and much of my effort as a student has been in the area of
statistical methodology for use in statistical genetics. Most of the work presented here represents a
chain of methodological developments that find novel points of contact between the linear mixed
model (LMM), related statistical models, and applications in human genetics.
The chapters of this dissertation represent distinct but related contributions to statistical ge-
netics. The order in which these topics are presented in the following chapters is a post hoc ratio-
nalization of a collection of results, but as a contribution to the historical record I will present the
chronological order of developments and the motivations for moving through the series of related
projects in this introduction.
The starting motivation for this work was recognition of several trends, opportunities, and
deficiencies in the contemporary (2014 at the time) practice of human population-based genetic
analyses. One of the major trends I wanted to acknowledge in a graduate research project was
that while the data sets used in genetic research continued to grow in terms of numbers of ob-
servations at their known but dramatic, exponential pace, a new property of the data sets that
2were being analyzed at the time was a vast increase in the number of phenotypes available. This
included moves towards realization of the promise of research using electronic medical records
[e.g. Denny et al. (2013)], release of early combined genotype and RNAseq data sets with gene
expression measured on hundreds of individuals [Lappalainen et al. (2013)], progress towards re-
lease of large-scale biobank data with UK Biobank in the vanguard [Sudlow et al. (2015)], progress
in preparation of tissue-specific expression data sets [Lonsdale et al. (2013)], and preparation of
many other massive molecular phenotype screens, such as the metabolome [Laakso et al. (2017)]
and the human metabiome [Bonder et al. (2016)]. There was an opportunity to develop and use
statistical methods that could leverage these collections of phenotypes. A particular deficiency in
contemporary practice was the inability to efficiently screen the combined genotype and expres-
sion data sets for trans-eQTLs – that is associations of genetic variants with expressions of genes
whose coding regions are many millions of base pairs away or on different chromosomes from the
genetic variant. A goal for the work below was to address these opportunities and deficiencies in
our development of new data analysis tools.
The development of the ideas in this document started chronologically with the material in the
appendix of Chapter 3. I started working with my academic advisor, Dr. Noah Zaitlen, after my
first year in the PhD program with a rotation project where the objective was to develop a multi-
variate extension of the "summary statistics" method and software program LDPred [Vilhjálmsson
et al. (2015)].
A summary statistics method is one where the results of a genome-wide association study
(GWAS) – effect size estimates for each SNP with their standard errors, p-values, and test-statistics
– are post-processed to approximate the results from a different analysis that one could do if the
original microdata (genotypes, phenotypes, and covariates) used in the GWAS were available.
Such microdata is generally not publicly or widely available, and in some cases running a GWAS
and then a further summary statistic based analysis may be more efficient than running a micro-
data based analysis [e.g. Bulik-Sullivan et al. (2015)].
Our point of departure, LDPred, is a summary statistics method that uses GWAS effect size
3estimates and a reference "LD panel" – a correlation matrix from a reference data set for the SNPs
analyzed in the GWAS – to approximate the effect size estimates that would be obtained from a
joint regression analysis of the phenotype as a function of all SNPs, and possibly of additional
covariates as well. The microdata analyses that are approximated are the joint effect size estimates
and predictions of a linear mixed model (LMM) with random effect size distribution for the SNP
effect sizes, and sparse extension of a linear mixed model where only a fraction of SNPs have
non-zero effect sizes.
My initial task was to develop a summary statistic method for approximating random effect
size estimates from a multivariate linear mixed model or the multivariate sparse extension of a
linear mixed model. As presented in the appendix of Chapter 3, I succeeded in extending the
statistical derivations that underlie LDPred to the multivariate case. It appears that even if one
is interested in a single trait, leveraging measurements of additional, genetically correlated traits
using the approach shown below will allow more accurate genetic effect size estimates and poly-
genic predictions or polygenic risk scores.
An additional result that became apparent in the development of the summary-statistics ap-
proach to sparse multivariate mixed model effect size estimates was that the sparse model effect
size estimates could factor into three terms: (1) The multivariate infinitessimal (non-sparse) model
effect size estimate; (2) A study-specific "shrink" factor based on the genetic covariance, the num-
ber of observations (N) and the number of SNPs with random effects (M); and (3) The posterior
probability of the SNP being causal. This suggests that rather than using the computationally ex-
pensive MCMC scheme of LDPred, the sparse mixed model effect size estimates may be generated
by post-processing the non-sparse effect size estimates. For the univariate case, these non-sparse
mixed model effect size estimates are just standard BLUPs, so we have the result that univariate
sparse model effect size estimates can be approximated by post-processing of standard BLUPs.
With a method to approximate computationally expensive sparse model effect estimates by post-
processing BLUPs, we in effect have a new type of summary statistic method, where the starting
4summary statistics are BLUP effect size estimates from a standard LMM. This approach for ap-
proximating sparse model results using standard BLUPs is developed in Chapter 3. I further de-
velop this idea of using standard univariate BLUPs as the input to a new type of summary-statistic
method by showing that non-sparse but multivariate effect size estimates may be approximated
from a collection of univariate BLUPs, or from a combination of univariate BLUPs and approxi-
mate BLUPs generated from GWAS summary statistics as in LDPred.
In Chapter 3, I show how to efficiently calculate effect size estimates, and thus polygenic risk
scores, that are more accurate than standard BLUP effect sizes and phenotypic predictions by
exploiting sparse genetic architectures and measurements of genetically correlated traits. The
first application we considered for these improved polygenic scores was in extensions of an ef-
ficient approximation to mixed model association tests implemented in the method GRAMMAR
[Aulchenko et al. (2007)].
The motivation for GRAMMAR was the appreciation that mixed model association tests as
implemented in EMMA [Kang et al. (2008)] or GCTA [Yang et al. (2011)] have greater power
than association tests based on linear regression, and that the mixed model approaches control
confounding by population structure better than adjustment with genetic principal components.
Unfortunately, the mixed model association tests are much more computationally expensive than
linear regression, since for each tested SNP a generalized least squares calculation is made, with
timeO(N2) for analyses with N observations. This gives a total compute time for running tests on
M SNPs of O(MN2). By contrast a GWAS running linear regression may be run in time O(MN).
GRAMMAR runs efficient association tests that are related to mixed model association tests
by:
1. Fitting a linear mixed model for the trait of interest (calculation of a genetic relatedness
matrix (GRM) and estimation of heritability or variance components).
2. Generating the BLUP predictions on the phenotype scale – a type of PRS based on the LMM.
3. Subtracting the BLUPs from the phenotype.
54. Finally, running association tests for SNPs of interest with the mixed model residuals.
The initial plan for application of the sparse and multivariate modifications of BLUP effect
size that are presented in Chapter 3 was to calculate improved polygenic scores, and then to do an
improved residual analysis in the style of GRAMMAR. Unfortunately, residual analyses based on
the modified BLUPs turned out to be worse than GRAMMAR – and even worse than unadjusted
linear regression in every regard: effect estimate bias, power, and poor control for population
structure. I realized that this was because the modified BLUP models severely over-fit the data
used to generate the BLUPs, so the in-sample mixed model residuals are deflated and perform
poorly in association tests. In fact, this is a problem with GRAMMAR as well. GRAMMAR had
a known problem with bias and lower power than standard mixed model association tests, so a
follow-up method named GRAMMAR-γ had been presented [Svishcheva et al. (2012)] to estimate
the average effect size bias or test statistic deflation, and to justify multiplying GRAMMAR test
statistics by a constant > 1 for easy power gains. My thought was that if the problems (bias and
low power) with mixed model residual methods is due to over-fitting, I’ll just use cross-validation
and get out-of-sample prediction errors instead of residuals for use in mixed-model inspired lin-
ear regression models. As shown in Chapter 2, it turns out that these cross-validated residual
analyses and the closely-related analyses where out-of-sample predictions are used as adjustment
covariates do not yield biased effect estimates, and that their power matches mixed model asso-
ciation tests in the case of univariate infinitessimal genetic architectures. As shown in Chapter 3,
when sparse genetic architectures are exploited, the cross-validated residual methods have greater
power than standard mixed model association tests.
Cross-validation of the sparse or multivariate genetic predictions as presented in Chapter 3
could be an expensive proposition, but for the case of predictions from a standard univariate lin-
ear mixed model, I was able to rearrange a short-cut formula [Hastie et al. (2009)] for getting the
out-of-sample prediction errors from a leave-one-out cross-validation scheme on linear models to
get the out-of-sample genetic predictions on the phenotype scale, or cross-validated BLUPs, in
6linear time after calculation of the standard BLUPs. I call these quantities cvBLUPs, and Chapter 2
shows their derivation and applications. One application I considered was the GRAMMAR-style
residual analysis, but I developed and ended up using a different but related analysis. In a proper
residual analysis, the variable that is projected or subtracted out of the outcome should also be
projected out of the remaining covariates that are tested or included in the residual regressions.
GRAMMAR only projects the genetic effects (BLUPs) out of the phenotype or the outcome in the
regression model – not out of the test-SNP or adjustment covariates in an association test. Rather
than subtracting cvBLUPs from the phenotype in a residual (or in this case, out-of-sample pre-
diction error) analysis, I use the cvBLUPs as adjustment covariates. In association tests, using
cvBLUPs as covariates effectively allows both the phenotype and the test-SNPs to be conditioned
on the genetic effects represented by the cvBLUPs. This use of cvBLUPs as adjustment covari-
ates allows extensions such as adjustment with multiple cvBLUPs, say one set calculated for each
chromosome. And it allows cvBLUP adjusted regression to be interpreted as a better form of
genetic-PC adjusted regression for control of confounding by batch effects and population struc-
ture. As presented in Chapter 2, "better PC adjusted regression" means allowing a single cvBLUP
adjustment factor to adapt to a data set and to represent the number and identity of genetic PCs
that should be used in the analysis.
Chapters 2 and 4 present additional applications of cvBLUPs. Chapter 4 presents the devel-
opment of a method for trans-eQTL analyses based on cvBLUPs. In this method named GBAT,
developed with Xuanyau Liu and Noah Zaitlen, gene based association tests (GBAT) for trans-
eQTLs are implemented by generation of cvBLUPs for gene expression based on the genotypes of
SNPs in a cis-window around the gene’s coding region. Then linear regression is used to test for
association of the genetic predictions for expression of gene 1 (cvBLUPs) with actual expression of
distant (trans) gene 2. Significant associations suggest that gene 1 is a regulator of gene 2. Using
cvBLUPs, this method does not rely on external reference data sets for a genetic prediction model
as in TWAS [Gusev et al. (2016)] or PredXcan [Gamazon et al. (2015)].
Another application of cvBLUPs that is presented in Chapter 2 is the fast screening of genetic
7correlations or genetic-phenotypic cross-correlations by analysis of the cvBLUPs calculated in uni-
variate analyses. This is illustrated with an analysis of the METSIM (metabolic syndrome in men)
cohort [Laakso et al. (2017)]. In this data set, around 250 metabolic, biometric, and demographic
traits were measured. In a pairwise bivariate mixed model analysis to estimate genetic correla-
tions, there would be 250*249/2 pairs to consider, and using traditional mixed model algorithms
as in GCTA, the computation effort would be about 8 times that of a univariate analysis. This gives
a total compute time roughly 249000 times that of a univariate analysis. By contrast, a cvBLUP
based approach to approximate genetic correlations would only require 250 univariate analyses,
for a 1000-fold speedup.
This same METSIM cohort is further analyzed in Chapter 5. This chapter presents joint work
with Apolline Gallois, Arthur Ko, Päivi Pajukanta, Noah Zaitlen, Hugues Aschard and others. In
addition to the large number of metabolic traits, a special feature of this data set, is that many
subjects were phenotyped at two time points. In addition to general data handling and heritabil-
ity estimation for the traits, my focus in the study was the joint analysis of the two time points.
cvBLUPs were not used in the analyses presented in this final chapter, but including cvBLUPs
as adjustment covariates is a direction for future work. The association analyses presented in
this chapter use a computationally expensive variable selection method to choose adjustment co-
variates [Aschard et al. (2017)] that would no be feasible to combine with standard mixed model
association analyses. However, inclusion of a cvBLUP adjustment factor should be a simple and
efficient way to combine the benefits of the already computationally demanding regression ap-
proach used with the additional benefits from mixed model association tests in improved power
and control of confounding by population structure.
The results of Chapters 2, 4, and 5, have been prepared for publication and are available on
bioRχiv [Mefford et al. (2019), Liu et al. (2018), Gallois et al. (2018)].
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Chapter 2
Efficient estimation and applications of
cross-validated genetic predictions †
2.1 Abstract
Large-scale cohorts with combined genetic and phenotypic data, coupled with methodological
advances, have produced increasingly accurate genetic predictors of complex human phenotypes
called polygenic risk scores (PRS). In addition to the potential translational impacts of identifying
at-risk individuals, PRS are being utilized for a growing list of scientific applications including
causal inference, identifying pleiotropy and genetic correlation, and powerful gene-based and
mixed model association tests. Existing PRS approaches rely on external large-scale genetic co-
horts that have also measured the phenotype of interest. They further require matching on ances-
try and genotyping platform or imputation quality. In this work we present a novel reference-free
method to produce PRS that does not rely on an external cohort. We show that naive imple-
mentations of reference-free PRS either result in substantial over-fitting or prohibitive increases
†A manuscript related to his chapter is available at bioRχiv . doi: https://doi.org/10.1101/517821. Joel Andrew
Mefford*, Danny Park, Zhili Zheng, Arthur Ko, Mika Ala-Korpela, Markku Laakso, Päivi Pajukanta, Jian Yang, John
Witte, Noah Zaitlen. Efficient estimation and applications of cross-validated genetic predictions.
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in computational time. We show that our algorithm avoids both of these issues, and can pro-
duce informative in-sample PRS over any existing cohort without over-fitting. We then demon-
strate several novel applications of reference-free PRS including detection of pleiotropy across 246
metabolic traits and efficient mixed-model association testing.
2.2 Introduction
Individual genetic polymorphisms typically explain only a small proportion of the heritability,
even for traits that are highly heritable [Nolte et al. (2017)]. Polygenic risk scores (PRS), aggre-
gate the contributions of multiple genetic variants to a phenotype [Torkamani et al. (2018)]. These
scores can be calculated using routinely recorded genotypes [Torkamani et al. (2018); Nolte et al.
(2017)], are strongly associated with heritable traits [Nolte et al. (2017)], and are independent of
environmental exposures or other factors that are uncorrelated with germ line genetic variants.
These properties have motivated a rapidly expanding list of applications from basic science (e.g.
causal inference and Mendelian randomization [Burgess and Thompson (2013)], hierarchical dis-
ease models [Cortes et al. (2017)], and identification of pleiotropy [Krapohl et al. (2016)]) to trans-
lation (e.g. estimating disease risk [Khera et al. (2018); Maas et al. (2016)], identifying patients who
are likely to respond well to a particular therapy [Natarajan et al. (2017)], or flagging subjects for
modified screening [Seibert et al. (2018)]).
Polygenic risk scores are calculated as a weighted sum of genotypes. In some applications all
genotyped SNPs may be used, but often only a small set are given nonzero weight. A subset of
SNPs selected to contribute to a PRS may be a genome-spanning-but-uncorrelated (LD-pruned)
set or a set of SNPs with independent evidence of association with the phenotype of interest.
Gene-specific polygenic risk scores are also generated using selected sets of SNPs within a region
of the genome, such as a window around the coding region of a particular gene [Gusev et al.
(2016); Gamazon et al. (2015)]. The weights on the SNPs included in a polygenic score are often
derived from the marginal regression coefficients of an external GWAS [Dudbridge (2016); Wray
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et al. (2007)], but they may instead be based on predictive models using all SNPs. Joint predictive
models include LMMs and their sparse extensions [Yang et al. (2011); Zhou et al. (2013); Vilhjálms-
son et al. (2015)] and other regularized regression models such as the lasso or elastic net [Warren
et al. (2014); Gusev et al. (2016); Gamazon et al. (2015); Rakitsch et al. (2012)]. The predictions
from these joint analyses using genome wide variation are also approximated by post-processing
of GWAS summary statistics [Vilhjálmsson et al. (2015); Gusev et al. (2016)].
For these SNP weights to accurately reflect the SNPs’ joint association with the phenotype and
to generate informative and interpretable polygenic risk scores, the reference data set must match
the target data set in many ways: the populations must have similar ancestry; the trait of interest
must be measured and in a similar way; and identical genotypes must be assayed or imputed.
Further, the reference data must be large enough to accurately learn the PRS weights.
An alternative approach is to use the studied data set to build a reference-free PS. This elimi-
nates the need for an external reference data set with matched genotypes, phenotypes, and pop-
ulations. However, as we show below, naive approaches can easily over-fit genetic effects. This
over-fitting results in PRS correlated with non-genetic components of phenotype, that will induce
bias or other errors in downstream applications. Cross-validation is one established approach to
mitigate over-fitting, which in this context involves holding out and computing a polygenic score
for each sample in turn. The main hurdle to this approach is computation time, as standard leave-
one-out cross validation requires fitting the PRS model N times in a sample with N individuals.
Here we report an efficient method to generate PRS by using the out-of-sample predictions
from a cross-validated linear mixed model (LMM). Our approach generates leave-one-out (LOO)
polygenic risk scores, which we call cvBLUPs, with computational complexity linear in sample size
after a single LMM fit. In addition to eliminating the reliance on external data and guaranteeing
the PRS are generated from a relevant population and phenotype, we describe several applications
that are only feasible with cvBLUPs. We first demonstrate several desirable statistical properties
of cvBLUPs and then consider applications including evidence of polygenicity across metabolic
phenotypes, a novel formulation of mixed model association studies, and selection of relevant
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principal components for control of confounding by population structure. To facilitate their use,
we have incorporated the calculation of cvBLUPs in the in the genetic analysis program GCTA
[Yang et al. (2011)].
2.3 Methods
We consider the continuous phenotype y measured on N individuals which depends on an N-by-
M matrix of additively coded genotypes G, other covariates X, and random noise e:
y = Xβ+ GβG + e
e ∼ N(0, σ2e IN) (2.1)
For each subject i, the polygenic score PSi is calculated as in Equation 2.2:
PRSi = ∑
SNP j∈S
gij β̂g,j. (2.2)
where S is the set of SNPs in the polygenic model, gij is the number of alleles corresponding to the
SNP weights at SNPj carried by subject i, and β̂g,j is the SNP weight. β̂g,j is often chosen to be the
estimated effect size of SNP j in an external GWAS.
Our objective is to produce a leave-one-out cross-validated polygenic score (PRS) for each
subject. We generate our PRS as a genetic prediction from a linear mixed model (LMM). LMMs
are widely used for genetic prediction [Robinson et al. (1991)], heritability estimation [Yang et al.
(2010); Kang et al. (2008, 2010); Lippert et al. (2011); Zhou and Stephens (2012)], and other poly-
genic analyses [Lee et al. (2012); Zhou and Stephens (2012); Kang et al. (2008); Lippert et al. (2011)].
The LMM (Equation 2.3) jointly models the contributions of all SNPs Z and other covariates X to
the phenotype y. Following others [Yang et al. (2011)], we define Z by centering and scaling
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columns of G to have mean 0 and variance 1.
y = Xβ+ Zb + e
b ∼ N
(
0,
σ2g
M IM
)
e ∼ N(0, σ2e )
(2.3)
The key LMM parameters are the genetic variance σ2g and the noise variance var(e) = σ2e . We
estimate these by REML [Patterson and Thompson (1971); Kang et al. (2008); Yang et al. (2011)] or
Hasman-Elston regression [Chen (2014)]. These variance estimates are then used to estimate b, the
genetic effect sizes (i.e. weights), or Zb, the genetic predictions (i.e. BLUPs):
b̂ =
σ̂2g
M Z
TΣ̂−1(y− Xβ̂), (2.4)
Zb̂ = Z
σ̂2g
M Z
TΣ̂−1(y− Xβ̂)
= σ̂2g KΣ̂−1(y− Xβ̂)
= Hy˜
= ŷBLUP
(2.5)
where K is the genetic relatedness matrix (GRM) computed from the centered and scaled geno-
types Z by K = 1M ZZ
T. The estimated phenotypic covariance, Σ̂ = σ̂2g K + σ̂2e IN , where IN is the
N-by-N identity matrix, decomposes the covariance to components due to shared genetics (Zb)
and to noise (e).
While the BLUPs in Zb̂ could be used as a polygenic score, we show below that this in gen-
eral over-fits the noise (e) and is therefore inappropriate for most PRS applications. To address
this problem, we propose to use leave-one-out (LOO) cross-validated BLUPs instead of ordinary
BLUPs, which guarantees independence between genetic predictions and e. Unfortunately, stan-
dard LOO approaches will multiply computational time by a factor of N.
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We avoid this penalty by leveraging the fact that for linear models, where fitted values are a
linear transformation of phenotypes, ŷ = Hy˜, the LOO prediction errors can be calculated from a
single model fit [Hastie et al. (2009)]. BLUPs from LMMs fall in this category of linear predictors
by applying H := σ̂2g KΣ̂−1 to y˜ := (y − Xβ̂), i.e. the phenotype after removing estimated fixed
effects.
In more detail, the LOO prediction errors are the differences between the LOO genetic predic-
tions and the observed residual phenotypes after subtracting fixed effects, ei,loo = yi,loo − y˜i. The
residuals r are the difference between the BLUPs and the residual phenotypes ri = Zi b̂− y˜i. For a
linear model, these are related by a simple equation [Hastie et al. (2009)]:
ei,loo =
ri
1− Hi,i (2.6)
where Hi,i is the i’th diagonal element of the matrix H. Intuitively this says that due to over-fitting,
the in-sample residuals ri are deflated by (1− Hi,i) relatively to their unbiased LOO counterparts.
We can rearrange these expressions to calculate the LOO predictions, or cvBLUPs, given the
standard BLUPs, the phenotype residuals y˜ = y− Xβ̂, and the diagonal elements of the H matrix:
ŷi,cvBLUP =
ŷi,BLUP − Hi,iy˜i
1− Hi,i (2.7)
Because all of these elements are computed when fitting an LMM, cvBLUPs can be produced
with no additional computational complexity.
2.4 Results
2.4.1 Empirical confirmation of cross-validated predictions
To examine the properties of the proposed cvBLUP formulation we conducted a set of simulations.
We generated 1000 data sets with N = 1000 subjects under the model y = Xβ+ gβg + Zb + e. X
17
consists of 5 normally distributed covariates and Xβ jointly explain 20% of the phenotypic vari-
ance. g represents an additively coded SNP with allele frequency 0.5, and gβg contributes 2% of
the phenotypic variance. Z represents M = 1000 independent SNPs with minor allele frequen-
cies drawn i.i.d. and uniformly from [0.05, 0.5]. Effect sizes bj are drawn i.i.d. from N
(
0,
σ2g
M
)
with the genetic variance σ2g accounting for 39% of the phenotypic variance. The residual noise
e ∼ N(0, σ2e ) also accounts for 39% of the phenotypic variance, giving a heritability h2 ≈ 50%.
For each simulated data set, we first estimate variance components and then compute BLUPs and
cvBLUPs as described above.
Figure 1 shows scatter plots for one simulation of non-genetic (e) and genetic factors (Zb) plot-
ted against in-sample BLUPs (Left) and cvBLUPs (Right). As expected, the standard BLUPs are
highly correlated with e but the cvBLUPs are not, a central required property of genetic predictors
for most applications. In contrast, both BLUPs and cvBLUPs are highly correlated with the true
Zb, emphasizing the subtlety in constructing valid polygenic risk scores.
Table 1 shows the mean correlations of true simulated values with standard BLUPs and cvBLUPs.
Again, standard BLUPs are clearly correlated with the noise term e due to over-fitting, but cvBLUPs
are appropriately uncorrelated with e. Standard BLUPs, but not cvBLUPs, are also correlated
with the unmodeled causal SNP. This type of correlation causes downstream problems for resid-
ual analyses, predictions, and causal inference. Importantly, the cvBLUPs are independent of all
unmodeled effects as desired.
TABLE 2.1: Mean correlations (and standard errors) of BLUPs and cvBLUPs with
each component of the additive simulation model, y = Xβ+ gβg + Zb + e. Statisti-
cally significant correlations (α = 0.05) in bold face.
BLUP cvBLUP
y 0.8241 (0.0013) 0.4058 (0.0013)
Xβ 0.0004 (0.0007) 0.0005 (0.0009)
Zb 0.7884 (0.0005) 0.6212 (0.0008)
e 0.4749 (0.0008) 0.0009 (0.0012)
Unmodeled Causal SNP 0.0840 (0.0010) 0.0009 (0.0010)
Unmodeled Null SNP 0.0006 (0.0010) 0.0012 (0.0010)
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FIGURE 2.1: Correlations of genetic predictions, BLUP and cvBLUP, with true ge-
netic factors Zb and independent environmental factors e in a simulation of a contin-
uous phenotype with h2 ≈ 50%, 1000 subjects, and 1000 independent SNPs having
random effect sizes. BLUPs are correlated with e while cvBLUPs are not. Lines and
p-values are from linear regression fits. R2 values: A:0.21, B:0.0019, C:0.64, D:0.38.
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2.4.2 Genetic predictions and cross-trait predictions using cvBLUPs
We next applied cvBLUP in an analysis of Finnish men from the METSIM cohort [Laakso et al.
(2017)]. This cohort is comprised of 10197 men aged 45 to 73 at recruitment between 2005 and
2010 in Kuopio, Finland. Blood serum samples were collected from each participant, and 228
metabolites in the samples were quantified by NMR. In addition to the metabolites, biometric
traits including height and weight, and epidemiological traits such as diagnoses or family history
of diabetes and CHD were recorded for a total of 248 phenotypes. Continuous phenotypes were
quantile normalized. All samples were genotyped at 665,478 SNPs on the Illumina OmniExpress
chip. After removing subjects with missing rates above 5 percent and SNPs with missing rates
above 5 percent, 10070 subjects and 609131 SNPs remain.
We initially consider genetic predictions of the metabolic, biometric, and epidemiological traits
in an unrelated subset of subjects (with genetic relatedness less than 0.05). Since the metabolic
traits are expected to be affected by statins and by pharmaceutical interventions for diabetes,
we exclude subjects with diabetes or who use statins from the initial analysis and calculation
of cvBLUPs. There are no comparable data sets with the set of metabolic measurements available
in the METSIM cohort, but cvBLUPs allow computationally efficient genetic predictions of all 246
phenotypes (excluding diabetes status and statin use). With the genetic prediction models learned
in the restricted set of subjects, we extended predictions to the excluded subjects with standard
BLUP effect size estimates (Equation 4). Thus, cvBLUPs allow analyses of reference-free genetic
predictions in a subset of subjects that is restricted to avoid confounding by known environmental
exposures (statins and responses to diagnoses of diabetes) or by family structure; and these genetic
predictions may then be extended to subjects who are initially excluded to avoid confounding.
We first estimated σ2g and σ2e for each phenotype using linear mixed models [Yang et al. (2011)].
Overall, 198 of 246 phenotypes have statistically significant heritability at the 0.05 significance
level by Wald tests. The significant heritabilities range from 14.6 to 46.1 percent with a mean and
standard deviation of 27.5 and 8.0 percent respectively. The 48 non-significant heritabilities range
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from 0 to 14.4 percent with a mean and standard deviation of 8.3 and 4.3 percent respectively.
We next used the method described above to compute leave-one-out polygenic risk scores (i.e.
cvBLUPs). Figure 2 and Supplemental Table 12 show the correlation of the phenotypes (rows)
with cvBLUPs (columns) for all 246 phenotypes grouped by hierarchical clustering [Kolde and
Kolde (2018)] of rows and applying the same permutation to columns. The blue diagonal shows
the expected positive correlation between a cvBLUP and its own phenotype with mean 0.065 and
standard deviation 0.037. Focusing on the 198 traits with significant heritabilities the correlations
of cvBLUP and phenotype have mean 0.078 and standard deviation 0.027.
The off-diagonal blue patches in the figure represent cvBLUPs that are positively correlated
and predictive of different phenotypes, while red patches represent cvBLUPs that are predic-
tive but negatively correlated with different phenotypes. The off-diagonal correlations show the
widespread pleiotropy of genetic effects on metabolism with over 16203 off-diagonal cvBLUP-
phenotype associations at FDR=0.05 [Benjamini and Yekutieli (2001)]. Many cvBLUP-trait corre-
lations are sign-consistent with the respective trait-trait correlations. For example, HDL and LDL
cholesterol are well known be negatively correlated [Terry et al. (1989)], and our results demon-
strate this is partially due to negative genetic pleiotropy. That is, we observe that SNPs associated
with increased LDL are also associated with decreased HDL in aggregate (and vice versa).
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FIGURE 2.2: Correlations of phenotypes (rows) and genetic predictions (cvBLUPs,
columns) across 246 phenotypes. Many cvBLUPs are strongly correlated with addi-
tional phenotypes. A larger version of the figure and a table of the correlations are
included in the supplementary materials
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2.4.3 cvBLUPs in association testing
In addition to use in detection of pleiotropy, polygenic modelling is a widely used tool in associa-
tion testing [Kang et al. (2008); Yang et al. (2014); Lippert et al. (2011); Zhou and Stephens (2012);
Loh et al. (2015)], and we therefore consider cvBLUPs in this this context. We compare the relative
performance of five groups of methods. First, unadjusted regression; second, principal component
adjusted regression; third, standard linear mixed model (LMM) association tests; fourth, LMM
residual based methods; and fifth, cvBLUP adjusted regression. Standard LMM-based methods
use association tests where the covariance of the observations based on the genetic relatedness
of the subjects is estimated and used to calculate effect estimates and test statistics by general-
ized least squares [Kang et al. (2008); Yang et al. (2014); Lippert et al. (2011); Zhou and Stephens
(2012)]. The LMM residual-based methods perform association tests on the BLUP residualized
phenotypes and possibly genotypes. Then, to try and account for the bias inherent in using the
overfit BLUPs, they perform an adjustment step on the resulting test statistics and effect sizes.
These methods were pioneered by GRAMMAR/GRAMMAR-γ and include the recent BOLT and
BOLT-INF methods [Aulchenko et al. (2007); Svishcheva et al. (2012); Loh et al. (2015)].
The typical sources of confounding for associations with germ-line genetic markers are popu-
lation structure, family structure, and batch effects in the data collection [Listgarten et al. (2010)].
Genetic principal components as adjustment covariates may suffice to control for confounding by
population structure or batch effects but linear mixed models are often more effective at control-
ling these sources of confounding [Kang et al. (2010)], while also helping to control confounding
by family structure and boosting power to detect true associations over standard fixed-effect re-
gression models [Yang et al. (2014)]. These benefits of linear mixed models come at the expense of
an increased computational burden over standard linear regression.
In genome wide association studies the statistical significance of each variant gj is tested indi-
vidually. Here, the SNP is jointly analyzed with covariates X and the contributions of unmodeled
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variants contribute to a larger error term η = Z(−j)b(−j) + e.
y = Xβ+ gjβg,j + η (2.8)
Often a better estimate of the effect size for a particular SNP gj may be made by accounting
for the contributions of the other variants to the phenotype y, and by blocking the effects of con-
founders of the associations of genotypes and the phenotype – by adjustment with an appropriate
set of fixed effect covariates or other means [Zaitlen et al. (2012a,b); Yang et al. (2014)].
Here we demonstrate the use of cvBLUPs as adjustment covariates in a linear regression model
that efficiently captures some of the benefits of a standard mixed model association study. To com-
pare the performance cvBLUP adjusted analyses to existing methods for association testing under
a range of study scenarios, simulations were used. Methods compared were: unadjusted linear
regression, PC adjusted linear regression, a standard LMM association test (GCTA), and BOLT
association tests. BOLT results were collected both for the infinetissimal genetic model (BOLT-
INF) and the sparse causal genetic model (BOLT-LMM). Association tests conducted with cvBLUP
adjustment, GCTA, and BOLT were done with leave-one-chromosome-out schemes wherein the
variance components, cvBLUPs, and phenotypic predictions and residuals (BOLT) were calculated
using only SNPs that are on different chromosomes than the test-SNPs.
In each simulation, data sets were generated with N = 2000 subjects under the model y =
Xβ+ gβg + Zb + e. Here X consists of normally distributed covariates drawn to contribute i.i.d.
noise to the phenotypes in the independent-subject simulation, but to be correlated with the sub-
jects’ ancestral populations in the simulations with population structure and with family in the
simulations with confounding by family structure. Xβ was scaled to contribute 10% of the phe-
notypic variance. g represents a set of 5 additively coded causal SNPs with effect sizes βg set to
a common fixed value of 0.25. A set of 5 null SNPs were also drawn but did not contribute to
the phenotype y. Z represents M = 2000 independent SNPs modeled with random effect sizes.
For simulations run under the infinitessimal genetic model, the random effects bj were drawn
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from N
(
0,
σ2g
M IM
)
with the genetic variance σ2g accounting for 40% of the phenotypic variance.
For the sparse non-infinitessimal model, a fraction mc = 2% of the SNPs in Z were selected to be
causal with effect sizes drawn from N
(
0,
σ2g
Mmc IM
)
The residual noise e ∼ N(0, σ2e ) accounts for
40% of the phenotypic variance, giving a heritability h2 ≈ 50%. Effect estimates and test statistics
produced by the various analysis methods are summarized for 1000 null SNPs and 1000 causal
SNPs.
In Table 2.2, the results of analyzing data sets with independent subjects and an infinitessimal
genetic architecture are shown. All methods produced unbiased effect estimates and well cali-
brated tests under the null (χ2Null ≈ 1), but the cvBLUP and mixed-model based methods were
more powerful – with greater average test statistics for the causal SNPs. The BOLT effect estimates
were biased, with effect sizes deflated towards zero. This deflation of BOLT effect estimates is seen
across the simulation scenarios, however we do not detect deflation of the BOLT effect estimates
in the real-data analyses of the METSIM cohort data below, where there are much ratios of counts
of SNPs to number of subjects. Bias in BOLT may be due to the empirical estimation of a deflation-
correction factor for the residual based test based on the GRAMMAR-γ adjusted residual analysis
method Loh et al. (2015); Svishcheva et al. (2012). In analogous simulations with a sparse genetic
model (Table 2.9, Supplement), BOLT-LMM is considerably more powerful because it explicitly
models the sparse genetic architecture. When the true genetic contribution to the phenotype, Zb,
(not including the test-SNPs) is included as a covariate in a linear regression association test of
causal SNPs g, the power is greatly increased.
In Table 2.3, the results of analyzing data sets with confounding by population structure are
shown. Subjects were drawn from 5 distinct populations with pairwise Fst set to 0.03. Population
specific allele frequencies were generated by the Balding-Nickels model [Balding and Nichols
(1995)]. The component Xβ in the generating model was drawn to be correlated with population,
but X was not used in the analyses. In this scenario, unadjusted linear regression and linear regres-
sion with fewer than 4 principal components as adjustment covariates give inflated test statistics
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and excessive false positives under the null, χ2Null > 1. Correcting for population structure by in-
clusion of 4 principal components, cvBLUP adjustment, or use of the mixed model based methods
gives well calibrated test statistics under the null, χ2Null ≈ 1. For causal test SNPs, cvBLUP and
mixed model based methods give greater test statistics than PC-adjusted linear regression with 4
PCs, indicating greater power. Linear regression with adjustment with the true genetic effect Zb
gives high power for detecting causal SNPs, but does not control for inflation of test statistics at
null SNPs due to population structure – χ2Null = 3.55  1. Covariate adjustment with cvBLUPs
controls the confounding by population structure and improves the power as do the LMM based
methods. These methods use all SNPs and detect the shifts in allele frequencies across populations
when there is confounding by population structure.
cvBLUPs correct for population structure because they are weighted combinations of ALL
principal components, where weights are based on the the singular value corresponding to the
principal component and on the strength of the association of the principal component with the
outcome (see Supplement). Conceptually, cvBLUPs control for population structure as if all PCs
were considered and the most relevant ones for the analysis were kept.
In Table 2.4, the results of analyzing data sets with confounding by family structure are shown.
Here the 2000 subjects in each simulation represented 200 families with 10 subjects each. Families
were generated in pedigrees with four founders and six of their descendants, with descendants’
genotypes selected independently by drop-down from their parents. In the data generating model,
there were covariate effects correlated with family membership, Xβ but these covariates were not
included in the analyses, creating confounding by family structure. In this scenario, unadjusted
linear regression, and PC-adjusted linear regression have inflated test statistics (χ2Null > 1) and
correspondingly high false discovery rates. Standard linear mixed models (GCTA) control for the
confounding by family structure, with accurate effect estimates β̂g under the null and alternative,
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TABLE 2.2: Simulations with infinitesimal genetic model, without population or
family structure. Mean and standard errors for effect estimates and test statistics of
association tests at 1000 Null SNPs with true βg0: β̂g0 and χ2Null; and at 1000 causal
SNPs with an alternative hypothesis of true βg = 0.25: β̂g and χ2
Model mean(βg0) se(βg0) mean(χ2Null) se(χ
2
Null) mean(βg) se(βg) mean(χ
2) se(χ2)
LR -4.00E-04 1.30E-03 0.99 0.05 0.250 1.30E-03 47.11 0.66
LR + 4 PCs -5.00E-04 1.30E-03 0.99 0.05 0.250 1.30E-03 46.97 0.66
LR + cvBLUP -1.30E-03 1.10E-03 1.00 0.05 0.249 1.20E-03 58.53 0.81
LR + BLUP -1.00E-03 6.00E-04 1.05 0.05 0.096 6.00E-04 36.63 0.56
LMM -1.30E-03 1.10E-03 1.00 0.05 0.249 1.20E-03 56.62 0.76
BOLT-INF -1.30E-03 1.00E-03 1.01 0.05 0.219 1.00E-03 56.13 0.76
BOLT-LMM -1.30E-03 1.00E-03 1.00 0.05 0.219 1.00E-03 56.04 0.75
LR + true genetic effect -1.00E-03 9.00E-04 1.04 0.05 0.250 9.00E-04 96.28 1.26
TABLE 2.3: Simulations with infinitesimal genetic model and population structure.
Mean and standard errors for effect estimates and test statistics of association tests
at 1000 Null SNPs with true β = g0: β̂g0 and χ2Null; and at 1000 causal SNPs with an
alternative hypothesis of true βg = 0.25: β̂g and χ2
Model mean(βg0) se(βg0) mean(χ2Null) se(χ
2
Null) mean(βg) se(βg) mean(χ
2) se(χ2)
LR -1.2E-03 2.30E-03 2.94 0.14 0.250 2.20E-03 47.28 0.92
LR + 1 PC -8.00E-04 2.10E-03 2.44 0.12 0.250 1.90E-03 48.20 0.85
LR + 2 PCs -1.00E-04 1.80E-03 1.94 0.09 0.253 1.70E-03 49.00 0.80
LR + 3 PCs -3.00E-04 1.60E-03 1.49 0.07 0.252 1.50E-03 48.90 0.76
LR + 4 PCs 1.00E-03 1.30E-03 1.02 0.05 0.250 1.30E-03 47.86 0.70
LR + cvBLUP 4.00E-04 1.20E-03 1.00 0.04 0.240 1.20E-03 56.8 0.81
LMM -2.00E-04 1.20E-03 0.99 0.05 0.252 1.20E-03 56.97 0.79
BOLT-INF -1.00E-04 1.00E-03 0.97 0.04 0.214 1.00E-03 54.34 0.76
BOLT-LMM -1.00E-04 1.00E-03 0.97 0.04 0.214 1.00E-03 54.37 0.76
LR + true genetic effect 2.20E-03 1.80E-03 3.55 0.16 0.250 1.80E-03 89.28 1.56
and barely inflated test statistics under the null – χ2Null having mean and standard deviation 1.10
and 0.05 respectively. In this scenario, cvBLUP adjusted analyses and the results from BOLT have
biased effect estimates under the alternative, and deflated (conservative) test statistics under the
null. This suggests over-adjustment for family structure in both cvBLUP-adjusted analyses and
BOLT.
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TABLE 2.4: Simulations with infinitessimal model and family structure. Mean and
standard errors for effect estimates and test statistics of association tests at 1000 Null
SNPs with true βg0 = 0: β̂0 and χ2Null; and at 1000 causal SNPs with an alternative
hypothesis of true βg = 0.25: β̂g and χ2
Model mean(βg0) se(βg0) mean(χ2Null) se(χ
2
Null) mean(βg) se(βg) mean(χ
2) se(χ2)
LR -1.30E-03 1.60E-03 1.52 0.07 0.252 1.60E-03 48.81 0.77
LR + 4 PCs -5.00E-04 1.50E-03 1.49 0.06 0.253 1.60E-03 48.93 0.75
LR + cvBLUP 4.00E-04 1.00E-03 0.81 0.03 0.183 9.00E-04 36.20 0.52
LMM 5.00E-04 1.40E-03 1.10 0.05 0.251 1.30E-03 48.57 0.68
BOLT-INF 5.00E-04 9.00E-04 0.77 0.03 0.166 9.00E-04 33.65 0.46
BOLT-LMM 5.00E-04 9.00E-04 0.84 0.04 0.166 9.00E-04 36.24 0.51
LR + true genetic effect 5.00E-04 1.00E-03 1.21 0.05 0.252 1.00E-03 98.24 1.31
Finally, we applied these methods to the METSIM data described above. All p-values were
GC adjusted for comparison purposes. All mixed model-based methods, including LR+cvBLUP
were more powerful than standard linear regression. As expected BOLT-LMM had the highest
power due to modelling of non-infinitessimal structure. In this data analysis there is no observed
evidence of bias in effect size estimates by BOLT, such as a systematic deflation of effect estimates
relative to estimates made by standard linear regression or standard LMM fixed effect estimates,
suggesting that it may not be a problem in practice.
TABLE 2.5: GWAS results for baseline low-density lipoprotein cholesterol (LDLC)
using an unrelated subset of subjects from the METSIM cohort. LR: linear regres-
sion, LMM: linear mixed model with GLS analysis of SNP effects implented in
GCTA, cvBLUP: cross-validated prediction-adjusted linear regression, BOLT-INF;
BOLT assuming infinitesimal genetic model, BOLT-LMM: BOLT using mixture of
Normal distributions as prior for SNP effect sizes, i.e. sparse genetic architecture.
cvBLUP-adjusted analyses, LMM, and BOLT were used in a leave-one-chromosome-
out scheme with variance components, cvBLUPs, covariance models (LMM, GCTA),
and genetic predictions and residuals (BOLT) generated using SNPs on chromo-
somes other than that of the test-SNPs.
LR LMM BOLT-INF BOLT-LMM cvBLUP
lambdaGC 1.02 1.02 1.02 1.02 1.02
p-values below 1e-06 31 32 32 35 33
Ratio of effect size estimates1e-06 0.991 1 0.999 0.999 0.998
Standard error in ratio of effect sizes1e-06 0.00243 0 0.000561 0.000561 0.00088
p-values below 5e-08 15 15 15 16 16
Ratio of effect size estimates5e-08 0.996 1 0.998 0.998 0.999
Standard error in ratio of effect sizes5e-08 0.00232 0 0.000977 0.000977 0.00122
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TABLE 2.6: GWAS results for baseline high-density lipoprotein cholesterol (HDLC)
using an unrelated subset of subjects from the METSIM cohort. LR: linear regres-
sion, LMM: linear mixed model with GLS analysis of SNP effects implemented in
GCTA, cvBLUP: cross-validated prediction-adjusted linear regression, BOLT-INF;
BOLT assuming infinitesimal genetic model, BOLT-LMM: BOLT using sparse genetic
architecture.cvBLUP-adjusted analyses, LMM, and BOLT were used in a leave-one-
chromosome-out scheme with variance components, cvBLUPs, covariance models
(LMM, GCTA), and genetic predictions and residuals (BOLT) generated using SNPs
on chromosomes other than that of the test-SNPs.
LR LMM BOLT-INF BOLT-LMM cvBLUP
lambdaGC 1.04 1.04 1.04 1.04 1.04
p-values below 1e-06 15 15 14 14 16
Ratio of effect size estimates1e-06 1.02 1 0.992 0.992 0.999
Standard error in ratio of effect sizes1e-06 0.00294 0 0.00134 0.00134 0.000866
p-values below 5e-08 13 11 11 13 12
Ratio of effect size estimates5e-08 1.01 1 0.997 0.997 1
Standard error in ratio of effect sizes5e-08 0.00288 0 0.000681 0.000681 0.000897
Leveraging cvBLUPs to compute linear mixed model shrink parameters
Finally, we examine the use of cvBLUPs in estimating LMM shrink parameters. The BLUP effect
size estimates from a linear mixed model are "shrunk" to be smaller in magnitude to exploit a
bias-variance trade-off that reduces their mean squared error. With the estimated genetic variance
component σ̂2g , the estimated distribution of effect estimates bj ∼ N
(
0,
σ̂2g
M
)
is an empirical prior
on the effect sizes, which yields estimates that are biased toward the prior mean of 0. Equivalently,
the BLUP effect sizes estimates are ridge regression estimates with a penalty parameter λ related
to the LMM variance components: λ =
1− h2
h2
=
σ̂2g
σ̂2e
.
When SNPs are independent, the LMM shrinkage estimates of the effect sizes b for given esti-
mates of the variance components is found to be [Vilhjálmsson et al. (2015)]
b̂j ∼ N
(
h2
h2 + MN
b,
h2
h2 + MN
σ̂2g
M
)
(2.9)
and the shrink, h
2
h2+ MN
, can be calculated directly from the number of individuals and SNPs.
However, when SNPs are in LD, it is more complicated to estimate the effective number of SNPs
[Patterson et al. (2006)] and hence the shrink. Here we show how cvBLUPs can be used to estimate
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the shrink directly.
First, in the case of independent SNPs, the LMM estimates of the SNP effects b̂ would be
reduced in magnitude and variance relative to the true values b, as in Equation 2.9, and there
would be a corresponding decrease in the variance of polygenic risk scores for a new individual
with normalized genotypes Znew, calculated using b̂ as weights rather than the true effect sizes b:
var
(
Znewb̂
)
=
(
h2
h2 + MN
)
var (Znewb)
=
(
h2
h2 + MN
)
σ2g
(2.10)
Equation 2.10 suggests the direct estimation of the shrink by taking the ratio of σ̂2g to var
(
Znewb̂
)
.
We confirm this approach is approximately unbiased via simulation. For multiple settings of N
(number of subjects), M (number of SNPs) and h2 (heritability), heritability and variance com-
ponents were estimated and the value of the standard independent-SNP model for the shrink is
compared to the empirical BLUP shrink var(BLUP)
σ̂2g
and the empirical cvBLUP shrink var(cvBLUP)
σ̂2g
. In
each simulation setting, the BLUP shrink is much larger than the independent model value or the
cvBLUP shrink due to over-fitting by the standard BLUPs. However, the cvBLUP formula and the
independent-SNP model are consistent for all parameter settings.
Because this approach does not require identification of an effective number of SNPs, it extends
directly to the case where there is linkage disequilibrium. We applied this approach to simulated
data from the METSIM cohort used above. We estimated the shrink parameter for simulated
phenotypes based on the real genotypes at 609131 SNPs with minor allele frequencies greater than
0.01 on the 6263 unrelated (at the 0.05 level) subjects. Twenty simulations were run using fractions
of causal SNPs between 0.0001 and 1.0. Causal SNPs were chosen by simple random sampling
with equal probability from the genotyped SNPs. SNP effect sizes were normally distributed and
trait heritability was 50 percent. The shrink formula for independent SNPs suggested a shrink of
about 0.0045-0.0055, while the cvBLUP shrink – the ratio of the variance of the cvBLUPs to the
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estimated genetic variance component ranged from 0.06-0.08.
In this setting, with LD between the SNPs, the independent SNP formula for the shrink is
invalid. In particular the effective number of SNPs M˜ is much smaller than the total number of
SNPs leading to a shrink estimate over ten times smaller than the the cvBLUP based estimate.
TABLE 2.7: Estimation of the shrink parameters for BLUPs and cvBLUPs in simu-
lations with independent SNPs. The independent shrink is that derived in Formula
2.9 for independent SNPs.
N M h2 ĥ2 Independent Shrink BLUP Shrink cvBLUP Shrink
400 400 0.5 0.512 (0.102) 0.335 (0.003) 0.627 (0.007) 0.389 (0.006)
400 800 0.5 0.502 (0.119) 0.200 (0.003) 0.560 (0.010) 0.217 (0.005)
400 1200 0.5 0.494 (0.128) 0.139 (0.003) 0.530 (0.011) 0.150 (0.004)
800 400 0.5 0.492 (0.062) 0.496 (0.002) 0.695 (0.004) 0.573 (0.004)
800 800 0.5 0.501 (0.066) 0.334 (0.002) 0.619 (0.005) 0.383 (0.004)
800 1200 0.5 0.500 (0.075) 0.248 (0.002) 0.581 (0.006) 0.280 (0.004)
1200 400 0.5 0.505 (0.052) 0.600 (0.002) 0.770 (0.003) 0.700 (0.003)
1200 800 0.5 0.501 (0.051) 0.426 (0.002) 0.661 (0.003) 0.494 (0.003)
1200 1200 0.5 0.501 (0.051) 0.332 (0.002) 0.614 (0.004) 0.378 (0.003)
400 400 0.1 0.105 (0.080) 0.089 (0.006) 0.199 (0.010) 0.106 (0.006)
400 800 0.1 0.114 (0.096) 0.052 (0.004) 0.174 (0.011) 0.060 (0.004)
400 1200 0.1 0.114 (0.104) 0.035 (0.003) 0.170 (0.011) 0.044 (0.003)
800 400 0.1 0.102 (0.044) 0.165 (0.006) 0.238 (0.008) 0.169 (0.006)
800 800 0.1 0.101 (0.056) 0.090 (0.005) 0.178 (0.008) 0.094 (0.004)
800 1200 0.1 0.105 (0.066) 0.063 (0.004) 0.160 (0.008) 0.067 (0.004)
1200 400 0.1 0.098 (0.032) 0.222 (0.006) 0.283 (0.007) 0.225 (0.006)
1200 800 0.1 0.101 (0.035) 0.130 (0.004) 0.208 (0.006) 0.132 (0.004)
1200 1200 0.1 0.098 (0.041) 0.088 (0.003) 0.170 (0.006) 0.090 (0.004)
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TABLE 2.8: Estimates of the shrink parameter for simulated phenotypes based on
the real genotypes METSIM cohort and various genetic architectures or fractions of
causal SNPs. The independent shrink is that derived in Formula 2.9 for independent
SNPs.
Fraction Causal SNPs Independent Shrink BLUP Shrink cvBLUP Shrink
1.0 0.0050 (1.60E-04) 0.514 (0.015) 0.076 (0.002)
0.1 0.0053 (1.71E-04) 0.539 (0.016) 0.079 (0.002)
0.01 0.0055 (1.73E-04) 0.556 (0.016) 0.080 (0.002)
0.001 0.0047 (5.45E-05) 0.477 (0.005) 0.067 (0.001)
0.0001 0.0040 (1.20E-04) 0.409 (0.011) 0.058 (0.001)
2.5 Discussion
Here we describe a new and computationally efficient approach for generating polygenic risk
scores directly from a linear mixed model. We show that the LMM framework allows direct cal-
culation of out-of-sample genetic predictions. Our approach will have immediate utility for the
growing list of applications that rely on PS, and we provide examples of several additional ap-
plication areas, including detection of pleiotropy, powerful association testing, and estimation of
polygenic shrink.
The elimination of over-fitting by cvBLUPs relative to BLUPs suggests a solution to the bias
problem in residual based methods. Rather than post-hoc correction of residual test statistics as in
GRAMMAR-γ and BOLT, the LMM residuals may be replaced by out-of-sample prediction errors
with cross-validated predictors: use (y− cvBLUP) instead of standard residuals (y− BLUP)
There are several limitations of this approach. First, cvBLUPs are calculated from the stan-
dard LMM framework, which corresponds to the infinitessimal genetic model. As we see in in
supplementary Tables 2.9-2.11, in simulations with sparse genetic architectures, sparse models
have considerably higher power. In future work, we intend to use sparse analogues of cvBLUPs
generated as cross-validated predictions. Unfortunately, sparse models including the BOLT-LMM
model and LASSO are not amenable to the fast leave-one-out cross-validation as in Equation (2.7).
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Another limitation is that when used as adjustment covariates cvBLUPs do not control con-
founding by family structure or cryptic relatedness as well as standard mixed model association
tests. Rather than using all subjects for computation of cvBLUPs, an alternative protocol is to cal-
culate cvBLUPs for an unrelated subset, and also to calculate BLUP effect size estimates b̂ (Equa-
tion 3.2) using these unrelated subjects. This procedure will tend to block confounding by genetic
structure remaining in the nominally unrelated subset and will improve power by accounting for
the polygenicity of the trait, but it could under-adjust for confounding by family structure be-
cause by construction the training set for learning the polygenic model does not contain closely
related subjects. Methods involving cross-validated predictions from multiple models or cvBLUPs
from mixed models with multiple variance components may prove useful, by analogy with other
multiple variance component methods that include sparse relatedness matrices to indicate family
membership [Zaitlen et al. (2013), Tucker et al. (2015)]
In our cross-trait analysis of the METSIM data set we show that the cross-correlations of PRS
for one trait and actual (normalized) phenotypic measures for other traits. We are working to
extend these cross-trait analyses – in particular by using correlations of cvBLUPs for pairs of traits
as estimates of the genetic correlation. However, even naive correlations of cvBLUPs give an
effective picture of the genetic correlations between traits. Since cvBLUPs are efficiently calculated
one at a time, and genetic correlations are then estimated in trivial pairwise analyses of traits,
the pair-wise correlations of hundreds or thousands of traits may be efficiently calculated this
way. Furthermore, in the pair-wise analyses of the METSIM phenotypes, and in our pair-wise
analyses of RNA expression that underlie our trans-eQTL analysis [Liu et al. (2018)] we actually
generate asymmetric cross-correlation matrices because the correlation of cvBLUP for trait A with
measured trait B is not the same as the correlation of measured trait A with cvBLUP for trait B. We
are exploring applications of these asymmetric matrices for network analysis and causal inference.
Efficient generation of out-of-sample genetic predictions using leave-one-out cross-validation
of the predictions from a linear mixed model is an effective way to generate polygenic risk scores,
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and opens the application of analyses based on PRS to scenarios where there is no available refer-
ence data to generate a typical scoring model. It is now well known that PRS and genetic predic-
tions transfer poorly to populations that are distinct from the reference data set used to learn the
genetic model [Martin et al. (2017); Scutari et al. (2016)]. We look forward to using reference-free
PRS methods based on cvBLUPs for applications with data from under-represented populations.
The principle of using cross-validated predictions from polygenic models as PRS may be ex-
tended to predictions from sparse or complex models, but the cross-validated predictions from
a standard linear mixed model, which we call cvBLUPs, are particularly simple to calculate and
have novel and interpretable applications. To make the results of this work accessible to the com-
munity, we have implemented them in the GCTA software package [Yang et al. (2011)].
2.6 Appendices
2.6.1 Formula for efficient leave-one-out cross-validation of the linear mixed model
Let
y = Xβ+ Zb + e (2.11)
represent a linear mixed model with continuous outcome y, fixed effect covariates X, fixed effect
sizes β, additively coded genotypes Z, random genetic effect sizes b and unmodeled or envi-
ronmental factors e. The genetic effect sizes b and environmental factors e are modeled as i.i.d.
normally distributed random variables with variances 1Mσ
2
g and σ2e respectively:
b ∼ N
(
0,
σ2g
M IM
)
e ∼ N(0, σ2e IN) (2.12)
By convention the genotypes are scaled to have mean 0 and variance 1, and the SNP effect sizes are
assumed to have effect sizes independent of MAF on this scale. So the total genetic contributions
to the phenotype Zb are normally distributed with mean 0 and variance σ2g . The scaled genotypes
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Z are used to calculate a SNP-based genetic relatedness matrix K:
K = 1M ZZ
T. (2.13)
The observations y in the linear mixed model are normally distributed with a covariance Σ that
depends on K and the variance components σ2g and σ2e
y ∼ N(Xβ,Σ)
Σ = σ2g K + σ2e IN
Σ̂ = σ̂2g K + σ̂2e IN
H = σ̂2g KΣ̂−1
βˆ =
(
XTΣ̂−1X
)−1 (
XTΣ̂−1y
)
bˆ =
σ̂2g
M Z
TΣ̂−1(y− Xβˆ)
yˆ = BLUP
= Hy
=
σ̂2g
M ZZ
TΣ̂−1(y− Xβˆ)
= Zbˆ
(2.14)
To simplify notation, let fixed effect sizes β and fixed effects Xβ = 0:
bˆ =
σ̂2g
M Z
TΣ̂−1y
yˆ =
σ̂2g
M ZZ
TΣ̂−1y
= Zbˆ
(2.15)
35
Exclude observation i from the genetic predictive model fit and then make an out-of-sample
(oos) prediction for observation i:
bˆ−i =
σ̂2g
M Z
T
−iΣ̂
−1
−i y−i
yˆi,oos = Zi bˆ−i
(2.16)
Now generate the augmented vector y+i as the vector of outcomes y with observation yi re-
placed with it’s out-of-sample prediction from a model trained on the remaining observations,
yˆi,oos.
Consider the ridge regression interpretation of the mixed model with the ridge penalty λ =
σ̂2e
σ̂2g
=
1− h2
h2
. Assume the variance components or heritability have been estimated in a prior step
or are known.
For the reduced data set with the outcome for observation i removed we have:
bˆ−i = argmin
b
1
2 ∑k 6=i
(y−i − Z−ib)2 + λ2 ||b||
2
2 (2.17)
For the augmented data set with the outcome for observation i replaced by an out-of-sample
prediction we have:
bˆ+i = argmin
b
1
2 ∑k 6=i
(yk − Zkb)2 + (yˆi,oos − Zib)2 + λ2 ||b||
2
2 (2.18)
For the augmented model, (yˆi,oos − Zi bˆ) = 0, and the remaining terms in the expression for bˆ+i
are the same as for the reduced model bˆ−i, so bˆ+i = bˆ−i.
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Now consider the differences in the predictions for the ith value from the augmented model
and the model with all observations:
yˆ+i − yˆi = Zi bˆ+i − Zi bˆ
= Zi
σ̂2g
M Z
TΣ̂−1y+i − Zi σ̂
2
g
M Z
TΣ̂−1y
= Zi
σ̂2g
M Z
TΣ̂−1 (y+i − y)
= Hi,. (y+i − y)
(2.19)
Here, Zi
σ̂2g
m Z
TΣ̂−1 is the ith row of the matrix H, or Hi,.. The vectors y+i and y only differ at the
ith element, so:
yˆ+i − yˆi = Hi,. (y+i − y)
= Hi,i
(
Zi bˆ−i − yi
) (2.20)
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Finally,
Zi bˆ−i − Zi bˆ = Hi,i
(
Zi bˆ−i − yi
)
= Hi,iZi bˆ−i − Hi,iyi
(1− Hi,i)Zi bˆ−i = Zi bˆ− Hi,iyi
Zi bˆ−i =
Zi bˆ− Hi,iyi
1− Hi,i
Zi bˆ−i =
Zi bˆ− Hi,iyi
1− Hi,i
yˆi,oos = Zi bˆ−i
=
Zi
σ̂2g
M
ZTΣ̂−1y− Hi,iy
1− Hi,i
=
yˆi − Hi,iy
1− Hi,i
=
Hi,. − Hi,i
1− Hi,i y
(2.21)
2.6.2 Relationship between principal components and cross-validated BLUPs
Genetic principal components are routinely used as quantitative measures of study participants’
ancestry [Patterson et al. (2006); McVean (2009)] and as such are used as adjustment covariates in
association studies to block confounding by population structure [Patterson et al. (2006)]. Linear
mixed models provide another framework for controlling potential confounding by population
structure [Yang et al. (2014)]. Both PCs and LMMs are methods that account for ancestry and
other forms of genetic structure in a data set by analyses of the genetic relatedness matrix (GRM)
K = 1m ZZ
T. Specifically, PCA involves calculating some number of eigenvetors of the GRM – or
equivalently left singular vectors of the scaled genotype matrix Z – and using them as adjustment
covariates in regression analyses, while LMMs model observed outcomes as non-independent,
with the random effects that contribute to the outcome y correlated to a degree related to the
amount of shared genetic variation between each pair of subjects: cov(y) = Σ = σ2g K + σ2e In.
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In principal component adjusted analyses, some number of PCs are used as adjustment covari-
ates in linear regression. With linear mixed models, generalized least squares with an estimate of
the sample covariance Σ̂ is used.
Principal component adjusted analysis has several disadvantages. First, it is not clear how
many principal components should be used. In GWAS it has become conventional to use a stan-
dard number of PCs, say 10, but it is generally not clear whether that will be enough to account for
the components of genetic structure that are confounded with non-genetic factors in a study. Sec-
ond, it is not clear which PCs should be included. Conventionally, PCs are sorted in descending
order by the magnitude of the corresponding eigenvalues, and PCs with the largest eigenvalues
are used. However, selected PCs may not be associated with any non-genetic factors and may not
relieve any confounding. Finally, in association testing applications, tests needlessly lose power
due to over-adjustment when PCs that do not adjust for confounding are included as covariates.
By construction PCs represent axes of variation in the genotype data, so some may be highly cor-
related with a test SNP, and inclusion of correlated covariates increases the standard errors around
test SNP effect estimates.
The spectral decomposition of the GRM K is:
K = UΛUT (2.22)
where U is a unitary matrix whose columns are the genetic PCs or eigenvectors of K, and Λ is a
diagonal matrix of the corresponding eigenvalues.
Principal component adjusted regression includes Uk (first k columns of U) as regression co-
variates to improve the estimation or testing of βg:
y = Xβ+ gβg +Ukγ+ e (2.23)
This leaves open the question of how many or which PCs should be included. As an alternative
to standard practice, we can try using all of the PCs, and use regularization to keep the model
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estimable. We can also minimize problems due to over-adjustment by calculating the PCs U using
a GRM K∗ or scaled genotype matrix Z∗ that does not include SNPs in linkage disequilibrium with
or on the same chromosome as the test-SNP g.
Towards a connection to cvBLUPs, rescale the columns of U by the corresponding singular
values :
Us = U
√
Λ (2.24)
Rescaling U to Us puts a higher prior on PCs with larger eigenvalues. Now compress the
contribution of the principal components to the outcome by calculating a vector of phenotypic
predictions using ridge regression with a penalty λ on the principal components:
yˆpc = UsUTs (UsUTs + λIn)−1(y− Xβˆ) (2.25)
If we define λ =
σ2e
σ2g
=
1− h2
h2
and recall that Us = U
√
(Λ), so that UsUTs = UΛUT = K∗, we
have:
yˆpc = σ2g K(σ2g K∗ + σ2e In)−1(y− Xβˆ) (2.26)
But this is just a BLUP. So, BLUPs arise from a limiting case of trying to do PC-adjusted re-
gression with all PCs. Therefore cross-validated predictions from ridge regression on all PCs are
cvBLUPs.
cvBLUPs as adjustment covariates are similar to a compression of all PCs into a single covari-
ate, with the PCs given prior weights that emphasize the PCs with larger eigenvalues, but do not
exclude any. The PCs are also weighted by their relevance to the outcome because they represent
predictions from a ridge regression model that implicitly has ridge regression effect sizes for the
association of the PC with the outcome. Over-fitting in the ridge regression step is avoided by
the leave-one-out cross-validation. Finally, loss of power by over adjustment is avoided by ex-
cluding the chromosome or SNPs in linkage disequilibrium with test SNP from the GRM used for
calculation of the cvBLUPs. In fact, unlike PC adjustment but similar to standard LMM analyses,
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cvBLUP adjustment boosts the power of association studies by modeling genetic contributions to
the phenotype other than the SNP of interest, thereby increasing the signal to noise ratio.
2.6.3 Additional results with cvBLUP-adjusted association testing
TABLE 2.9: Simulations with sparse genetic model and independent subjects. Mean
and standard errors for effect estimates and test statistics of association tests at 1000
Null SNPs with true β = 0: β̂0 and χ2Null; and at 1000 causal SNPs with an alternative
hypothesis of true β = 0.25: β̂ and χ2
Model mean(β0) se(β0) mean(χ2Null) se(χ
2
Null) mean(β) se(β) mean(χ
2) se(χ2)
LR -1.10E-03 1.40E-03 1.14 0.05 0.249 1.30E-03 47.48 0.70
LR + 4 PCs -9.00E-04 1.40E-03 1.13 0.05 0.249 1.30E-03 47.38 0.68
LR + cvBLUP -1.10E-03 1.30E-03 1.14 0.05 0.248 1.20E-03 58.15 0.83
LMM -1.10E-03 1.30E-03 1.14 0.05 0.248 1.20E-03 56.22 0.78
BOLT-inf -9.00E-04 1.10E-03 1.14 0.05 0.219 1.00E-03 55.81 0.77
BOLT-LMM -9.00E-04 1.10E-03 1.09 0.05 0.219 1.00E-03 80.99 1.05
LR + true genetic effect -6.00E-04 1.00E-03 1.13 0.05 0.249 9.00E-04 94.32 1.26
TABLE 2.10: Simulations with sparse genetic architecture and population structure.
Mean and standard errors for effect estimates and test statistics of association tests
at 1000 Null SNPs with true β = 0: β̂0 and χ2Null; and at 1000 causal SNPs with an
alternative hypothesis of true β = 0.25: β̂ and χ2
Model mean(β0) se(β0) mean(χ2Null) se(χ
2
Null) mean(β) se(β) mean(χ
2) se(χ2)
LR -1.50E-03 2.30E-03 2.88 0.14 0.245 2.20E-03 46.30 0.90
LR + 4 PCs -6.00E-04 1.30E-03 1.01 0.05 0.248 1.20E-03 46.57 0.66
LR + cvBLUP -6.00E-04 1.10E-03 0.97 0.05 0.238 1.10E-03 54.76 0.78
LMM -7.00E-04 1.20E-03 1.00 0.05 0.247 1.20E-03 55.22 0.76
BOLT-inf -8.00E-04 1.00E-03 0.97 0.05 0.211 1.00E-03 52.78 0.73
BOLT-LMM -8.00E-04 1.00E-03 1.02 0.05 0.211 1.00E-03 77.75 1.05
LR + true genetic effect -2.30E-03 1.90E-03 3.65 0.17 0.247 1.90E-03 87.22 1.56
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TABLE 2.11: Simulations with sparse genetic architecture and family structure.
Mean and standard errors for effect estimates and test statistics of association tests
at 1000 Null SNPs with true β = 0: β̂0 and χ2Null; and at 1000 causal SNPs with an
alternative hypothesis of true β = 0.25: β̂ and χ2
Model mean(β0) se(β0) mean(χ2Null) se(χ
2
Null) mean(β) se(β) mean(χ
2) se(χ2)
LR 1.30E-03 1.60E-03 1.57 0.07 0.248 1.60E-03 47.46 0.73
LR + 4 PCs 1.20E-03 1.60E-03 1.53 0.07 0.248 1.60E-03 47.33 0.73
LR + cvBLUP 1.50E-03 9.00E-04 0.72 0.03 0.184 9.00E-04 35.81 0.49
LMM 2.00E-03 1.30E-03 0.98 0.05 0.249 1.30E-03 47.34 0.64
BOLT-inf 1.30E-03 9.00E-04 0.69 0.03 0.168 8.00E-04 33.39 0.44
BOLT-LMM 1.30E-03 9.00E-04 0.86 0.04 0.168 8.00E-04 64.13 0.79
LR + true genetic effect 1.70E-03 1.00E-03 1.14 0.05 0.250 1.00E-03 93.55 1.21
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Chapter 3
Sparse genetic predictions derived from
BLUPs
3.1 Improving the Accuracy of Genetic Predictions
In the previous chapter I showed how cross-validated genetic predictions could be efficiently com-
puted directly from a linear mixed model, and I gave several examples of their application to hu-
man genetics. One shortcoming of that work is the assumption that all variants are causal, with
effect sizes drawn from a Normal distribution (i.e. the infinitesimal model). Work from several
groups, including Loh et al. (2015) and Zhou et al. (2013), has provided evidence that the majority
of variants are not causal, or at least have effect sizes much closer to zero than those of a small set
of strongly-causal SNPs.
To increase the accuracy of genetic predictions related to BLUPs, in this chapter I relax the
infinitesimal model assumption by allowing causal genetic effects to be sparsely distributed across
the genome, and generate a family of corresponding Cross-Validated Predictions (CVPs). Based
on derivations of the BLUP effect size estimates in infinitessimal and sparse genetic models, I
develop an efficient approach to post-process a vector of standard BLUP effect sizes calculated
over a data set to yield the corresponding sparse effect estimates for a particular fraction causal,
pc. I show results over simulated data sets wherein using these sparse (or "sparsified" ) genetic
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predictions as adjustment covariates for GWAS improves power when the underlying causal SNP
distribution is sparse.
I first review a classic result to ground the reader as well as establish notation. I recast Best Lin-
ear Unbiased Predictors (BLUPs) as empirical Bayesian estimates of effect sizes [e.g. Dudbridge
(2013)]. With this starting point, I extend the cvBLUP framework to develop the corresponding
sparse genetic predictions. These models will be developed and demonstrated in the following
stages:
1. SNP effect size estimates in the Bayesian sparse linear mixed model: Relation to BLUPs
from the standard linear mixed model and the posterior probability of causality. This section
follows Vilhjálmsson et al. (2015).
2. Post-processing standard BLUPs to allow for a sparse genetic architecture.
3. Sparse genetic predictions and adapting to the fraction of causal SNPs, pc.
4. Use of sparse genetic predictions as adjustment covariates for GWAS. This is an extension of
the GWAS applications of cvBLUPs in the previous chapter, Section 2.4.3.
3.2 BLUPs as empirical Bayes estimates of effect sizes.
The LMM (Equation 3.1) jointly models the contributions of all SNPs Z and other covariates X to
the phenotype y. Following others [e.g. Yang et al. (2011)], we define Z by centering and scaling
the columns of an N-by-M (subject by SNP) additively coded genotype matrix to have mean 0 and
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variance 1.
y = Xβ+ Zb + e
b ∼ N
(
0,
σ2g
M IM
)
e ∼ N(0, σ2e IN)
var(y− Xβ) = σ2g + σ2e = σ2p
(3.1)
The distribution of the random effect sizes b in Equation 3.1 may be interpreted as a prior
for Bayesian estimates b̂ of the random effect sizes b given a data set with observed {y, X, Z}.
With the variance components σ2g and σ2e estimated from data, the estimated distribution of the
random effect sizes may be interpreted as an empirical prior for an empirical Bayesian estimate
of b (Equation 3.2). Estimates b̂j from a LMM will use this prior information and be “shrunk”
or biased towards the prior expected value of zero relative to the true value bj – or relative to
an unbiased marginal estimate such as a standard GWAS summary statistic b˜j. This bias is more
than compensated for by a decrease in sampling variance in order to minimize the mean squared
error of the estimate. These shrunken estimates are linear in terms of the columns of the genotype
matrix Z and are the "best" linear estimates of b in terms of mean squared error in the framework of
Equation 3.1, so they are known as Best Linear Unbiased Estimators (BLUPs). They are unbiased
in the weak sense that elements of b are asserted to have expected values of zero on repeated
draws of the random vector b, and the BLUP effect estimates (Equation 3.2) also have expected
values of zero (Equation 3.3).
b̂ =
σ̂2g
M Z
TΣ̂−1
(
y− Xβ̂
)
Σ̂ =
σ̂2g
M ZZ
T + σ̂2e IN = σ̂2g K + σ̂2e IN
β̂ = (XTX)−1XTy
(3.2)
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E b̂|σ̂2g , σ̂2e = E σ̂
2
g
M Z
TΣ̂−1
(
y− Xβ̂
)
=
σ̂2g
M Z
TΣ̂−1E
(
y− Xβ̂
)
=
σ̂2g
M Z
TΣ̂−1E
(
Xβ+ Zb + e− Xβ̂
)
=
σ̂2g
M Z
TΣ̂−1 (E Zb + E e)
=
σ̂2g
M Z
TΣ̂−1 (0+ 0)
= 0
(3.3)
Marginal estimates b˜j (Equation 3.4) are made without using the prior information, so they
are unbiased in the sense that E b˜j = bj, at least when SNPs are independent and there is no
confounding. These marginal effect size estimates have greater variance and mean squared error
than the BLUPs. Marginal estimates for the effect size of a particular SNP j are made ignoring
the remaining SNPs Z(−j), so their contributions to the outcome contribute to an unmodeled error
term η = Z−jb−j + e. To simplify notation, assume there are no fixed effect covariates X and that
the phenotype y is centered to have mean 0, or that y←− y− Xβ̂.
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Assuming independent SNPs (independent columns of Z) the expected value of the marginal
estimate of bj is:
b˜j =
(
ZTj Zj
)−1
ZTj y
=
(
ZTj Zj
)−1
ZTj
(
Zjbj + η
)
= 1N Z
T
j
(
Zjbj + η
)
= 1N Z
T
j Zjbj +
1
N ∑
i 6=j
ZTj Zibi +
1
N Z
T
j e
E
(
b˜j
)
= E
(
1
N Z
T
j Zjbj
)
+ 0+ 0
E
(
b˜j
)
= bj
(3.4)
The sampling variance of the marginal estimate is:
var
(
b˜j|bj
)
= E
(
b˜j − E
(
b˜j
))2
= E
(
1
N Z
T
j Zjbj +
1
N ∑
j 6=i
ZTj Zibi +
1
N Z
T
j e− bj
)2 (3.5)
Most terms cancel in the quadratic expansion, because b˜j is unbiased and
E
(
ZTj Zi
)
= 0
E
(
bjbi
)
= 0
E
(
eTZj
)
= 0
(3.6)
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So:
var
(
b˜j|bj
)
= E
(
1
N Z
T
j Zjbj +
1
N ∑
i 6=j
ZTj Zibi +
1
N Z
T
j e− E
(
b˜j
))2
= E
(
1
N Z
T
j Z(−j)b(−j) +
1
N Z
T
j e
)2
= E
(
1
N2
(
ZTj Z(−j)b(−j)
) (
ZTj Z(−j)b(−j)
)T)
+ E
(
1
N2
(
ZTj e
) (
ZTj e
)T)
= E
(
1
N2
(
ZTj
(
Z(−j)b(−j)bT(−j)Z
T
(−j)
)
Zj
))
+ E
(
1
N2
(
ZTj ee
TZj
))
= E
(
1
N2
(
ZTj
(
Z(−j)
(
σ2g
M IM−1
)
ZT(−j)
)
Zj
))
+ E
(
1
N2
(
ZTj
(
σ2e IN
)
Zj
))
= E
(
1
N2
(
ZTj
(
M−1
M σ
2
g K
)
Zj
))
+ E
(
1
N2
(
ZTj
(
σ2e IN
)
Zj
))
= E
(
1
N2
(
ZTj
(
σ2g K + σ2e IN − 1Mσ2g ZjZTj
)
Zj
))
= E
(
1
N2 tr
(
ZjZTj
(
σ2g K + σ2e IN − 1Mσ2g ZjZTj
)))
=
σ2p−
σ2g
M
N
≈ σ
2
p
N
(3.7)
With a marginal estimate b˜j having a normal sampling distribution with this mean and vari-
ance ( and a corresponding implied, maximized likelihood ), and with the normal prior distri-
bution for the effect size bj ∼ N
(
0,
σ2g
M
)
, we compute the posterior distribution of bj given the
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estimate:
(
bj|b˜j)
)
(Equations 3.8-3.9):
Prior : bj ∼ N
(
0,
σ2g
M
)
= N(µ0, σ20 )
Likelihood :
(
b˜j|bj
)
∼ N
(
bj,
σ2p−
σ2g
M
N
)
= N(x¯, s2)
Posterior variance : σ2 =
1
1
σ20
+
1
s2
=
σ20 s
2
σ20 + s2
posterior mean : µ =
µ0
σ20
+
x¯
s2
1
σ20
+
1
s2
= σ2
(
µ0
σ20
+
x¯
s2
)
(3.8)
So,
var(bj|b˜j) =
(
σ2p
N
)(
σ2g
M
)
σ2p
N +
σ2g
M
=
(
σ2p
N
)(
h2
h2 + MN
)
E(bj|b˜j) = var(bj|b˜j)
0+ bj(
σ2p
N
)

= bj
(
h2
h2 + MN
)
= E b˜j
(
h2
h2 + MN
)
= b̂j
= BLUP
(3.9)
The relationship demonstrated in Equation 3.9 shows that for an individual SNP j with a true
effect size bj, the expected value of the marginal effect estimate b˜j is proportional to the expected
value of the BLUP effect estimate, or equivalently the empirical Bayesian estimate of the effect
size given known or well estimated variance components. The proportionality constant or "shrink
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factor"
(
h2
h2+ MN
)
shows that the BLUP effect estimates are more shrunken when the heritability of
the trait is low and when the ratio of SNPs under consideration (M) is large relative to the number
of observations (N). If the random genetic effect estimates are normally distributed with variance
σ2g
M , then the average (unsigned) SNP effect size over SNPs or draws of the random effects is
√
σ2g
M .
BLUP effect estimates and their sampling variances will each be proportional to the shrink factor
S =
h2
h2 + MN
, so the expected value of of a marginal SNP t-test statistic based on BLUPs – an effect
estimate for bj divided by its standard error (Equation 3.10) – is less than the expected value of
marginal t-test statistics from a standard marginal GWAS:
(
σ2g N
σ2p M
) 1
2
.
E b̂j√
var(bj|b˜j)
=
E bj
(
h2
h2 + MN
)
√√√√( σ2p
N
)( h2
h2 + MN
)
=
(
σ2g
M
) 1
2
(
h2
h2 + MN
) 1
2
(
σ2p
N
) 1
2
=
(
σ2g
M
) 1
2
(
h2
h2 + MN
) 1
2
(
σ2p
N
) 1
2
=
(
σ2g N
σ2p M
) 1
2
(
h2
h2 + MN
) 1
2
=
(
h2
N
M
) 1
2
S
1
2
<
(
h2
N
M
) 1
2
(3.10)
Individually the BLUP effect estimates for particular SNPs, b̂j, are biased towards zero and
arguably, by Equation 3.10, the BLUP effect estimates are individually less significant than the
corresponding GWAS summary statistics b˜j. However, the BLUP effect estimates are estimated
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jointly, and show particular promise when used jointly to make polygenic predictions or polygenic
risk scores, as shown below and in chapters 2 and 4.
3.3 SNP effect estimates in the Bayesian sparse linear mixed model:
Relation to standard LMM BLUPs and the posterior probability of
causality.
We are now going to relax the infinitessimal assumption, or the prior that all SNP random effect
sizes are normally distributed. Various priors on the effect size distributions possible, including
those motivated by biology such as up-weighting SNPs in known functional regions. Sparse ex-
tensions of LMMs have been successfully used in other genetic analysis models, including the
point-normal distribution [Guan et al. (2011),Vilhjálmsson et al. (2015)] and mixtures of high and
low variance normals for causal and non-causal SNPs respectively [Zhou et al. (2013),Loh et al.
(2015)]. For simplicity, we use a spike-slab mixture prior, with a point mass at zero to represent the
"spike" distribution of effect sizes of null SNPs, and a normal distribution to represent the effect
sizes of the fraction pc of causal SNPs. Using the spike-slab prior on SNP effect sizes, we derive the
resulting posterior distribution, and show its relationship to standard BLUP effect size estimates.
The key innovation of the following derivations of sparse effect estimates and genetic predic-
tions is that the issue of linkage disequilibrium (e.g. bias of marginal effect estimates) are handled
implicitly by post-processing standard BLUPs which had been generated by a procedure that ac-
counts for LD (Equation 3.2).
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3.3.1 The sparse univariate model
The sparse linear mixed model is defined by a modification of the hierarchical formulation of the
LMM in Equation 3.1. The normal prior distribution for the effect sizes b is replaced with a spike-
slab mixture prior having a degenerate point mass δ0 as the "spike" of the mixture distribution.
bj ∼

N
(
0,
σ2g
Mpc
)
pc
δ0 1− pc
(3.11)
The corresponding marginal distribution (GWAS) effect estimate b˜j given a particular realized
value of the true genetic effect bj is also a mixture distribution.
(b˜j|bj) ∼

N
(
bj,
σ2p − b2j
N
)
pc
N
(
0,
σ2p
N
)
1− pc
(3.12)
By separately considering the cases where a particular SNP j is causal or not causal and an as-
sumed or estimated probability of the SNP being causal, pc, we get an expression for the posterior
distribution of SNP j’s effect size given a summary statistic from a GWAS: E(bj|b˜j). In Equation
3.13 we see that this conditional expectation in the sparse model, which is analogous to the stan-
dard BLUP effect estimate from the infinitessimal model, is in fact proportional to the standard
BLUP. The constant of proportionality between the standard and sparse posterior distributions for
SNP j’s effect size factorizes into the posterior probability of a SNP being causal, Pr(bjcausal|b˜j),
and a constant term that depends on the trait heritability (h2), the number of SNPs in Z (M), the
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number of observations (N), and the fraction of SNPs with non-zero effect sizes (pc).
E(bj|b˜j) = E(bj|b˜j, bjcausal) Pr(bjcausal|b˜j) + E(bj|b˜j, bj¬causal) Pr(bj¬causal|b̂j)
= E(bj|b˜j, bjcausal) Pr(bjcausal|b˜j) + 0× Pr(bj¬causal|b˜j)
= E(bj|b˜j, bjcausal) Pr(bjcausal|b˜j)
= var(bj|b˜j, bjcausal)
0+ bj(
σ2p
N
)
× Pr(bjcausal|b˜j)
=
(
σ2p
N
)(
σ2g
Mpc
)
σ2p
N +
σ2g
Mpc
0+ bj(
σ2p
N
)
× Pr(bjcausal|b˜j)
= BLUP×
(
h2 + MN
h2 + MpcN
)
× Pr(bjcausal|b˜j)
(3.13)
This relationship between the posterior expectation of bj given b˜j in the sparse model and stan-
dard BLUPs holds when there are no other causal SNPs in LD with the SNP being assessed. Oth-
erwise a set of effect estimates would first have to be "decorrelated" by using the study’s empirical
LD matrix or a reference LD matrix as is done in the method LDPred [Vilhjálmsson et al. (2015)].
However, a result of Equation 3.13 is to show that if standard BLUPs are calculated directly or
simulated by decorrelating and scaling a set of GWAS summary statistics, then these BLUP effect
estimates may be converted to the corresponding sparse genetic effect estimates by multiplication
with a study specific constant and by the posterior probability of the SNP being causal given its
marginal effect estimate, Pr (bjcausal|b˜j).
3.3.2 Post-processing standard BLUPs to allow for sparse genetic architecture.
The expression for a sparse posterior effect size in Equation 3.13 depends on the marginal effect
size estimate b˜j through the posterior probability of the SNP being causal given the marginal
estimate, Pr(bjcausal|b˜j). If we exchange this term for the posterior probability of a SNP being
causal given the standard BLUP effect estimate, Pr(bjcausal|b̂j), then we will have a formula to
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estimate the effect size for SNP j under the sparse model in terms of the standard BLUP effect sizes
and the ratio of the "shrink" of the mixed model effect estimates when only fraction pc of SNPs are
causal to the shrink for standard (infinitessimal) BLUP effect sizes (Equation 3.14).
E(bj|b˜j) = b̂j,sparse
= BLUP×
(
h2 + MN
h2 + MpcN
)
× Pr(bjcausal|b̂j)
(3.14)
The posterior probability of a SNP being causal given a BLUP effect estimate (and variance
component estimates and pc), Pr(bjcausal|b̂j), is found by Bayes’ Rule (Equation 3.15) in terms
of the prior probability or assumed fraction of SNPs being causal, pc, and the densities of the
sampling distributions for mixed model effect estimates (Equation 3.16).
Pr(bjcausal|b̂j) =
P(b̂j|bjcausal) Pr(bjcausal)
P(b̂j|bjcausal) Pr(bjcausal) + P(b̂j|bj¬causal) Pr(bj¬causal)
=
P(b̂j|bjcausal)pc
P(b̂j|bjcausal)pc + P(b̂j|bj¬causal)(1− pc)
(3.15)
The distribution across SNPs for the standard BLUP effect estimates is given in Equation 3.16
based on the sampling variance of a BLUP effect estimate for a particular SNP j given a realized
value of a random effect size, as derived from a posterior distribution’s variance in Equation 3.9.
The sampling error variance is in turn assumed to be equal to the phenotypic variance minus the
expected variance explained by the BLUPs (shrink (S) × σ2g ) multiplied by S and divided by N.
The effect size distribution for causal SNPs will have a greater variance than for null SNPs by the
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addition of a term: S times the prior variance for causal SNP effect sizes,
σ2g
Mpc .
P(b̂j|bjcausal) ∼ N
(
b̂j; 0, S
σ2g
Mpc
+
(
S
N
)(
σ2p − Sσ2g
))
P(b̂j|bj¬causal) ∼ N
(
b̂j; 0,
(
S
N
)(
σ2p − Sσ2g
))
S =
(
h2
h2 + MN
) (3.16)
The effect of multiplying a standard BLUP effect estimate by the posterior probability of being
causal given the standard BLUP effect estimate in Equation 3.13 is to apply a non-linear trans-
formation to the effect sizes. Since non-causal SNPs have a lower sampling variance than causal
SNPs, a SNP j with a lower BLUP effect size estimate than a SNP k will have a lower posterior
probability of being causal than the SNP k. The result of applying the transformation in Equation
3.13 is then to map the BLUP effect estimate for j proportionally closer to zero when generating
the corresponding sparse-model effect estimate than how SNP k is mapped to the sparse model.
Figure 3.1 illustrates this non-linear transformation of effect sizes that de-emphasizes SNPs with
low SNP effect sizes as being likely non-causal.
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FIGURE 3.1: The nonlinear transformation (Equation 3.14) to convert standard BLUP
effect estimates to sparse-model effect estimates. This transformation uses the poste-
rior probability of a SNP being causal given a standard BLUP effect size estimate
(Equation 3.15) to map small effect sizes proportionally closer to zero than large
BLUP effect size estimates. When the prior probability of a SNP being causal or
the proportion of causal SNPs (pc) is 1, this transformation is the identity transform,
as illustrated by the diagonal line with simulated effect sizes indicated with circles
in the figure. The lower the value of pc, the more aggressively the transform shrinks
small standard (infinitessimal) BLUP effect sizes towards zero. The transform can ac-
tually increase the magnitude of large effect estimates to maintain the total estimated
heritability of a set of SNPs.
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3.3.3 Cross-validated and sparsified BLUPs
In linear mixed models, both the estimates of the random effect sizes b̂ and the estimates of the
total random effects on the phenotype scale, Zb̂ are known as BLUPs. The shortcut formula 2.7
used to generate cvBLUPs works on the standard phenotype scale BLUPs Zb̂ to generate a set
of leave-one-out out-of-sample predictions as if each observation i is left out of the effect size
estimation in turn. The BLUP effect estimates b̂(i) are generated in the reduced data set, and the
total genetic effect for the left-out subject is then calculated: Zi,.b̂(i). Using Equation 2.7, the BLUP
effect estimates b̂(i) never have to be explicitly calculated when generating cvBLUPs.
The over-fitting of standard BLUPs Zb̂ as illustrated in Figure 2.1 is due to a conspiracy across
all BLUP effect estimates b̂ to hold too much information about the phenotype y in the data set
used to train the linear mixed model, such that when all random effects are aggregated in Zb̂ there
is a substantial echo of non-genetic contributions to the outcome in the training data set, e in Equa-
tion 3.1. The transformation of the BLUP effect sizes used to simulate sparse mixed model effect
estimates in Equation 3.14 is non-linear and non-uniform across SNPs. In preliminary analyses,
shrunken SNP effect sizes based on these non-affine transformations yield genetic predictions on
the phenotype scale that are less correlated with the unmodeled or environmental factors than
standard BLUPs, but there may still be a substantial correlation.
In order to generate cross-validated predictions (CVPs) from the sparse linear mixed model by
the post-processing of standard linear mixed model effect estimates following Equation 3.14, the
cross-validation scheme has to be run explicitly because the shortcut formula (Equation 2.7) is not
applicable. For a leave-one-out cross-validation scheme this involves generation of N estimates of
BLUP effect sizes in the following scheme:
1. Generate sets standard BLUP effect estimates b̂(i) with each subjects i left out in turn.
2. Transform the BLUPs to yield the sparse effect size estimates of Equation 3.15.
3. Calculate the genetic effect for the left-out subject i: Zi,.b̂(i,sparse)
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Without the benefit of the short-cut formula, cross-validated predictions (CVPs) from sparse
genetic models may be unpractical in application without further reductions in computational
complexity. One possible approach is to calculate the standard BLUP effect estimates and shrink
them in using k-fold cross-validation with k<N. In simulations using sparse CVPs as adjustment
covariates for GWAS, 5-fold cross-validation generally worked about as well as leave-one-out
cross-validation for controlling population structure, with a small or undetectable decrease in
power relative to LOOCV while still having more power than unadjusted GWAS, and more power
than standard cvBLUP adjusted GWAS when the data was simulated using sparse genetic models.
Another approach to speed up applications using sparse CVPs would be to generate the BLUP
effect estimates using recent alternatives to the standard mixed-model calculations as in Equation
3.2. One possibility is calculating the BLUP effect estimates using BOLT [Loh et al. (2015)] or the
efficient conjugate-gradient approach used in BOLT.
3.3.4 Setting or adapting to pc, the fraction of SNPs that are causal in the sparse PRS
model
For the generation of sparse genetic predictions using the transformation of standard BLUPs of
Equation 3.14, pc, the fraction of causal SNPs with non-zero effect sizes for association with a
phenotype has to be specified. This model parameter may be estimated by optimizing for out-of-
sample prediction performance over a grid of values of the fraction causal in the interval (0, 1] or
by a recursive search such as Brent’s method.
In analyses of simulated phenotypes using polygenic scores based on sparsified CVPs Zi,.b̂(i,sparse)
as adjustment covariates for GWAS, cvBLUPs based on the infinitessimal model improved power
better than sparse CVPs when an infinitessimal data generating model was used, and sparse CVPs
imporved power most when a sparse data generating model was used (Section 3.4). Notably, in
simulations, using the true fraction causal pc in the sparsification transformation of Equation 3.14
generally did not yield CVPs that improve GWAS power the best: Often setting pc in [0.05, 0.10]
yielded CVPs that improved power better than pc = 0.02 when the phenotypes were generated
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with 2 percent of SNPs contributing to the trait. But there also wasn’t much difference in the per-
formance of different sparse CVPs as adjustment covariates, so one reasonable implementation
guide would be to not spend effort optimizing pc but rather to either use cvBLUPs, where the
implied pc = 1.0, or reference sparse CVPs, say those generated with pc = 0.05.
We also tried an adaptive method that tunes a set of sparse cross-validated predictions to a
particular data set with the following scheme:
1. Estimate 2 or more sets of cross validated genetic predictions (CVPs) with different settings
of the prior fraction causal parameter pc. In explorations of this approach, these included
standard cvBLUPs (pc = 1.0).
2. Find a linear combination of the CVPs that well approximates the given trait. In prelimi-
nary analyses of this approach, we tried combining sets of CVPs by fitting a linear model
that predicts the "centered phenotypes" (y − Xβ̂ or outcome minus estimated fixed effect
contribution to the phenotype) as a linear combination of the CVPs with different sparsities.
We then got the leave-one-out out-of-sample predictions from this linear model using the
shortcut formula (Equation 2.7).
Results using this approach are shown with the name "combined sparse CVP" in the tables in
of results in Section 3.4 using CVPs with various sparsities as adjustment covariates for GWAS as
in Chapter 2.
3.4 Results of using sparse cross-validated predictions (CVPs) as ad-
justment covariates in simulated GWAS
In this section, I extend the analysis of cvBLUP adjusted GWAS from Section 2.4.3 to include
results of adjusted linear regression analyses where sparse CVPs rather than standard, infinitessi-
mal model cvBLUPs are used as the mixed-model derived adjustment factors. As in Section 2.4.3
the results are for simulated association tests for continuous traits with heritability of h2 = 0.5,
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M = 2000 independent SNPs modeled with random effect sizes, and observations made on
N = 2000 subjects. The SNPs under consideration have minor allele frequencies (MAFs) between
0.05 and 0.5. The tables below (Tables 3.1-3.6) show the mean effect estimates and test statistics
for 1000 Null SNPs and 1000 causal SNPs analyzed by CVP adjusted linear regression, with other
methods used for comparison. These test-SNPs were generated with different MAFs but always
had true effect sizes βg0 = 0 for the Null SNPs and βg = 0.25 for the causal SNPs.
In the tables of results:
• LR represents unadjusted linear regression for marginal analyses of the test-SNPs.
• LMM represents a standard mixed model association test for the fixed-effect effect size of a
test-SNP as implemented in GCTA [Yang et al. (2011)].
• BOLT-INF is the infinitessimal mixed model association test as implemented in BOLT [Loh
et al. (2015)].
• BOLT-LMM is the sparse mixed model association test as implemented in BOLT [Loh et al.
(2015)]. Note that when using the sparse mixed model option in the BOLT software, the
effect estimates for test SNPs reported are calculated under the infintessimal mixed model,
while the test-statistics and p-values are calculated with a sparse prior on the effect size
distribution, and that the fraction of SNPs that are causal is estimated during the model-
fitting procedure.
• LR + sparse CVP 0.02 represents CVP adjusted linear regression where the prior probability
of a SNP being causal, pc in Equations 3.14 and 3.15, is 0.02. Similarly for CVP 0.10 and CVP
0.50.
• LR + combined sparse CVP represents CVP adjusted linear regression where the cross-
validated prediction used is the combined sparse prediction defined in Section 3.3.4 and
built from the standard cvBLUPs and sparse CVPs with pc = 0.02, 0.10, and 0.50.
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Table 3.1 shows results of analyses with an infinitessimal genetic architecture where 2000 inde-
pendent causal SNPs are modeled in the genotype matrix or genetic relatedness matrix (GRM) for
the mixed-model based methods. Also, in the simulations represented in this table, there was no
confounding by population structure. Since there is no population structure, there is no inflation
of test statistics for Null SNPs ( mean χ2Null ≈ 1). All of the methods give unbiased effect estimates
βg0 ≈ 0 and βg ≈ 0.25. And all of the mixed model methods have about the same power, with test
statistics χ2 ≈ 57 for causal SNPs, while unadjusted linear regression give test statistics of only
around 47 for causal SNPs.
Finally LR+Zb represents linear regression with Zb used as an adjustment factor, where Zb is
the true contribution to the phenotype of all causal SNPs other than the independent causal test-
SNPs. In this simulation scenario, including Zb as a covariate accounts for about 50 percent of the
variance in the phenotype and dramatically increases power. In real applications, the true SNP
effect sizes b are not known, so Zb may not be calculated or used as a covariate.
TABLE 3.1: Simulations with infinitesimal genetic model, without population struc-
ture. Mean and standard errors for effect estimates and test statistics of association
tests at 1000 Null SNPs with true βg0: β̂g0 and χ2Null; and at 1000 causal SNPs with
an alternative hypothesis of true βg = 0.25: β̂g and χ2
Model mean(βg0) se(βg0) mean(χ2Null) se(χ
2
Null) mean(βg) se(βg) mean(χ
2) se(χ2)
LR -4.4e-04 0.0013 0.99 0.05 0.250 1e-03 47.11 0.66
LMM -0.0013 0.0011 1.00 0.05 0.249 1e-03 56.62 0.76
BOLT-INF -0.0013 1e-03 1.01 0.05 0.219 1e-03 56.13 0.76
BOLT-LMM -0.0013 1e-03 1.00 0.05 0.219 1e-03 56.04 0.75
LR + cvBLUP -0.0013 0.0011 1.00 0.05 0.249 1e-03 58.53 0.81
LR + sparse CVP:0.02 -0.0013 0.0012 1.00 0.05 0.250 1e-03 57.47 0.79
LR + sparse CVP:0.10 -0.0013 0.0011 1.00 0.05 0.250 1e-03 57.86 0.80
LR + sparse CVP:0.50 -0.0013 0.0011 1.00 0.05 0.249 1e-03 58.47 0.81
LR + combined sparse CVP -0.0013 0.0011 1.00 0.05 0.249 1e-03 58.27 0.81
LR + Zb -0.0001 0.0009 1.04 0.05 0.250 1e-03 96.28 1.26
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Table 3.2 shows the results of analyses as in Table 3.1, but where the data is generated with only
2 percent of the 2000 independent SNPs with randome effect sizes having non-zero effect sizes.
That is, pc = 0.02 in the data generating model. The salient difference with the results in 3.1 is that
when there is a sparse genetic architecture, methods that model the sparsity allow more powerful
association tests for causal SNPs. This is illustrated in the column "mean(χ2), where the mean test
statistic for causal test-SNPs is greater for the spase-methods (BOLT-LMM and LR+sparse CVPs)
than the infinitessimal mixed model based methods (LMM=GCTA, BOLT-INF, LR+cvBLUP).
TABLE 3.2: Simulations with sparse genetic architecture having two percent of SNPs
causal. Mean and standard errors for effect estimates and test statistics of association
tests at 1000 Null SNPs with true βg0: β̂g0 and χ2Null; and at 1000 causal SNPs with
an alternative hypothesis of true βg = 0.25: β̂g and χ2
Model mean(βg0) se(βg0) mean(χ2Null) se(χ
2
Null) mean(βg) se(βg) mean(χ
2) se(χ2)
LR -0.0011 0.0014 1.14 0.05 0.249 1e-03 47.48 0.70
LMM -0.0011 0.0013 1.14 0.05 0.248 1e-03 56.22 0.78
BOLT-INF -9.4e-04 0.0011 1.14 0.05 0.219 1e-03 55.81 0.77
BOLT-LMM -9.4e-04 0.0011 1.09 0.05 0.219 1e-03 80.99 1.05
LR + cvBLUP -0.0011 0.0013 1.14 0.05 0.248 1e-03 58.15 0.83
LR + sparse CVP:0.02 -1.7e-04 0.0013 1.15 0.05 0.250 1e-03 63.22 0.90
LR + sparse CVP:0.10 1.3e-04 0.0012 1.14 0.05 0.249 1e-03 73.16 1.02
LR + sparse CVP:0.50 -6.6e-04 0.0012 1.13 0.05 0.249 1e-03 69.46 0.97
LR + combined sparse CVP -3.8e-04 0.0010 1.11 0.05 0.249 1e-03 84.73 1.15
LR + Zb -6.0e-04 0.0010 1.13 0.05 0.249 1e-03 94.32 1.26
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Table 3.3 shows results for same set of association testing methods applied to simulated data
generated under an infinitessimal model as in Table 3.1, but now in the presence of confounding
by population structure. As in Section 2.4.3, this data with population structure has subjects drawn
from 5 distinct populations with pairwise Fst=0.03 and population-specific MAFs for SNPs drawn
from the Balding-Nickels model [Balding and Nichols (1995)]. The points to note in this table are
that in the presence of confounding by population structure, unadjusted linear regression yields
inflated test statistics (χ2Null = 2.81 for LR), but that all of the mixed-model-based methods controll
for population structure (χ2Null ≈ 1) and have equivalent power (χ2 ≈ 56 for causal SNPs).
TABLE 3.3: Simulations with infinitesimal genetic model and population structure.
Individuals were drawn from five distinct populations having pairwise Fst=0.03.
Unmodeled environmental effects are associated with ancestry and confound asso-
ciation tests. Mean and standard errors for effect estimates and test statistics of asso-
ciation tests at 1000 Null SNPs with true βg0: β̂g0 and χ2Null; and at 1000 causal SNPs
with an alternative hypothesis of true βg = 0.25: β̂g and χ2
Model mean(βg0) se(βg0) mean(χ2Null) se(χ
2
Null) mean(βg) se(βg) mean(χ
2) se(χ2)
LR 0.0022 0.0022 2.81 0.13 0.250 2e-03 47.28 0.92
LMM -1.7e-04 0.0012 0.99 0.05 0.252 1e-03 56.97 0.79
BOLT-INF -1e-04 0.0010 0.97 0.04 0.214 1e-03 54.34 0.76
BOLT-LMM -1e-04 0.0010 0.97 0.04 0.214 1e-03 54.37 0.76
LR + cvBLUP -2.1e-04 0.0011 0.95 0.04 0.242 1e-03 56.53 0.81
LR + sparse CVP:0.02 7.5e-05 0.0012 1.01 0.05 0.243 1e-03 55.76 0.81
LR + sparse CVP:0.10 7.7e-06 0.0012 0.99 0.04 0.243 1e-03 56.07 0.81
LR + sparse CVP:0.50 -1.6e-04 0.0011 0.96 0.04 0.243 1e-03 56.50 0.81
LR + combined sparse CVP -2.3e-04 0.0011 0.95 0.04 0.242 1e-03 56.36 0.81
LR + Zb 0.0022 0.0018 3.55 0.16 0.250 2e-03 89.28 1.56
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Table 3.4 shows results from simulations comparable to Table 3.3 with confounding by popu-
lation structure, but now with a sparse genetic architecture with only 2 percent of the SNPs with
random effect sizes having non-zero realizations of the effect sizes. Here all of the sparse-CVP ad-
justed regression analyses have inflated test statistics for Null test-SNPs (χ2Null >> 1). This illus-
trates a problem that sparse CVP adjusted linear regression shares with Zb-adjusted (true genetic
effect adjusted) regression in the presence of population structure: A sparse genetic prediction
model does not capture the confounding by population structure that cvBLUPs do capture.
TABLE 3.4: Simulations with population structure and a sparse genetic architecture
having two percent of SNPs causal. Individuals were drawn from five distinct pop-
ulations having pairwise Fst=0.03. Unmodeled environmental effects are associated
with ancestry and confound association tests. Mean and standard errors for effect
estimates and test statistics of association tests at 1000 Null SNPs with true βg0: β̂g0
and χ2Null; and at 1000 causal SNPs with an alternative hypothesis of true βg = 0.25:
β̂g and χ2
Model mean(βg0) se(βg0) mean(χ2Null) se(χ
2
Null) mean(βg) se(βg) mean(χ
2) se(χ2)
LR -0.0015 0.0023 2.88 0.14 0.245 2e-03 46.30 0.90
LMM -6.8e-04 0.0012 1.00 0.05 0.247 1e-03 55.22 0.76
BOLT-INF -7.9e-04 0.0010 0.97 0.05 0.211 1e-03 52.78 0.73
BOLT-LMM -7.9e-04 0.0010 1.02 0.05 0.211 1e-03 77.75 1.05
LR + cvBLUP -6.4e-04 0.0011 0.97 0.05 0.238 1e-03 54.76 0.78
LR + sparse CVP:0.02 -2.0e-3 0.0020 3.00 0.15 0.246 2e-03 60.32 1.13
LR + sparse CVP:0.10 -2e-03 0.0018 2.60 0.13 0.245 2e-03 69.53 1.21
LR + sparse CVP:0.50 -1e-03 0.0011 1.07 0.05 0.238 1e-03 65.28 0.93
LR + combined sparse CVP -0.0021 0.0014 1.96 0.09 0.242 1e-03 78.74 1.22
LR + Zb -0.0023 0.0019 3.65 0.17 0.247 2e-03 87.22 1.56
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Table 3.5 shows for simulated GWAS of continuous traits with infinitessimal genetic architec-
ture and confounding by population structure as in Table 3.3, but now 4 genetic principal compo-
nents (left singular vectors of the matrix of 2000 SNPs having random genetic effects in the sim-
ulations) are used as fixed-effect covariates. Now there is no inflation of the test statistics for the
Null test-SNPs (χ2Null ≈ 1) with any of the methods considered, and all of the mixed model based
methods have equivalent power (χ2 ≈ 57), which is greater than the power of the PC-adjusted
linear model (χ2 ≈ 48).
TABLE 3.5: Analyses run using four genetic principal components as fixed effect
covariates. Simulations with infinitesimal genetic model and population structure.
Individuals were drawn from five distinct populations having pairwise Fst=0.03.
Unmodeled environmental effects are associated with ancestry and confound asso-
ciation tests. Mean and standard errors for effect estimates and test statistics of asso-
ciation tests at 1000 Null SNPs with true βg0: β̂g0 and χ2Null; and at 1000 causal SNPs
with an alternative hypothesis of true βg = 0.25: β̂g and χ2
Model mean(βg0) se(βg0) mean(χ2Null) se(χ
2
Null) mean(βg) se(βg) mean(χ
2) se(χ2)
LR -5.1e-04 0.0013 0.96 0.05 0.253 1e-03 47.95 0.71
LMM -1.6e-04 0.0012 1.00 0.05 0.250 1e-03 56.34 0.8
BOLT-INF -8.3e-05 0.0011 1.03 0.05 0.222 1e-03 56.27 0.79
BOLT-LMM -8.3e-05 0.0011 1.02 0.05 0.222 1e-03 56.20 0.80
LR + cvBLUP -1.9e-04 0.0012 1.01 0.05 0.253 1e-03 58.69 0.85
LR + sparse CVP:0.02 -1.1e-04 0.0012 1.01 0.05 0.253 1e-03 57.74 0.84
LR + sparse CVP:0.10 -1.2e-04 0.0012 1.01 0.05 0.253 1e-03 58.10 0.85
LR + sparse CVP:0.50 -1.7e-04 0.0012 1.01 0.05 0.253 1e-03 58.63 0.85
LR + combined sparse CVP -1.3e-04 0.0012 1.00 0.05 0.252 1e-03 58.29 0.85
LR + Zb 4.9e-04 9.2e-04 0.96 0.05 0.252 1e-03 95.0 1.33
Finally, Table 3.6 shows the results of simulated association tests for a continuous trait with
a sparse genetic architecture in the presence of population structure, as in Table 3.4, but now
with 4 genetic principal components as adjustment covariates. With the inclusion of the principal
components, there is no longer inflation of test statistics for Null SNPs when the sparse CVP
factors are used as adjustment covariates. As in the results in Table 3.2, in context of a sparse
genetic architecture, the test-statistics for causal SNPs are substantially greater when using the
methods that model the sparse effect size distribution (including sparse CVP adjustment) than
when using methods based on the infinitessimal model.
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TABLE 3.6: Analyses run using four genetic principal components as fixed effect
covariates. Simulations with a sparse genetic architecture having two percent of
SNPs causal. Individuals were drawn from five distinct populations having pair-
wise Fst=0.03. Unmodeled environmental effects are associated with ancestry and
confound association tests. Mean and standard errors for effect estimates and test
statistics of association tests at 1000 Null SNPs with true βg0: β̂g0 and χ2Null; and at
1000 causal SNPs with an alternative hypothesis of true βg = 0.25: β̂g and χ2
Model mean(βg0) se(βg0) mean(χ2Null) se(χ
2
Null) mean(βg) se(βg) mean(χ
2) se(χ2)
LR -6.2e-04 0.0013 1.01 0.05 0.248 1e-03 46.57 0.66
LMM -1e-03 0.0011 0.99 0.05 0.246 1e-03 54.63 0.73
BOLT-INF -0.0011 0.0010 1.00 0.05 0.219 1e-03 54.60 0.73
BOLT-LMM -0.0011 0.0010 0.95 0.05 0.219 1e-03 79.47 1.03
LR + cvBLUP -1e-03 0.0012 1.00 0.05 0.248 1e-03 56.83 0.78
LR + sparse CVP:0.02 -8e-04 0.0011 0.97 0.05 0.249 1e-03 61.51 0.87
LR + sparse CVP:0.10 -0.0011 0.0010 0.98 0.05 0.249 1e-03 71.32 0.98
LR + sparse CVP:0.50 -0.0012 0.0011 1.00 0.05 0.248 1e-03 67.60 0.92
LR + combined sparse CVP -0.0015 9.7e-04 1.00 0.05 0.249 1e-03 82.57 1.11
LR + Zb -0.0016 9.1e-04 0.97 0.05 0.248 1e-03 91.62 1.22
3.5 Discussion
In this chapter I develop a model that relates standard BLUP effect size estimates to the random
effect size estimates from sparse linear mixed models. This allows generation of sparse effect
size estimates or predictions from sparse models by post-processing the BLUPs from standard
linear mixed models. This may prove to be an efficient alternative to other methods for estimating
realized random effect sizes or making predictions from sparse mixed model methods including
BSLMM [Zhou et al. (2013)], BOLT-LMM [Loh et al. (2015), and LDPred [Vilhjálmsson et al. (2015)].
I present an application of these sparsified cross-validated predictions (CVPs) as adjustment
covariates for association tests. In simulations when the genetic architecture is actually infinites-
simal (non-sparse, normally distributed random effect size distribution), the sparse CVPs are
highly correlated with standard cvBLUPs; and sparse CVP adjustment gives very similar results to
cvBLUP adjustment and standard mixed model association tests as implemented in GCTA. How-
ever, when there is a sparse genetic architecture, the sparse CVPs do not control for confounding
by population structure as do standard cvBLUPs or mixed models. This is because population
structure is encoded in the differences in minor allele frequencies in SNPs across the genome, but
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this signal is not well captured in the reduced set of non-null SNPs emphasized in the sparse
CVPs. In the presence of a sparse architecture, adjustment with sparse CVPs can boost power rel-
ative to cvBLUP adjustment or standard mixed model association tests, but if there is population
structure and a sparse genetic architecture, the CVPs will only yield valid tests if the confound-
ing by population structure is controlled by inclusion of a sufficient number of genetic principal
components as adjustment covariates.
So, while one benefit of using cvBLUPs as adjustment covariates in association studies is that
a single cvBLUP factor effectively substitutes for "just as many PCs as are needed" (see Section
2.6.2), sparse CVPs do not control confounding by population structure and must be used along
with a sufficient set of genetic PCs as covariates for valid association tests. In preliminary analyses,
inclusion of both cvBLUPs and sparse CVPs as covariates in association tests in the context of
a sparse genetic architecture and confounding by population structure did not control the test
statistic inflation due to population structure. It appears that cvBLUPs loose their effectiveness
for controlling confounding by population structure because of high correlation with sparse CVPs
(near collinearity), but exploring and working around this problem is left for future work.
Generally, assuming some level of sparsity gives more powerful tests in adjusted analyses
than cvBLUP adjustment, but pc, the prior probability or assumed fraction of causal SNPs does
not strongly affect the results. In fact, as shown in Table 3.2, the most powerful tests may not even
occur when pc is set to the true fraction causal in the data generating model: In the simulations
summarized in that table, the generating model had a 2 percent fraction of causal SNPs, but CVPs
generated with pc = 0.10 yielded more powerful tests than CVPs generated with pc = 0.02.
Future directions for elaboration of this work include leveraging annotation of genetic variants
such as location in open chromatin or distance from transcription start sites to learn differential
sparsity as a function of those annotations. Another direction to pursue in future work is more ef-
ficient calculation or approximation of effect size estimates when individuals or sets of individuals
are excluded from a data set in a cross-validation scheme.
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3.6 Appendix
3.6.1 Multivariate mixed models and building multivariate conditional predictions
from univariate effect estimates.
In this appendix I derive the relationships between multivariate (multiple-phenotype) BLUPs,
marginal effect estimates, and univariate BLUPs – and then extend the derivation to show the
relationships between the previous cvBLUP and CVP models and multivariate sparse genetic pre-
dictions. Development of applications for these models remains as future work, but these deriva-
tions provide a framework for leveraging genetically correlated phenotypes and sparsity when
developing genetic predictions from various data resources – from GWAS summary statistics to
raw genetic data in multi-phenotype data sets. By leveraging relevant information in correlated
phenotypes and sparsity, more accurate genetic predictions may be developed for use as poly-
genic risk scores or other applications including the prediction-adjusted GWAS of the previous
chapters.
3.6.2 The multivariate infinitessimal model
The multivariate mixed model can be expressed in the same format as the univariate LMM (Equa-
tion 2.3), but with different dimensions implied for the matrices and vectors in the model.
y = Xβ+ Zb + e (3.17)
In the multivariate case, y is an N-by-K matrix of K phenotypes for N subjects; X is an N-by-p
matrix of fixed effect covariates including an intercept term, β is a p-by-K matrix of fixed effect
sizes; Z is the N-by-M matrix of scaled additively coded genotypes as before; b is an M-by-K
matrix of random effects, where each column b.,k is a vector of random effects for the kth trait, as
used in the univariate analyses above; and e is a N-by-K matrix of environmental or unmodeled
contributions to the phenotypes.
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A benefit of this multivariate model over the univariate models is that the columns of β, B and
e may not be assumed to be independent, so information from the whole collection of phenotypes
may be leveraged to improve inference of the effect sizes.
We simplify the presentation by assuming there are no fixed effects and the phenotypes are
centered to have mean values of zero, or equivalently, y←− y− Xβ̂.
Here we assume that the random effects for each SNP in Z are independent but that the
columns are related with the values for a row of b drawn from a normal distribution (Equation
3.18).
cov(bj,.) =
1
M
Σg
=
1
M

σ2g1 ρg12
√
σ2g1σ
2
g2 . . .
ρg12
√
σ2g1σ
2
g2 σ
2
g2 . . .
. . . . . . . . .

(3.18)
Similarly, the environmental contributions to the phenotypes represented in the columns of e
are normally distributed with covariance Σe (Equation 3.19).
cov(ei,.) = Σe
=

σ2e1 ρe12
√
σ2e1σ
2
e2 . . .
ρe12
√
σ2e1σ
2
e2 σ
2
e2 . . .
. . . . . . . . .

(3.19)
If there were no linkage disequilibrium between the SNPs in Z, the covariance of the centered
phenotypes in y would be Σp = Σg + Σe, but because of LD and estimation errors for the variance
components and correlations in these covariance matrices, the empirical correlation of the centered
phenotypes may differ from Σp.
As in the univariate analysis, we consider the relationship between BLUP effect estimates and
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marginal effect estimates as provided by a GWAS. By treating the random effects distribution for
the SNP effect sizes as a prior distribution, and using the normal sampling distribution of marginal
effect estimates to imply the likelihood or contribution of observed data to inference of the SNP
effect sizes, we find a posterior random effect distribution corresponding to multivariate BLUPs,
initially for the case of a single SNP that is independent of other causal SNPs. As before, this is the
starting point for further elaborations.
bj,. ∼ N
(
0,
1
M
Σg
)
(3.20)
(b˜j,.|bj,.) ∼ N
bj,., Σp −
1
M
Σg
N
 (3.21)
Using normal-normal conjugate updates we get the posterior multivariate effect size distribu-
tion given a vector of marginal univariate (GWAS) effect sizes b˜j,.:
(bj,.|b˜j,.) ∼ N
(
E(bj,.|b˜j,.), var(bj,.|b˜j,.)
)
var(bj,.|b˜j,.) =
(
MΣ−1g + N
(
Σp − 1MΣg
)−1)−1
E(bj,.|b˜j,.) = var(bj,.|b˜j,.)
(
N
(
Σp − 1MΣg
)−1) bj,.
=
(
MΣ−1g + N
(
Σp − 1MΣg
)−1)−1 (N (Σp − 1MΣg)−1) bj,.
(3.22)
Without confounding or linkage disequilibrium between causal SNPs, the univariate GWAS
effect estimates b˜j,. are unbiased estimators of the unknown genetic effect sizes bj,., so we consider
an estimator for E(bj,.|b˜j,.) that works as a non-uniform shrink of a vector of GWAS results.
E (bj,.|b˜j,.) ≈
(
MΣ−1g + N
(
Σp − 1MΣg
)−1)−1 (
N
(
Σp − 1MΣg
)−1)
b˜j,. (3.23)
Equation 3.22 shows how the multivariate BLUP effect estimates E (bj,.|b˜j,.) are shrinkage estimates of
the realized effects bj,., but unlike in Equation 3.9 the shrinkage factor is not a constant across all SNPs for
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a particular phenotype. Rather, the shrinkage factor for a particular SNP depends on the realized values of
the genetic effect sizes for that SNP on other, correlated phenotypes. So, for example, if SNP j has a large
effect size but SNP k has a low effect size for phenotype 1, then the BLUP effect estimates for positively
correlated phenotype 2 are expected to be less shrunk for SNP j than for SNP k.
Equation 3.23 shows how multivariate BLUPs relate to marginal GWAS effect estimates. This represents
the regularization or "shrink" of the LMM effect estimates due to an empirical prior on the effect sizes that
is built from the trait heritabilities and their genetic correlations (Equation 3.20). This transformation does
not allow for confounding or bias of the GWAS effect estimates due to other causal SNPs in linkage dise-
quilibrium with the SNP j. To allow generation of multivariate BLUP effect estimates, we adapt Equation
3.23 to build multivariate LMM effect estimates from univariate BLUP effect estimates in Equation 3.24. We
do this heuristically, by:
1. Assuming that the univariate BLUPs have already adequately dealt with linkage disequilibrium in
the joint estimation of effect sizes with Equation 3.2.
2. "Unshrinking" the standardard BLUPs by dividing the BLUP effect size estimates for each phenotype
k by the shrink factor Sk.
3. Applying the multivariate shrink factor to the vector of effect sizes.
mvBLUPj,. =
(
MΣ−1g + N
(
Σp − 1MΣg
)−1)−1(
N
(
Σp − 1MΣg
)−1)
diag(S−11 , . . . , S
−1
k )BLUPj,.
Sk =
h2k
h2k +
M
N
(3.24)
This non-uniform shrinkage result (Equation 3.24) suggests paths for future work with multivariate and
summary statistics methods. In particular, instead of sets of univariate BLUP effect estimates (Equation 3.2)
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being used as for bj,. at the end of the last line of Equation 3.24, we could substitute approximate BLUPs
derived from marginal (GWAS) effect size estimates. Conceptually, these approximate BLUPs could be
generated by left multiplying a vector of marginal effect size estimates for a set of SNPs by the inverse of
the LD or covariance matrix for those SNPs. The method LDPred [ Vilhjálmsson et al. (2015)] can convert a
set of GWAS summary statistics into simulated univariate BLUPs by using the infinitessimal model option.
We could also use mixtures of real and approximate BLUP for different phenotypes in the multivariate
analysis.
3.6.3 The multivariate sparse model
Following the development of the relationship between standard BLUP effect estimates and sparse mixed
model effect estimates in Section 3.3.1, and the multivariate infinitessimal model in Section 3.6.2, we next
develop a relationship between marginal effect estimates for a number of genetically correlated traits and
multivariate mixed model effect estimates at both causal and null SNPs.
We consider a spike-slab mixture prior distribution for the effect sizes, where the effect sizes are multi-
variate normal for causal SNPs and identically zero for null SNPs (Equation 3.25).
bj,. ∼

N
(
0, 1MpcΣg
)
pc
0 1− pc
(3.25)
The sparse prior distribution induces a mixture-of-normals distribution for marginal (GWAS) effect
estimates for a SNP j, initially assumed to be uncorrelated with other causal SNPs (Equation 3.26).
(b˜j,.|bj,.) ∼

N
(
bj,.,
Σp − 1MpcΣg
N
)
pc
N
(
0, 1NΣp
)
1− pc
(3.26)
As in the univariate case, we treat the mixture distributions for the random genetic effects b as priors
and use the sampling distribution of marginal effect estimates for a particular SNP (b˜j,.|bj,.) to imply the
likelihood for the effect size distribution. We combine these terms to find the posterior distribution of the
effect size given the marginal (GWAS) effect estimates, (bj,.|b˜j,.). Also, as in the univariate case, we approach
the expected value of the posterior effect size distribution by first considering the joint posterior distribution
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of the genetic effect size and the causal status (causal or not causal) of a SNP bj,., and then we integrate out
the causal status. Here, we only consider the case when a SNP is causal for all phenotypes or none of the
phenotypes.
E (bj,.|b˜j,.) = E (bj,.|b˜j,., bj,.causal) Pr (bj,.causal|b˜j,.) + E (bj|b˜j, bj,.¬causal) Pr (bj,.¬causal|b̂j,.)
= E (bj,.|b˜j,., bj,.causal) Pr (bj,.causal|b˜j,.) + 0× Pr (bj,.¬causal|b˜j,.)
= E (bj,.|b˜j,., bj,.causal) Pr (bj,.causal|b˜j)
(3.27)
In Equation 3.27 we see that the expected value of the multivariate sparse posterior distribution of
genetic effect sizes given marginal estimates – or the multivariate, sparse analog of BLUPs – factorizes
into the posterior expected value of effect sizes given marginal effect size estimates at causal SNPs (as
in Equation 3.23 ) and the posterior probability of the SNP being causal given the marginal effect size
estimates.
In order to simplify the calculation of a version of these sparse multivariate effect estimates we start
by substituting the simulated multivariate BLUPs based on the posterior expected effect size in the multi-
variate case given univariate BLUP effect size estimates (mvBLUP) for E (bj,.|b˜j,., bj,.causal), as in Equation
3.24. We further simplify the calculation of the posterior expected effect size for the multivariate sparse
model by calculating the posterior probability of being causal given the (simulated) multivariate BLUPs
b̂j,. = (bj,.|b˜j,., bj,.) rather than given the marginal estimates b˜j,.. This mapping from a pair of univariate
BLUP effect size estimates from two genetically correlated traits to a sparse conditional (multivariate) effect
estimate for one of those traits is illustrated in Figure 3.2.
The posterior probability of a SNP being causal is calculated using Bayes rule, Pr (bjcausal) = pc, and
the normal probability densities of the BLUPs in a multivariate analog of Equation 3.15. Here Sk is the
univariate BLUP "shrink" factor for trait k, as in Equation 3.16.
Pr (bjcausal|b̂j) =
P (b̂j|bjcausal) Pr (bjcausal)
P (b̂j|bjcausal) Pr (bjcausal) + P (b̂j|bj¬causal) Pr (bj¬causal)
(3.28)
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P (b̂j,.|bj,.causal) ∼ N
(
b̂j,.; 0,
σ2g
Mpc
+
1
N
(
Σp − diag(S
1
2
k )Σgdiag(S
1
2
k )
))
P (bj,.|bj,.¬causal) ∼ N
(
b̂j,.; 0,
1
N
(
Σp − diag(S
1
2
k )Σgdiag(S
1
2
k )
))
Sk =
h2k
h2k +
M
N
(3.29)
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FIGURE 3.2: The multivariate sparse mapping of standard BLUP effect estimates to
effect estimates from a model with a sparse genetic architecture that leverages mea-
surements of genetically correlated traits. As in the univariate sparse map of Figure
3.1 small effect sizes are mapped proportionally closer to zero than large effect sizes.
However, if a SNP has a small effect size estimate for one trait but a large effect
size estimate for a genetically correlated trait, then the strong shrink towards zero
is suppressed. A strong effect size in a correlated trait is seen as evidence that a
SNP may be causal even if the standard BLUP effect estimate is small. The figure
illustrates the transformation of bivariate, infinitessimal BLUPs for two traits to the
sparse genetic effect estimates for the one of the two traits. The transformation il-
lustrated corresponds to both traits having heritability of 0.5, a genetic correlation of
0.5, no correlation of environmental (non-genetic) contributions to the phenotypes,
and an assumed fraction causal or prior probability of a particular SNP being causal
of pc = 0.2. As in the univariate case (Equation 3.14), the multivariate transforma-
tion corresponds to multiplication of the standard univariate BLUPs for each trait
by their posterior probability of being causal (Equation 3.28) and by a ratio of scal-
ing factors corresponding to the multivariate and univariate shrink factors (Equation
3.27)
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3.6.4 Discussion of the multivariate results
In this appendix I develop a method to generate effect size estimates from multivariate and multivariate-
sparse mixed models by post-processing sets of standard BLUPs from univariate analyses using the stan-
dard (infinetessimal) linear mixed model. While applications of these results are left as future work, I think
the approach may prove useful by showing a way to improve estimates of genetic effect sizes for a trait
of interest by leveraging measurements of additional, genetically correlated traits. With the ongoing trend
toward vast increases in the the numbers of phenotypes available for analysis in genetic studies – from elec-
tronic medical records, massive screens of molecular phenotypes, imaging studies, and elsewhere – even
when the focus of interest is on a single trait, there may be genetically correlated traits or other types of
related measurements to exploit.
Earlier in this chapter I show that BLUP effect size estimates from a linear mixed model are shrunken
towards zero relative to their true realized values or relative to unbiased marginal effect estimates because
of a prior probability distribution on the affect sizes. That idea is extended in this chapter to consider the
effect sizes across a set of phenotypes for a particular genetic marker to be correlated, with a multivariate
prior distribution. The effect of such a multivariate prior is to enforce a non-uniform shrink in a multivariate
mixed model for different genetic effect estimates towards the prior expected value of zero. In particular,
if a SNP has a large effect size in a correlated trait, then shrink of a mixed model estimate relative to a
marginal effect estimate will be less severe than if the genetically correlated trait has a small effect size.
This principle that multivariate mixed model effect estimates will be less shrunk or will have larger
magnitudes when correlated traits have large effect estimates applies whether an infinitessimal or sparse
genetic architecture is assumed, but the influence of correlated traits on effect estimates for a particular trait
is particularly strong with sparse genetic architectures because that whole set of correlated traits is used
to estimate the posterior probability of a SNP being causal, with a non-zero effect size for each trait. This
is illustrated in Figure 3.27, where a standard BLUP for phenotype 1 is post-processed to form a sparse
mixed model effect estimate for phenotype 1 as in the previous chapter. As before, small BLUP effect sizes
are more aggressively shrunk towards zero than large effect sizes, but now even if a BLUP effect estimate
for phenotype 1 is very small, it is not strongly moved towards zero in the transformation if genetically
correlated phenotype 2 has a large effect estimate. This is important because under the working assumption
that causal SNPs have normally distributed effect sizes, the mode of the effect size distribution for causal
SNPs is at zero and many causal SNPs have small univariate effect estimates. The multivariate effect size
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post-processing developed in this chapter keeps relatively large effect estimates for the small effect size
estimates of SNPs that have evidence of causality in related traits. This has promise as an effective way to
use multiple phenotype measurements to improve genetic predictions and polygenic risk scores.
The method presented here builds multivariate and multivariate-sparse effect estimates and predic-
tions from univariate BLUPs. The method could actually start with GWAS summary statistics (univariate
marginal effect estimates) by first running the infinitessimal model (non-sparse) version of LDPred [Vil-
hjálmsson et al. (2015)] to yield approximate BLUP effect size estimates. Then, further processing sets of
BLUPs, approximate BLUPs from summary statistics, or a combination of real and approximate BLUPs
for a set of correlated traits using the approaches developed here to improve the genetic effect estimates,
genetic predictions, and polygenic risk scores.
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Chapter 4
GBAT: a gene-based association test for
robust detection of trans-gene regulation
†
4.1 Abstract
The observation that disease associated genetic variants typically reside outside of exons has inspired
widespread investigation into the genetic basis of transcriptional regulation. While associations between
mRNA abundance of a gene and its proximal SNPs (cis-eQTLs) are now readily identified, identification
of distal associations (trans-eQTLs) has been limited by a heavy multiple testing burden, read-mapping
issues, and confounders. Here we develop a method, GBAT, that detects trans gene regulation via gene-
based tests of association. GBAT first predicts each gene’s expression levels from cis-genetic variation and
then tests for association between the predicted expression and the measured expression of genes in trans.
We implement our approach in a pipeline that accounts for read-mapping issues and apply it to detect trans
gene regulation in the Depression Genes and Networks cohort (DGN) RNAseq dataset (N=913). We iden-
tified 411 statistically significant trans associations involving 157 unique regulators and 319 trans-eGenes
†A manuscript related to this chapter is available at bioRχiv . doi: https://doi.org/10.1101/395970. Xuanyao Liu*,
Joel A Mefford*, Andrew Dahl, Meena Subramaniam, Alexis Battle, Alkes L Price, Noah Zaitlen. GBAT: a gene-based
association test for robust detection of trans-gene regulation.
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at 10% FDR. We found the regulators are highly enriched for transcription regulation activity (Benjamini-
Hochberg (BH) FDR = 5.3× 10−4) and identified several master regulators that are functionally important
in blood. We have implemented our approach for Gene-Based Association test for Trans gene regulation
in a software pipeline GBAT. We applied GBAT to a whole blood RNA sequencing dataset, the Depression
Genes and Networks cohort (DGN, N=913) and found 411 significant trans gene-gene association signals
at 10% FDR. We found that trans regulators are enriched in transcription factor activities, and identified
several functionally important master regulators.
4.2 Introduction
The vast majority of genetic variants associated with complex traits are found in non-coding regions of
the genome [Maurano et al. (2012)], leading to a natural hypothesis that their effects are mediated through
changes in transcriptional regulation. For computational and statistical reasons, efforts to date have fo-
cused on mapping cis-genetic effects on gene expression despite the fact trans effects explain more than
twice the variability in gene expression than cis effects [Price et al. (2011); Grundberg et al. (2012)]. Further-
more, while cis-genetic effects are widely shared across cell types[Consortium et al. (2015); Liu et al. (2017)],
disease outcomes frequently result from disregulation of genes in specific cell types [Finucane et al. (2015);
Trynka et al. (2013); Pickrell (2014); Farh et al. (2015); Calderon et al. (2017)]. In contrast, trans-genetic effects
are more cell-type-specific [Liu et al. (2017); Franzén et al. (2016)], and may therefore harbor disease-causing
variants not captured in cis analyses [Sun et al. (2018)].
Robust discovery of trans-eQTLs is very challenging for several reasons. First, trans effects are typ-
ically much smaller than cis effects and thus hard to detect [Westra et al. (2013)]. Second, genome-wide
scans for trans-eQTLs suffer from heavy burden of multiple testing [Grundberg et al. (2012); Westra et al.
(2013)]: a genome-wide trans eQTL test of over twenty thousand genes and one million SNPs results in
Bonferroni threshold of 2.5× 10−12. Third, sequencing reads mapping errors, such as multi-mapped reads
and reads from repetitive regions, lead to many false trans signals [Battle et al. (2014)]. Fourth, the use of
dimensionality reduction techniques to estimate confounding effects, such as PEER [Stegle et al. (2012)] or
SVA [Leek and Storey (2007)], can also be problematic in trans-eQTL studies. The use of dimensionality re-
duction techniques to estimate confounding effects successfully capture confounding factors and improve
association power in cis-eQTL mapping, but their naïve use in trans-eQTL studies can both reduce power
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[Kang et al. (2008); Joo et al. (2014)] and introduce false positives in trans-eQTL studies due to collider ef-
fects [Dahl et al. (2019)]. Indeed, PEER, SVA, and related papers have consistently recommended careful
fitting of covariates for detecting trans effects via supervised approaches conditioning on the SNP or gene
of interest. Unfortunately, per-SNP supervision is computationally infeasible in genome-side trans-eQTL
scans and is ignored in practice.
Here we address these issues through a new gene-based method for detecting trans-effects. Our ap-
proach is similar to recent gene-based GWAS approaches (TWAS and PrediXcan) that have proven success-
ful in the context of complex phenotypes [Gamazon et al. (2015); Gusev et al. (2016); Barbeira et al. (2018)].
Briefly, instead of testing for association between all SNP-trans gene pairs, we build cross-validated cis-
genetic predictions (CVGP) of each gene’s expression and test for association between all CVGP-trans gene
pairs. This reduces the number of tests by at least two orders of magnitude, substantially improving power
to detect trans-genetics effects that act through cis effects on a gene. Importantly, we carefully consid-
ered many possible sources of power loss and false positives in detecting trans signals and made efforts
to address these by using a rigorous read mapping pipeline and proper use of dimensionality reduction
approaches.
We have implemented our approach for Gene-Based Association test for Trans gene regulation in a
software pipeline GBAT. We applied GBAT to a whole blood RNA sequencing dataset, the Depression
Genes and Networks cohort (DGN, N=913) and found 411 significant trans gene-gene association signals
at 10% FDR. We found that trans regulators are enriched in transcription factor activities, and identified
several functionally important master regulators.
4.3 Materials and Method
4.3.1 GBAT methods
GBAT is a gene-based pipeline for detecting trans gene regulation signals and consists of three main steps
(Figure 4.1). First, to reduce the number of false positives due to mapping biases, GBAT filters out reads
that are multi-mapped [Consortium et al. (2017)]. We further discarded reads with > 2 mismatches. In
addition, GBAT further removes problematic mapped reads that are not marked as “multi-mapped” by
RNA-seq alignment algorithms by discarding reads that are mapped to repeat regions, marked by genomic
regions with low mappability. We downloaded the mappability of 36 k-mer of the reference human genome
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computed by the ENCODE project [Consortium et al. (2004)]. We define genomic regions with mappability
score <1 (i.e. 36 k-mers that could be mapped to two or more different genomic regions) as low mappability
regions.
Second, GBAT uses cvBLUP, a novel method to produce predictions of gene expression from SNPs cis
to each gene. The cross-validated prediction by cvBLUP is a cross validated version of a standard linear
mixed model (LMM) prediction, or best linear unbiased predictor (BLUP). We consider an LMM as below:
y = Xβ+ Zb + e, (4.1)
where y is the phenotype, in particular the expression of gene, measured on N individuals. X is a
matrix of covariates, including an intercept. Z is a standardized N × M matrix of M SNPs within the
cis region of the gene. b is the vector of effect sizes for the SNPs in Z, modeled as normally distributed
by b ∼ N
(
0, (σ2g)/MIN
)
. The total cis-genetic contribution to the phenotype is then the product Zb, with
distribution Zb ∼ N
(
0, σ2g K
)
, where K is the genetic relationship matrix defined as K = (ZZT)/M. Finally,
e is a vector of non-genetic effects, modeled as e ∼ N(0, σ2e IN). Phenotype y therefore has the distribution:
y ∼ N(Xβ, V), with V = σ2g K + σ2e IN . We use standard REML to get estimates of the LMM variance
components, σ̂2g and σ̂2e . The estimate of the narrow sense heritability h2g is then the ratio of estimated
genetic variance to total variance: ĥ2g =
hˆ2g
hˆ2g + ĥ2e
.
Finally, we test the association of each CVGPi with quantile normalized expression levels Ej of every
trans gene j (at least 1Mb away from gene i). Cis-eQTL studies typically include covariates such as PEER
factors or surrogate variables from SVA that are intended to model confounders [Stegle et al. (2012); Leek
and Storey (2007); Kang et al. (2008); Joo et al. (2014)]. To prevent false positives [Westra et al. (2013)] and
power loss in trans-eQTL studies [Franzén et al. (2016)], the use of supervised versions of PEER and SVA
is recommended [Westra et al. (2013); Dahl et al. (2019)]. Therefore, for each CVGPi, we run supervised
SVA conditional on CVGPi, such that the resulting surrogate variables SVi do not include the genetic effects
of gene i. We then use SVi as covariates. While including conditional SVs as covariate is computationally
efficient in our gene-based approach, it is infeasible in SNP-based trans-association testing.
In addition, GBAT regresses Ej on SVi and uses the quantile normalized residuals Ej’ for gene-based
testing using the regression: E′j ∼ CVGPi. We found that the p-values from model E′j ∼ CVGPi are well
calibrated (Figure 4.2). Skipping the normalization caused false positive inflation, as did using the models:
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Ej ∼ CVGPi + SVi or Ej ∼ CVGPi + SV (where SV is the naïve SVA not conditioning on CVGPi, Figure 4.2)).
FIGURE 4.1: Schematic of the GBAT pipeline. First, GBAT discards reads that are
mapped to homologous sequences in the genome in order to prevent false posi-
tives in trans association mapping. Discarded reads include multi-mapped reads
and reads that are mapped to regions of low mappability. After expression quan-
tification, GBAT predicts the the expression levels from cis genetic variants (cross-
validated cis-genetic prediction of gene i (CVGPi)) using cvBLUP. Lastly, GBAT per-
forms gene-based association tests between CVGPi and expression level of gene i to
identify gene-based trans association, while properly includes supervised SVA con-
ditional on each CVGPi (SVi) as covariates.
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FIGURE 4.2: Inflation of summary statistics in trans association testing of truly null-
pvalues obtained by permutation. We demonstrated this in a smaller DGN dataset
(N=150, out of computational consideration). In models: E′j ∼ CVGPi, Ej ∼ CVGPi
+ SVi or Ej ∼ CVGPi + SV, we permuted the sample IDs of CVGPi. Association
testing was performed on all trans gene pairs. The null summary association p-
values were obtained from all models, and we observe inflations of null p-values
when we skip the normalization (Figure 4.2a and ??)b. Therefore, using either model
in trans analysis will lead to more false positives. We found that the p-values from
model E′j ∼ CVGPi are well calibrated (Figure 4.2c). (A) The quantile-quantile (Q-
Q) plot of p-values in regression: Ej ∼ CVGPi + SVi, where SVi is the top 20 SVs
conditional on CVGPi. (B) The p-values in regression: Ej ∼ CVGPi + SV, where SV
is the top 20 SVs without conditioning on CVGPi. (C) The Q-Q plot of p-valus in
regression: E′j ∼ CVGPi , where E′j is the quantile normalized residuals of Ej ∼ SVi.
4.3.2 Simulations to assess the power of GBAT
We performed simulations to assess the power of gene-based approach (GBAT) for detecting trans effects,
in comparison to SNP-based approach. We used real imputed genotypes from DGN (sample size N=913)
and simulated a causal SNP→ cis-expression→ trans-expression model with realistic effect-sizes. To simu-
late the causal relationship of SNP→ cis-expression, we randomly chose a gene on chromosome 2 to 22 and
simulated the cis-expression by using a mixed linear model: Ecis = Xβ+ e, such that β ∼ N
(
0, (σ2cis)/Mp
)
for p and β = 0 for 1-p. Here M is the total number of SNPs in the cis region of the gene, and p is the propor-
tion of causal SNPs. We assumed scaled phenotypes with variance=1 and a range of cis-heritability (σ2cis)
(0.02-0.5, the average cis-heritability in DGN is 0.11). We then randomly chose a trans gene on chromosome
1 and simulated the causal relationship of cis-expression (Ecis)→ trans-expression (Etrans) with a range of
trans effects, measured by the percentage of variance of E_trans explained by Ecis (i.e. the trans-heritability,
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ranging from 0.02-0.5). To better reflect the imperfect genotyping of the individuals, we assumed that only
10% of the SNPs are genotyped, such that not all causal SNPs are observed. We simulated under different
genetic architectures (proportion of causal SNPs p = 0.1%, 1% and 10%) and sample sizes (N=200,400,600
and 913). To assess the power of GBAT, we applied cvBLUP to the “genotyped” SNPs to estimate CVGP
of Ecis. We then tested association between Etrans and CVGP of Ecis, while correcting for SVs supervised
on the CVGP. To assess the power of SNP-based approach, we tested association between Etrans and all
“genotyped” SNPs. We measured the power of both strategies to identify significant trans associations
(accounting for 1 million × 15000 SNPs-gene pairs for SNP-based approach and 5,000 (highly heritable
gene) × 15,000 gene-gene pairs for the GBAT approach, using Bonferroni correction), out of a total of 500
simulations.
4.3.3 Genotype and RNA-seq QC
Genotypes of DGN samples were genotyped on the Illumina HumanOmni 1-Quad BeadChip26. 922 sam-
ples have RNA-seq data available. We further removed related individuals and were left with 913 individ-
uals. We imputed the genotypes on the Michigan Imputation Sever (see URLs). We kept only SNPs with
genotyping rate > 99%, minor allele frequency > 5% and Hardy-Weinberg equilibrium < 10−6 using PLINK
2.0.
RNA-seq reads were mapped to the reference genome (NCBI v37) by TopHat in [Battle et al. (2014)]. We
further discarded reads that are mapped to multiple locations and reads with > 2 mismatches. Next, we re-
moved genomic regions with low mappability. We quantified expression with HTseq [Anders et al. (2015)].
Expression levels of 13,634 genes with at least 1CPM in at least 50% of the individuals were quantified.
Finally, expression levels of these genes are quantified as Reads Per Kilobase Million (RPKM).
4.3.4 SNP-based trans-eQTL mapping in DGN using Matrix eQTL
Matrix eQTL [Shabalin (2012)] was used to test association between all 13,447 genes used in gene-based
testing (after removing pseudogenes) and all imputed variants (MAF>5%) on different chromosomes of the
tested gene with an additive linear model. We included all biological and technical covariates (including
expression PCs, genetic PCs, cell type proportions etc.) available from [Battle et al. (2014)]. The correlation
between variant and gene expression levels was evaluated using the estimated t-statistic from this model.
We computed gene-level empirical FDR by first get the most extreme p-value per gene. Then, we permuted
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the samples labels of the expression levels, and further permuted gene labels within each sample. We
repeated the association tests for each permutated expression level and inter-chromosomal variants. We
took the most extreme p-value of each gene after the permutation and used it as the empirical NULL p-
values to compute empirical gene-level FDR. We set an FDR threshold of 10%.
4.3.5 Heritability enrichment analysis of regulators and trans targets in autoimmune
diseases
We estimated heritability enrichment of regulators and trans targets in 5 autoimmune diseases (lupus,
ulcerative colitis, Crohn’s disease, inflammatory bowel disease (IBD), rheumatoid arthritis) and 2 non-
autoimmune diseases (Alzheimer’s disease and schizophrenia). Summary association statistics of the 7
traits are publicly available from [Bentham et al. (2015); Jostins et al. (2012); Okada et al. (2014); Ripke et al.
(2014); Lambert et al. (2013)]. We created annotations from regulator and trans target genes by adding
100Kb buffers to both sides of each gene. Heritability enrichment was estimated by using stratified LDSC
[Finucane et al. (2015)] on the baseline 2.0 annotations and the new annotations.
4.4 Results
4.4.1 Assessing power of GBAT through simulations
We performed simulations to assess the power of gene-based approach (GBAT) for detecting trans effects,
in comparison to SNP-based approach. Using real genotypes from DGN, we simulated a causal SNP →
cis-expressiontrans-expression model with realistic effect-sizes (see Material and Methods). We measured
the power of both SNP-based and gene-based strategies to identify significant trans associations (account-
ing for 1 million × 15,000 SNPs-gene pairs for SNP-based approach and 5,000 (highly heritable gene) ×
15,000 gene-gene pairs for the GBAT approach, using Bonferroni correction). Across various genetic archi-
tectures of gene expression (proportion of causal SNPs p= 0.1%, 1% and 10%), different sample sizes (N =
100,200,400 and 913) and several combinations of cis- and trans- effects, we observed that the power of the
GBAT approach is substantially higher compared to the SNP-based method (Figure 4.3, Figure 4.4).
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FIGURE 4.3: Power of the GBAT approach. We simulated a causal SNP → cis-
expression → trans-expression model. The cis-heritability was set to 0.2 and the
trans-heritability was set to 0.1. Bonferroni correction was used to assess power (ac-
counting for 1 million × 15000 SNPs-gene pairs for SNP-based approach and 5,000
(highly heritable gene) × 15,000 gene-gene pairs). Power was computed as the frac-
tion of 500 simulations where significant association was identified. Colors represent
different methods.
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FIGURE 4.4: Power of the GBAT approach in simulations. We simulated realistic
cis and trans effects. The cis-heritability was set to 0.2 and the trans-heritability
was set to 0.1. Bonferroni correction was used to assess power (accounting for 1
million × 15,000 SNPs-gene pairs for SNP-based approach and 5,000 (highly heri-
table gene) × 15,000 gene-gene pairs). Power was computed as the fraction of 500
simulations where significant association was identified. Colors of points represent
different methods.
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4.4.2 GBAT efficiently identifies trans gene regulation signals in DGN
We next applied GBAT to the DGN dataset to detect trans- gene regulation signal from real expression
phenotypes in whole blood. After QC (see Material and Methods) and removing pseudogenes, expression
of 13,447 genes remained. We built cross-validated cis-genetic predictions (CVGP) each gene using cvBLUP
with variants within 100kb of the transcription start site. Prediction accuracy was assessed using squared
correlation (prediction R2) between observed and predicted expression levels. The average R2 is 0.08 across
all genes and the average cis SNP heritability (h2g) estimated by restricted maximum likelihood (REML) is
0.11 (Figure 4.5A). On average across all genes, the prediction R2 is 85% of the cis SNP heritability (h2g)
estimated by restricted maximum likelihood (REML) (Figure 4.5B). We note our prediction accuracy is
comparable to prediction methods modeling the sparse genetic architecture of cis- gene regulations (Figure
3 of [Gamazon et al. (2015)] and Figure 4 of [Gusev et al. (2016)]).
FIGURE 4.5: Prediction R2 by cvBLUPs in DGN. (A) Histogram of cis-h2g (above) and
prediction R2 (bottom). (B) Comparison of prediction R2 to cis-h2g. Grey dots denote
cis-h2g estimated by REML. Pink dots are the prediction R2 of each gene. Red dots
denote the mean prediction R2 for each bin of 50 genes.
We then tested each CVGP passing QC and with prediction R2>0.014 (p value < 2× 10−4, 5685 genes re-
maining) for association with all genes in trans (at least >1Mb away) that passed our QC (pseudogenes are
removed prior to the tests). We computed q-values [Storey and Tibshirani (2003)] from the p-values of all
inter-chromosomal gene pairs, and applied the threshold to all inter-chromosomal and intra-chromosomal
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gene pairs. We identified 437 trans signals at 10% FDR. We further removed 26 gene pairs that are cross-
mappable due to sequence similarity in the gene pairs [Battle et al. (2014); Saha et al. (2017)]. The final trans
gene regulation signal consists of 411 trans gene pairs and 157 unique regulators (Figure 4.6, Table 4.1).
Among the 411 trans gene pairs, 290 (70.6%) are inter-chromosomal (corresponding to 253 unique inter-
chromosomal trans-eGenes), and 121(29.4%) are intra-chromosomal (corresponding to 94 unique intra-
chromosomal trans-eGenes). In contrast, SNP-based eQTL mapping with Matrix eQTL23 identified only 90
inter-chromosomal trans-eGenes at 10% FDR in DGN (see Material and Methods, Table 4.2). Gene Ontol-
ogy enrichment analysis by the Database for Annotation, Visualization and Integrated Discovery (DAVID
v6.8) [Huang et al. (2008a)] showed that the top two enriched categories of the 157 trans regulators are
DNA binding (Benjamini-Hochberg (BH) FDR = 1.7× 10−4) and transcription factor activity (BH FDR =
5.3× 10−4,Table 4.3). We looked at heritability enrichment of regulators and trans target genes in autoim-
mune diseases and non-autoimmune diseases by using stratified LDSC [Finucane et al. (2015)] (see Material
and Methods). The annotation sizes of regulators are too small to have significant estimates for most traits.
However, both trans targets and trans targets + regulators showed significant enrichment of heritability in
autoimmune diseases including lupus, ulcerative colitis, Crohn’s disease and inflammatory bowel disease
(Figure 4.7). No enrichment was observed for non-autoimmune diseases.
To test for false positives, we split the DGN samples into two random non-overlapping subsets to
quantify the number of trans signals that replicate across the subsets. Treating the first split as the discovery
set, 35 out of 59 trans signals replicated. Since conditional SVA may not completely control false positives,
we reran all discovered associations with unsupervised SVA (without conditioning on the tested gene) and
without SVA covariates. The former recovered 99% (407/411) of trans signals; the latter recovered 27%
(109/411) trans signals, demonstrating that SVA correction can increase power [Dahl et al. (2019)].
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FIGURE 4.6: Trans gene regulation signal in DGN. X-axis are the regulators, and Y-
axis are the trans target genes whose expression is regulated by the regulators. The
size of the dots denote significance of trans association (-log10(p-value)). Color of
the dots denotes sign of effects.The dashed orange line is the x=y line.
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FIGURE 4.7: Heritability enrichment of trans gene regulators and target genes from
DGN in autoimmune diseases and non-autoimmune diseases. Heritability enrich-
ments were estimated by using stratified LDSC [Finucane et al. (2015)] on LDSC
baseline V2.0 annotation and three trans signal annotations. The three trans signal
annotations were created by adding 100Kb buffer regions to the regulator genes,
target genes and the combined regulator and target gene regions. Publicly available
summary association statistics of the 5 autoimmune diseases and 2 non-autoimmune
diseases are obtained from [Bentham et al. (2015); Jostins et al. (2012); Okada et al.
(2014); Ripke et al. (2014); Lambert et al. (2013)]
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4.4.3 Powerful detection of trans signals identifies master regulators
Among the 411 significant trans signals detected in DGN, we found 157 unique trans regulators. 20 regu-
lators were found to regulate more than 3 genes (Table 4.4), supporting the existence of master regulators.
For example, we identified NFKBIA (NF-Kappa-B Inhibitor Alpha) as a master regulator that regulates ex-
pression of four other genes in trans; two of which: NFKB2 and RELB, encode subunits of the NF-kappa-B
complex (Figure 4.8A). Consistent with the inhibiting effect of NFKBIA on NF-kappa-B subunits, our es-
timated effect sizes effect size on NFKB2 and RELB are both negative (NFKB2 β = −0.19, P=1.0× 10−08;
RELB β = −0.17, P = 2.4× 10−07).
We found that PLAGL1, a known transcription factor, regulates expressions of 21 other genes in the
DGN dataset (Figure 4.8B). PLAGL1 encodes a zinc-finger transcription factor that was previously shown
to be a master regulator of the imprinted gene network in mice and human [Iglesias-Platas et al. (2014);
Varrault et al. (2017)]. Over expression of PLAGL1 is associated with Transient Neonatal Diabetes Mellitus
and embryonic growth restriction [Iglesias-Platas et al. (2014)].
We also identified a master regulator encoded by SRCAP on chromosome 16 that regulates 88 other
genes (81 are inter-chromosomal signals, Figure 4.8C). SRCAP, short for Snf2 Related CREBBP Activator
Protein, encodes the core catalytic component of a chromatin-remodeling complex. SRCAP is known to
activate the expression of CREBBP, consistent with our positive estimated effect in the DGN dataset (β =
0.25; P = 1.3× 10−14). The SRCAP complex was shown to regulate key lymphoid fate in haematopoietic
system by remodeling chromatin and enhancing promoter accessibility of target genes38. In the DGN
dataset, the expression level of SRCAP is highly correlated with natural killer cell proportion (Pearson
correlation = 0.21, P = 7.9× 10−11) and T cell proportions (Pearson correlation=-0.15, P = 4.0× 10−06).
Remarkably, we found that 19 SRCAP target genes (out of 88 genes, 2.9 fold enrichment, Fisher’s test)
overlap with genes associated with blood cell type proportions (Table 4.5) from the GWAS catalog [Welter
et al. (2013)]. Our discovery highlights the gene co-expression network driven by SRCAP (Figure 4.3E)
is relevant to haematopoiesis and immune cell type proportions, and suggests that SRCAP is a master
regulator that controls lineage commitment during haematopoiesis.
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FIGURE 4.8: Directed gene network built on significant trans signal in DGN for mas-
ter regulators NFKBIA, PLAGL1 and SRCAP. Orange nodes denote regulators. Yel-
low nodes are trans-genes. Arrows point from regulators to trans-genes.
4.4.4 Missing steps in the GBAT pipeline results in false positives and loss of power
The GBAT pipeline was carefully designed to reduce false positives in detecting trans signals; failing to
properly perform the recommended steps may lead to an increase in false positives or loss of power. We
first looked at the effect of not thoroughly addressing issues in reads mapping. In a subset of DGN samples
(N=150, we used a smaller sample size for computational efficiency), we used GBAT to identify 10 trans sig-
nals at 10% FDR. In parallel, we performed an incomplete read removal by discarding only multi-mapped
reads, but not reads mapped to low mappability regions. This resulted in 32 trans signals (220% as many).
Most additional signals are likely to be false positives, as only 16 trans signal remained after removing gene
pairs that are cross-mappable due to sequence similarity.
We next tested the effect of using regression model Ej ∼ CVGPi + SVi, which we showed to suffer false
positive inflation issues (Figure 4.2), rather than our GBAT model of E′j ∼ CVGPi (see Material and Meth-
ods). In the complete DGN dataset (N=913), we found 571 trans signals at 10% FDR with regression model
E′j ∼ CVGPi + SVi, which is 39% more than the original 411 signals that we had originally obtained. We also
tested the effect of using the unsupervised SVA, which was shown to reduce power and introduce spurious
associations19. While it is hard to assess false positives, 384 signals were detected with unsupervised SVA
(without conditioning on the tested gene), indicating a slight loss of power.
100
4.5 Discussion
GBAT significantly improves power and computational efficiency for detecting trans gene regulatory sig-
nals using a gene-based approach. It minimizes detection of false trans signal by: first, thoroughly remov-
ing erroneously mapped reads that lead to artificial trans signals; second, utilizing supervised dimension
reduction to reduce false trans signals due to collider effects; third, correcting for a new source of inflation
in association statistics when covariates are used. The pipeline integrated cvBLUP to efficiently build cross-
validated cis-genetics expression levels. It allows training and predicting expression levels in the same
dataset without overfitting, and reduces data harmonization issues when external training dataset with the
proper population structure background or cell types are lacking. Other genetic prediction methods can
be used in place of cvBLUP when proper external training datasets are available. We note that though cis
effects are largely shared across different tissues [Consortium et al. (2015); Liu et al. (2017)], the cis effects
that are tissue specific could lead to false inference of trans effects (e.g. wrong sign of effect) or loss of power
(Figure 4.9).
Our pipeline has several limitations. First, mapping issues are not perfectly solved and this could still
lead to artificial trans signals. Our pipeline further incorporated post hoc removal of gene pairs that are
cross-mappable and minimize artificial trans signals. Therefore, vigorous removal of read mapping bi-
ases and carefully examining the cross mappability of trans signal are both critical to obtaining robust trans
signal. Second, batch effects and other confounders may not be sufficiently removed by relying on only sur-
rogate variables and PEER factors. We recommend further including biological and technical confounders
that are specific to the dataset, in addition supervised SVs or PEER factors, in order to thoroughly remove
confounding effects. Third, we used the infinitesimal model of cvBLUP for predicting gene expression. The
genetic architecture of cis gene regulation was shown to be sparse, but our analysis in DGN demonstrated
cvBLUP achieved comparable accuracy in comparison to models incorporating sparsity. Sparse models of
cvBLUP (which are available) may further improve power. Fourth, trans-eQTLs affecting the expression
of trans genes that are independent of cis expression will not be detected by GBAT. Fifth, we note that
gene-based associations do not infer causality in either disease or trans gene regulation settings.
GBAT can be used to detect other trans gene regulatory events, such as splicing, methylation, pro-
tein regulation or gene network response to stimulus. As larger studies become available for increasingly
diverse populations, tissues, and functional genomic measurements, we foresee more trans regulation dis-
coveries will reveal new disease genes and mechanisms.
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FIGURE 4.9: Consequences of non-shared cis effect in external training data on de-
tecting trans signals in the testing dataset. We list two scenarios under which non-
shared cis effects in the training dataset could lead to loss of power or wrong infer-
ence of trans effect size.
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TABLE 4.1: 411 trans signal in DGN detected by GBAT at 10% FDR.
Regulator Chr Trans target Chr P value
1 SNRNP48 chr6 GCNT2 chr6 1.98E-141
2 HCG27 chr6 HLA-G chr6 1.14E-47
3 SRCAP chr16 ZZEF1 chr17 1.25E-32
4 KCTD7 chr7 ERV3-1 chr7 1.82E-30
5 SRCAP chr16 SRRM2 chr16 1.60E-27
6 PKNOX1 chr21 ZNF687 chr1 7.90E-27
7 CD83 chr6 JARID2 chr6 4.70E-26
8 SRCAP chr16 KDM2A chr11 4.95E-26
9 PRDM4 chr12 AVIL chr12 1.28E-24
10 ZSCAN22 chr19 DSE chr6 2.01E-24
11 CBS chr21 ZNF687 chr1 1.10E-23
12 PWP1 chr12 AVIL chr12 1.79E-22
13 SRCAP chr16 NCOR2 chr12 5.74E-22
14 SRCAP chr16 ANKRD52 chr12 9.48E-22
15 PLAGL1 chr6 PAQR7 chr1 4.39E-21
16 NLRC5 chr16 BTN3A1 chr6 2.28E-19
17 SRCAP chr16 TNRC18 chr7 4.30E-19
18 SKIV2L chr6 HLA-G chr6 5.21E-19
19 NLRC5 chr16 HCP5 chr6 7.56E-19
20 U2AF1 chr21 ZNF687 chr1 1.10E-18
21 SRCAP chr16 ZNF592 chr15 1.22E-18
22 ZKSCAN4 chr6 IER3 chr6 1.39E-18
23 SRCAP chr16 EP300 chr22 2.15E-18
24 GRM2 chr3 MAPKAPK3 chr3 2.81E-18
25 SRCAP chr16 SPEN chr1 3.05E-18
26 SRCAP chr16 KMT2D chr12 3.14E-18
27 PLAGL1 chr6 MAPKAPK3 chr3 3.85E-18
28 PLAGL1 chr6 VAV1 chr19 9.40E-18
29 MEIS1 chr2 WDR92 chr2 2.07E-17
30 PGBD1 chr6 HLA-A chr6 3.80E-17
31 PLAGL1 chr6 IDI1 chr10 9.21E-17
32 DDAH2 chr6 HLA-DQB2 chr6 1.37E-16
33 CETP chr16 BTN3A1 chr6 1.96E-16
34 ZNF75A chr16 ZNF230 chr19 2.85E-16
35 SRCAP chr16 ANKRD11 chr16 3.37E-16
36 ZSCAN16 chr6 IER3 chr6 4.22E-16
37 SRCAP chr16 PRRC2B chr9 5.93E-16
38 PLAGL1 chr6 RGL4 chr22 6.32E-16
39 FBXO31 chr16 MAP1LC3B2 chr12 6.87E-16
40 CBS chr21 DUSP13 chr10 9.63E-16
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Table 4.1, continued.
Regulator Chr Trans target Chr P value
41 CELSR3 chr3 RBM6 chr3 1.81E-15
42 SRCAP chr16 PRRC2A chr6 2.02E-15
43 PLAGL1 chr6 TTC9 chr14 2.52E-15
44 ZKSCAN4 chr6 VARS2 chr6 6.23E-15
45 SRCAP chr16 CREBBP chr16 1.26E-14
46 SRCAP chr16 KMT2B chr19 1.26E-14
47 HLA-B chr6 HLA-G chr6 1.62E-14
48 SRCAP chr16 SETD1B chr12 1.86E-14
49 ZKSCAN4 chr6 TRIM38 chr6 6.14E-14
50 CETP chr16 HCP5 chr6 1.06E-13
51 PKNOX1 chr21 DUSP13 chr10 1.08E-13
52 ATP6V1G2 chr6 HLA-DQB2 chr6 1.43E-13
53 SRCAP chr16 TCF20 chr22 1.47E-13
54 SKIV2L chr6 HCG18 chr6 1.76E-13
55 ZNF497 chr19 DSE chr6 2.05E-13
56 ZNF263 chr16 ZNF230 chr19 2.35E-13
57 SRCAP chr16 DYNC1H1 chr14 2.53E-13
58 ZKSCAN4 chr6 TRIM10 chr6 3.34E-13
59 ZSCAN16 chr6 VARS2 chr6 3.40E-13
60 KIAA0391 chr14 NFKB2 chr10 4.91E-13
61 SRCAP chr16 KIAA0100 chr17 4.96E-13
62 ZNF165 chr6 IER3 chr6 4.98E-13
63 KIAA0391 chr14 RELB chr19 5.31E-13
64 ZNF132 chr19 DSE chr6 1.14E-12
65 ZSCAN26 chr6 HLA-F-AS1 chr6 1.25E-12
66 SRCAP chr16 PREX1 chr20 1.85E-12
67 SAMD3 chr6 DGKD chr2 2.01E-12
68 PWP1 chr12 CTDSP1 chr2 2.90E-12
69 SRCAP chr16 TNS3 chr7 3.01E-12
70 SRCAP chr16 PTPN23 chr3 3.20E-12
71 ZSCAN16 chr6 TRIM38 chr6 3.36E-12
72 PGBD1 chr6 VARS2 chr6 3.43E-12
73 ANKRD11 chr16 SRCAP chr16 3.85E-12
74 PLAGL1 chr6 HM13 chr20 3.93E-12
75 PIGL chr17 TBL1XR1 chr3 5.86E-12
76 PGBD1 chr6 HLA-F-AS1 chr6 6.32E-12
77 SRCAP chr16 TLN1 chr9 8.46E-12
78 SRCAP chr16 PCNXL3 chr11 8.56E-12
79 NLRC5 chr16 BTN3A3 chr6 9.03E-12
80 SRCAP chr16 POLR2A chr17 1.09E-11
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Table 4.1, continued.
Regulator Chr Trans target Chr P value
81 SRCAP chr16 FAM193A chr4 1.28E-11
82 PGBD1 chr6 TRIM38 chr6 1.29E-11
83 SRCAP chr16 SAMD4B chr19 1.31E-11
84 PLAGL1 chr6 RAB37 chr17 1.43E-11
85 ZNF585A chr19 ATP6V1E2 chr2 1.76E-11
86 CTDSP1 chr2 RNPEPL1 chr2 2.09E-11
87 HLA-DRB1 chr6 HLA-G chr6 2.14E-11
88 SRCAP chr16 PACS1 chr11 2.45E-11
89 PKNOX1 chr21 SP2 chr17 2.48E-11
90 PLAGL1 chr6 CYFIP2 chr5 2.52E-11
91 COG5 chr7 NACC1 chr19 3.06E-11
92 ZSCAN16 chr6 TRIM10 chr6 3.10E-11
93 ZKSCAN4 chr6 HLA-A chr6 3.12E-11
94 ZFP82 chr19 NID1 chr1 3.38E-11
95 TRIM39 chr6 SKIV2L chr6 3.82E-11
96 SRCAP chr16 RERE chr1 4.34E-11
97 SRCAP chr16 CHERP chr19 5.30E-11
98 PLAGL1 chr6 OGDH chr7 5.31E-11
99 SRCAP chr16 BAZ2A chr12 5.69E-11
100 SRCAP chr16 UBR4 chr1 5.77E-11
101 CLDN23 chr8 BLK chr8 6.87E-11
102 PLAGL1 chr6 JAK3 chr19 7.53E-11
103 LTA chr6 HLA-DQB1 chr6 8.10E-11
104 TRIM39 chr6 MICA chr6 8.43E-11
105 TRIM27 chr6 HCG18 chr6 8.65E-11
106 ZSCAN16 chr6 FLOT1 chr6 1.26E-10
107 TMEM79 chr1 RALY chr20 1.27E-10
108 PEX12 chr17 FKBP8 chr19 1.28E-10
109 SRCAP chr16 KMT2E chr7 1.30E-10
110 TNF chr6 HLA-DQB1 chr6 1.35E-10
111 EXOC1 chr4 SRSF11 chr1 1.46E-10
112 SRCAP chr16 LRRN2 chr1 1.46E-10
113 SRCAP chr16 NEU3 chr11 1.49E-10
114 PLAGL1 chr6 TGM3 chr20 1.59E-10
115 MIR3960 chr9 TMEM238 chr19 1.71E-10
116 ZKSCAN4 chr6 FLOT1 chr6 2.17E-10
117 SRCAP chr16 MYO9B chr19 2.21E-10
118 SMG5 chr1 RALY chr20 2.39E-10
119 CCHCR1 chr6 HLA-DRB5 chr6 2.60E-10
120 CBS chr21 SP2 chr17 2.62E-10
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Table 4.1, continued.
Regulator Chr Trans target Chr P value
121 ZNF641 chr12 KATNBL1 chr15 2.89E-10
122 PARP2 chr14 POP1 chr8 3.26E-10
123 SRCAP chr16 PLBD2 chr12 3.29E-10
124 SRCAP chr16 ATP11A chr13 3.35E-10
125 NAT6 chr3 CCDC71 chr3 3.43E-10
126 ZNF276 chr16 LDHD chr16 5.21E-10
127 ERV3-1 chr7 KCTD7 chr7 5.26E-10
128 PGBD1 chr6 IER3 chr6 5.96E-10
129 CBS chr21 DCTN4 chr5 7.55E-10
130 NOTCH4 chr6 HCG18 chr6 7.86E-10
131 HLA-F-AS1 chr6 VARS2 chr6 8.37E-10
132 ZNF75A chr16 ZNF222 chr19 8.83E-10
133 PLAGL1 chr6 CERS2 chr1 9.14E-10
134 SRCAP chr16 PPRC1 chr10 9.63E-10
135 HKR1 chr19 ATP6V1E2 chr2 9.68E-10
136 CENPV chr17 TBL1XR1 chr3 1.06E-09
137 EXOC1 chr4 N4BP2L2 chr13 1.13E-09
138 LYSMD2 chr15 POLB chr8 1.22E-09
139 HCG18 chr6 SKIV2L chr6 1.43E-09
140 FIGNL1 chr7 PPP2R5B chr11 1.92E-09
141 EXOC1 chr4 PRPF40A chr2 1.96E-09
142 MAPKAPK3 chr3 TEX264 chr3 2.00E-09
143 SRCAP chr16 GOLPH3 chr5 2.00E-09
144 C6orf136 chr6 SKIV2L chr6 2.17E-09
145 PLAGL1 chr6 GAPVD1 chr9 2.21E-09
146 U2AF1 chr21 SP2 chr17 2.27E-09
147 PAQR6 chr1 RALY chr20 2.31E-09
148 SRCAP chr16 NDUFAB1 chr16 2.34E-09
149 CLDN23 chr8 FAM167A chr8 2.35E-09
150 MAPKAPK3 chr3 GRM2 chr3 2.55E-09
151 PWP1 chr12 SSBP2 chr5 2.58E-09
152 LINC00909 chr18 PGLS chr19 2.61E-09
153 HLA-G chr6 SKIV2L chr6 2.62E-09
154 SRCAP chr16 ASAP1 chr8 2.63E-09
155 SRCAP chr16 KPNA6 chr1 2.68E-09
156 SRCAP chr16 EP400 chr12 2.86E-09
157 LTA chr6 HLA-DQB2 chr6 2.89E-09
158 SMG5 chr1 CTSZ chr20 2.93E-09
159 TEF chr22 EPHX1 chr1 2.99E-09
160 HLA-B chr6 HLA-DRB5 chr6 3.01E-09
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Table 4.1, continued.
Regulator Chr Trans target Chr P value
161 SRCAP chr16 SP2 chr17 3.02E-09
162 HSPA5 chr9 HYOU1 chr11 3.15E-09
163 ANKRD11 chr16 TNRC18 chr7 3.31E-09
164 SRCAP chr16 PIP5K1C chr19 3.33E-09
165 PLAGL1 chr6 PNPLA1 chr6 3.45E-09
166 ZNF165 chr6 FLOT1 chr6 3.56E-09
167 SRCAP chr16 ARID1A chr1 3.58E-09
168 NAT6 chr3 WDR6 chr3 3.66E-09
169 PLAGL1 chr6 CKAP4 chr12 3.66E-09
170 UBE2H chr7 EPB41 chr1 3.89E-09
171 U2AF1 chr21 DUSP13 chr10 4.05E-09
172 PLAGL1 chr6 AMPD2 chr1 4.12E-09
173 ANKRD11 chr16 MLXIP chr12 4.15E-09
174 EXOC1 chr4 ARGLU1 chr13 4.16E-09
175 SRCAP chr16 RPRD2 chr1 4.64E-09
176 DDAH2 chr6 HLA-DQA2 chr6 4.87E-09
177 SRCAP chr16 MYO18A chr17 5.00E-09
178 SRCAP chr16 SIPA1L3 chr19 5.19E-09
179 JMJD8 chr16 DACT1 chr14 5.30E-09
180 SRCAP chr16 PRR12 chr19 5.62E-09
181 ZNF266 chr19 SIK1 chr21 5.77E-09
182 SRCAP chr16 POLR1A chr2 5.93E-09
183 HSPA5 chr9 DNAJB11 chr3 6.05E-09
184 KIAA0391 chr14 GHRL chr3 6.16E-09
185 HLA-DQA2 chr6 HLA-G chr6 6.29E-09
186 EXOC1 chr4 CTNNB1 chr3 6.60E-09
187 PGBD1 chr6 ABT1 chr6 6.68E-09
188 PGBD1 chr6 BTN2A2 chr6 7.06E-09
189 PLAGL1 chr6 GPX3 chr5 7.07E-09
190 KIAA0391 chr14 ST3GAL2 chr16 7.29E-09
191 EXOC1 chr4 TTC14 chr3 7.33E-09
192 PGBD1 chr6 TRIM10 chr6 7.44E-09
193 MICB chr6 HLA-G chr6 7.94E-09
194 ZNF165 chr6 VARS2 chr6 8.29E-09
195 HYAL2 chr3 CD44 chr11 8.76E-09
196 SRCAP chr16 KDM6B chr17 8.82E-09
197 MZF1 chr19 DSE chr6 9.91E-09
198 SRCAP chr16 WIPF2 chr17 9.93E-09
199 NFKBIA chr14 NFKB2 chr10 1.01E-08
200 EXOC1 chr4 PRPF4B chr6 1.04E-08
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201 PRDM4 chr12 CTDSP1 chr2 1.07E-08
202 EXOC1 chr4 CLK1 chr2 1.16E-08
203 NFE2 chr12 EPS15L1 chr19 1.17E-08
204 GAR1 chr4 NUDC chr1 1.19E-08
205 ZSCAN16 chr6 HLA-A chr6 1.20E-08
206 NEK6 chr9 TPPP3 chr16 1.23E-08
207 TMEM79 chr1 CTSZ chr20 1.23E-08
208 MIR3960 chr9 PDXP chr22 1.31E-08
209 BLK chr8 MSRA chr8 1.44E-08
210 NEK6 chr9 MYADM chr19 1.47E-08
211 PLAGL1 chr6 AP5B1 chr11 1.50E-08
212 ZNF263 chr16 ZNF222 chr19 1.52E-08
213 DHRS13 chr17 FAXDC2 chr5 1.64E-08
214 SRCAP chr16 ANKRD17 chr4 1.78E-08
215 COQ2 chr4 EP400NL chr12 1.83E-08
216 EXOC1 chr4 HNRNPU-AS1 chr1 1.84E-08
217 NEK8 chr17 MYL4 chr17 1.88E-08
218 SRCAP chr16 GBF1 chr10 1.94E-08
219 PKNOX1 chr21 NCKAP1L chr12 1.98E-08
220 DCAKD chr17 KANSL1-AS1 chr17 2.02E-08
221 SRCAP chr16 YLPM1 chr14 2.23E-08
222 EXOC1 chr4 WDR75 chr2 2.27E-08
223 GRM2 chr3 HEMK1 chr3 2.41E-08
224 COX15 chr10 NCR3 chr6 2.43E-08
225 ATRIP chr3 UBA7 chr3 2.49E-08
226 PLAGL1 chr6 PRAM1 chr19 2.50E-08
227 SRCAP chr16 FASN chr17 2.57E-08
228 EXOC1 chr4 RBM25 chr14 2.58E-08
229 FIGNL1 chr7 MYL4 chr17 2.64E-08
230 SRCAP chr16 KAT6A chr8 2.70E-08
231 PLAGL1 chr6 MFSD12 chr19 2.73E-08
232 GAR1 chr4 APOBR chr16 2.78E-08
233 VWA7 chr6 PSMB9 chr6 2.90E-08
234 HEMK1 chr3 AMT chr3 2.93E-08
235 OTX1 chr2 LGALSL chr2 3.05E-08
236 EXOC1 chr4 BCLAF1 chr6 3.14E-08
237 CD83 chr6 DTNBP1 chr6 3.19E-08
238 CENPV chr17 ISL2 chr15 3.21E-08
239 SRCAP chr16 HECTD4 chr12 3.29E-08
240 SRCAP chr16 NOP9 chr14 3.40E-08
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241 PKN3 chr9 CEACAM6 chr19 3.46E-08
242 LYSMD2 chr15 BID chr22 3.67E-08
243 NFKBIA chr14 GHRL chr3 3.79E-08
244 NLRC5 chr16 HLA-F chr6 3.95E-08
245 ZFP90 chr16 MCOLN2 chr1 4.17E-08
246 EXOC1 chr4 AP2B1 chr17 4.19E-08
247 GAPDH chr12 POU6F1 chr12 4.35E-08
248 EFTUD2 chr17 KANSL1-AS1 chr17 4.44E-08
249 RNASEH1 chr2 RIMKLB chr12 4.47E-08
250 LST1 chr6 TAP2 chr6 4.73E-08
251 SRCAP chr16 ZNF142 chr2 4.85E-08
252 ANKRD11 chr16 AKNA chr9 5.14E-08
253 SRCAP chr16 NDUFB9 chr8 5.21E-08
254 ZBTB40 chr1 SIRT6 chr19 5.23E-08
255 SRCAP chr16 CIC chr19 5.45E-08
256 HCG27 chr6 HLA-DRB1 chr6 5.57E-08
257 PEX12 chr17 DMTN chr8 5.68E-08
258 SRCAP chr16 CHMP4A chr14 5.85E-08
259 PAQR6 chr1 CTSZ chr20 6.19E-08
260 HSPA5 chr9 HSP90B1 chr12 6.21E-08
261 ZNF718 chr4 PHKB chr16 6.23E-08
262 SRCAP chr16 RNF111 chr15 6.30E-08
263 PIGL chr17 G0S2 chr1 6.61E-08
264 ZBTB11-AS1 chr3 ZNF418 chr19 6.62E-08
265 ANKRD11 chr16 CMTM6 chr3 6.65E-08
266 DDAH2 chr6 HLA-G chr6 6.93E-08
267 PEX12 chr17 AQP1 chr7 6.95E-08
268 SRCAP chr16 HIGD2A chr5 7.00E-08
269 SRCAP chr16 SPG11 chr15 7.25E-08
270 NCKIPSD chr3 RBM6 chr3 7.46E-08
271 TRAF3IP2-AS1 chr6 TMEM234 chr1 7.65E-08
272 GAR1 chr4 HNRNPUL2 chr11 7.86E-08
273 SRCAP chr16 HTT chr4 7.86E-08
274 ZBTB25 chr14 CALY chr10 8.06E-08
275 LINC00174 chr7 ZNF117 chr7 8.27E-08
276 DNAJB9 chr7 VIMP chr15 8.79E-08
277 IER3 chr6 HLA-DQB1 chr6 9.00E-08
278 ZSCAN16 chr6 HLA-F-AS1 chr6 9.43E-08
279 SRCAP chr16 CLEC16A chr16 9.59E-08
280 PSMG4 chr6 ABCA1 chr9 1.03E-07
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281 TNF chr6 HLA-G chr6 1.07E-07
282 PIGL chr17 ISL2 chr15 1.09E-07
283 HCG18 chr6 MICA chr6 1.16E-07
284 NEIL2 chr8 CLDN23 chr8 1.19E-07
285 FIGNL1 chr7 OPTN chr10 1.20E-07
286 TMEM81 chr1 UBAP1 chr9 1.21E-07
287 NFE2 chr12 VIL1 chr2 1.24E-07
288 HIST1H2BD chr6 THG1L chr5 1.25E-07
289 TMEM79 chr1 MTCH1 chr6 1.25E-07
290 ZNF607 chr19 IP6K1 chr3 1.27E-07
291 EXOC1 chr4 SREK1 chr5 1.30E-07
292 IER3 chr6 C2 chr6 1.31E-07
293 SMG5 chr1 GABARAPL1 chr12 1.40E-07
294 LYSMD2 chr15 TMEM154 chr4 1.42E-07
295 KLHDC8B chr3 HYAL3 chr3 1.50E-07
296 SRCAP chr16 MOB3A chr19 1.53E-07
297 ZNF184 chr6 HLA-A chr6 1.56E-07
298 CLDN23 chr8 NEIL2 chr8 1.58E-07
299 ATP6V1G2 chr6 HLA-DQB1 chr6 1.66E-07
300 ZNF467 chr7 TRIM13 chr13 1.76E-07
301 LYSMD2 chr15 FAM65A chr16 1.76E-07
302 PPP2R3C chr14 RELB chr19 1.78E-07
303 GAR1 chr4 HNRNPM chr19 1.78E-07
304 SEC13 chr3 NFYC chr1 1.86E-07
305 SRCAP chr16 PPP4R2 chr3 1.89E-07
306 SRCAP chr16 BRD4 chr19 1.92E-07
307 ZFP30 chr19 DNAH6 chr2 1.94E-07
308 ZKSCAN4 chr6 HLA-F-AS1 chr6 1.96E-07
309 SRCAP chr16 HRH2 chr5 1.96E-07
310 EXOC1 chr4 DHX15 chr4 1.99E-07
311 TEF chr22 ASGR1 chr17 2.01E-07
312 ZSCAN26 chr6 VARS2 chr6 2.05E-07
313 FAM111B chr11 CIB1 chr15 2.08E-07
314 PKN3 chr9 DEFA4 chr8 2.26E-07
315 NEK6 chr9 FAR2 chr12 2.30E-07
316 PEX12 chr17 BAG6 chr6 2.34E-07
317 NFKBIA chr14 RELB chr19 2.37E-07
318 CTDSP1 chr2 SH3BP5L chr1 2.53E-07
319 ATF1 chr12 FGD4 chr12 2.56E-07
320 EXOC1 chr4 SKIV2L2 chr5 2.65E-07
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321 INSIG1 chr7 SREBF2 chr22 2.65E-07
322 ANKRD11 chr16 ELOVL5 chr6 2.76E-07
323 NPAS2 chr2 NR1D1 chr17 2.77E-07
324 PKN3 chr9 SLC2A5 chr1 2.81E-07
325 ZBTB11-AS1 chr3 ZNF551 chr19 2.84E-07
326 ZNF165 chr6 TRIM38 chr6 2.84E-07
327 ANKRD11 chr16 NCOR2 chr12 2.87E-07
328 ZSCAN26 chr6 TRIM38 chr6 2.95E-07
329 SMG5 chr1 TPD52L2 chr20 2.97E-07
330 SRCAP chr16 LRRK1 chr15 3.06E-07
331 TMEM79 chr1 ELOVL1 chr1 3.10E-07
332 AQP11 chr11 C11orf63 chr11 3.18E-07
333 HYAL2 chr3 FOSL2 chr2 3.19E-07
334 SRCAP chr16 BRPF3 chr6 3.23E-07
335 ZSCAN32 chr16 CMTM3 chr16 3.30E-07
336 RNF39 chr6 HCG27 chr6 3.34E-07
337 RABGEF1 chr7 ZNF138 chr7 3.35E-07
338 PKNOX1 chr21 DCTN4 chr5 3.35E-07
339 TNRC6C-AS1 chr17 TAP2 chr6 3.38E-07
340 ADORA2B chr17 TBL1XR1 chr3 3.43E-07
341 COPS8 chr2 ZFC3H1 chr12 3.43E-07
342 ZNF165 chr6 TRIM10 chr6 3.54E-07
343 EXOC1 chr4 RSRC2 chr12 3.64E-07
344 NEK6 chr9 RFX2 chr19 3.75E-07
345 ZKSCAN4 chr6 BTN2A2 chr6 3.79E-07
346 SRCAP chr16 HIVEP3 chr1 3.95E-07
347 PKN3 chr9 ABCA13 chr7 3.98E-07
348 TMEM131 chr2 HNRNPUL2 chr11 3.99E-07
349 CLEC11A chr19 VAV3 chr1 4.06E-07
350 ZSCAN16 chr6 HLA-DQB1 chr6 4.17E-07
351 SRCAP chr16 PROSER1 chr13 4.20E-07
352 ZNF790-AS1 chr19 TM9SF1 chr14 4.22E-07
353 SRCAP chr16 DMWD chr19 4.24E-07
354 R3HCC1L chr10 HNRNPL chr19 4.32E-07
355 EXOC1 chr4 CDC5L chr6 4.35E-07
356 SRCAP chr16 SUGP2 chr19 4.47E-07
357 NFYA chr6 EHD2 chr19 4.54E-07
358 HYAL3 chr3 CCDC71 chr3 4.57E-07
359 SRCAP chr16 CDK12 chr17 4.62E-07
360 POR chr7 ADPRHL1 chr13 4.70E-07
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361 TMEM131 chr2 SPCS1 chr3 4.77E-07
362 FAM117B chr2 KLHL17 chr1 4.78E-07
363 FDFT1 chr8 CLDN23 chr8 4.94E-07
364 MCEE chr2 BSPRY chr9 5.01E-07
365 KLF11 chr2 AACS chr12 5.03E-07
366 HHEX chr10 PPARD chr6 5.05E-07
367 SRCAP chr16 TMEM131 chr2 5.08E-07
368 NOA1 chr4 CECR6 chr22 5.08E-07
369 KIAA0391 chr14 TGIF2 chr20 5.11E-07
370 CYP1B1 chr2 E2F2 chr1 5.14E-07
371 ADAMTSL5 chr19 ABR chr17 5.26E-07
372 LINC00638 chr14 RPS19BP1 chr22 5.37E-07
373 PTK2 chr8 ZBTB24 chr6 5.38E-07
374 ZKSCAN4 chr6 HLA-DQB1 chr6 5.40E-07
375 TIGD6 chr5 GOT1 chr10 5.46E-07
376 JAKMIP2 chr5 PIPOX chr17 5.64E-07
377 PSMC3IP chr17 ARRDC4 chr15 5.76E-07
378 ATRIP chr3 RBM6 chr3 5.80E-07
379 HPS1 chr10 SLC29A3 chr10 5.83E-07
380 SRCAP chr16 WNK1 chr12 5.86E-07
381 RPS9 chr19 BAIAP2 chr17 5.88E-07
382 SRCAP chr16 SLC38A7 chr16 5.88E-07
383 WDR4 chr21 ZNF687 chr1 5.89E-07
384 SRCAP chr16 SLX4 chr16 5.92E-07
385 RNFT1 chr17 RAD51C chr17 6.10E-07
386 CETP chr16 HLA-F chr6 6.24E-07
387 NFKBIA chr14 TGIF2 chr20 6.25E-07
388 BLK chr8 CLDN23 chr8 6.55E-07
389 PLTP chr20 STX8 chr17 6.56E-07
390 GAR1 chr4 RRS1 chr8 6.58E-07
391 USP22 chr17 APPL2 chr12 6.65E-07
392 SGCB chr4 OCIAD1 chr4 6.67E-07
393 SRCAP chr16 ZSWIM8 chr10 6.68E-07
394 EXOC1 chr4 DIS3 chr13 6.78E-07
395 PANX2 chr22 MS4A1 chr11 6.78E-07
396 ANKRD11 chr16 SP3 chr2 6.84E-07
397 GPR137B chr1 CWF19L2 chr11 6.88E-07
398 A1BG-AS1 chr19 MYEOV chr11 6.99E-07
399 UBE2H chr7 PABPN1 chr14 7.03E-07
400 PROCA1 chr17 FAXDC2 chr5 7.04E-07
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401 TMEM81 chr1 LYL1 chr19 7.06E-07
402 PLA2G6 chr22 SH2D2A chr1 7.10E-07
403 ANKRD11 chr16 PCMTD1 chr8 7.11E-07
404 NRBP2 chr8 CCNY chr10 7.19E-07
405 LYSMD2 chr15 CTDP1 chr18 7.25E-07
406 SRCAP chr16 SEC61A1 chr3 7.25E-07
407 CLMN chr14 GAS8 chr16 7.35E-07
408 EXOC1 chr4 PSIP1 chr9 7.45E-07
409 ITM2B chr13 CMTM7 chr3 7.46E-07
410 ZBTB11-AS1 chr3 ZNF304 chr19 7.68E-07
411 SRCAP chr16 NDUFC1 chr4 7.71E-07
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TABLE 4.2: 90 trans-eGenes identified by SNP-based trans-eQTL mapping at 10%
FDR. Trans-eQTL mapping were performed with Matrix eQTL. Gene-level empirical
FDR were obtained by using empirical p values from permutations. The P value
column is the extreme p value of each gene reported by Matrix eQTL. Genes are
ordered by p values.
Gene p value Gene p value Gene p value
1 LOC399744 1.55E-91 ZNF547 1.61E-21 ESAM 4.92E-17
2 ZNF418 2.89E-55 GUCY1A3 9.51E-21 ZBTB47 6.86E-17
3 ZNF154 9.79E-38 HCP5 1.61E-20 SLC6A4 1.09E-16
4 FLJ45445 2.85E-37 U4 2.06E-20 ZIK1 1.13E-16
5 TTC9 1.03E-35 TSPAN9 6.13E-20 RNF144A-AS1 1.43E-16
6 DUSP22 3.37E-35 ZNF835 8.24E-20 CMTM5 2.55E-16
7 LOC440311 2.09E-32 HOMER2 1.12E-19 ANKRD22 3.34E-16
8 JAM3 5.04E-32 LOC646214 1.72E-19 SEC14L5 3.71E-16
9 BTN3A1 3.38E-31 MAPKAPK3 1.91E-19 MYL4 4.23E-16
10 PARVB 7.37E-30 GUCY1B3 1.99E-19 ITGA2B 4.47E-16
11 ZSCAN18 3.50E-29 PKHD1L1 2.08E-19 ZNF687 6.10E-16
12 DSE 3.10E-27 SLC24A3 2.57E-19 ZNF329 7.85E-16
13 ZNF671 1.03E-26 TTC7B 3.33E-19 PF4 9.34E-16
14 PCSK6 1.53E-26 LTBP1 4.02E-19 LOC729176 9.41E-16
15 MMRN1 4.37E-25 VSIG2 5.27E-19 HAUS5 1.21E-15
16 PAQR7 2.56E-24 SELP 5.57E-19 ADCY6 1.25E-15
17 HGD 8.07E-24 ZNF577 2.23E-18 TGM3 2.41E-15
18 ITGB3 9.83E-24 LY6G6F 2.75E-18 MYL9 2.99E-15
19 ZNF211 1.01E-23 ILK 6.12E-18 EGR3 4.00E-15
20 ZNF304 1.63E-23 ZNF274 6.43E-18 RAB27B 4.04E-15
21 ABLIM3 2.28E-23 SH3BGRL2 1.53E-17 ZNF419 5.01E-15
22 ZNF135 3.75E-23 C6orf25 1.82E-17 LOC200772 6.23E-15
23 POP1 4.36E-23 ACSBG1 1.88E-17 HCG26 8.55E-15
24 ALOX12 9.62E-23 VAV1 1.89E-17 HKR1 8.91E-15
25 PPBP 2.66E-22 PTGS1 2.15E-17 C15orf26 1.00E-14
26 PGLS 4.22E-22 TCRBV5S1A1T 2.66E-17 TUBA8 1.06E-14
27 KIAA0319L 5.88E-22 NRGN 3.10E-17 PRKAR2B 1.28E-14
28 SAMD14 8.16E-22 ZNF595 3.17E-17 CLU 1.50E-14
29 GP1BA 8.32E-22 LOC100288778 3.43E-17 KCNJ15 2.31E-14
30 GP6 1.10E-21 FERMT3 2.98E-14
31 ZNF551 1.31E-21
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TABLE 4.3: Gene-ontology enrichment of 157 regulators identified in DGN at
Benjamini-Hochberg (BH) FDR<0.05. Analysis was performed by using DAVID 6.8
[Huang et al. (2008a,b)]. Table is ordered by BH FDR.
Category Term N % Genes BH FDR
1 GOTERM_MF_DIRECT GO:0003677
DNA bind-
ing
35 20.71 ZNF276, HKR1, ZNF467, ZNF132,
ZNF75A, NFYA, MEIS1, PLAGL1,
ZNF184, NPAS2, ZFP90, PSMC3IP,
RABGEF1, ZSCAN26, ZNF607,
TIGD6, ZNF266, HEMK1, CIITA,
ZNF641, HIST1H2BD, OTX1, ZFP30,
TRIM27, ZBTB40, ZNF497, KCTD7,
ZBTB25, ZFP82, HHEX, PKNOX1,
PRDM4, ZSCAN32, SRCAP, PARP2
1.68E-04
2 GOTERM_MF_DIRECT GO:0003700
transcrip-
tion factor
activity,
sequence-
specific
DNA bind-
ing
24 14.20 ZNF263, ZNF641, NFE2, ZNF132,
ZFP30, OTX1, KLF11, NFYA,
ZNF585A, ATF1, ZNF165, ZKSCAN4,
ZBTB25, PLAGL1, ZFP82, NPAS2,
PKNOX1, ZSCAN22, PGBD1, ZS-
CAN32, ZSCAN26, MZF1, ZSCAN16,
ZNF607
5.31E-04
3 GOTERM_MF_DIRECT GO:0046872
metal ion
binding
37 21.90 ZNF276, HKR1, ZNF132, ZNF467,
ZNF75A, ZKSCAN4, PLAGL1,
ZNF184, NPAS2, ZSCAN22, MCEE,
ZFP90, U2AF1, ZSCAN26, CTDSP1,
ZNF607, ZNF266, ZNF263, ZNF641,
ZFP30, KLF11, TRIM27, ZBTB40,
ZNF497, ZNF585A, ZNF165, ZBTB25,
ZFP82, ZNF718, SNRNP48, PRDM4,
ZSCAN32, MZF1, NEK8, ZSCAN16,
PPP2R3C, CBS
8.96E-04
4 GOTERM_MF_DIRECT GO:0003676
nucleic acid
binding
23 13.61 ZNF276, ZNF263, ZNF641, HKR1,
ZNF132, ZFP30, KLF11, TRIM27,
ZBTB40, RNASEH1, ZNF75A,
ZNF585A, ZNF165, ZKSCAN4,
ZFP82, ZNF184, ZNF718, ZFP90, ZS-
CAN32, ZSCAN26, MZF1, ZNF607,
ZNF266
1.30E-03
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Category Term N % Genes BH FDR
5 GOTERM_BP_DIRECT GO:0006355
regulation
of tran-
scription,
DNA-
templated
31 18.34 ZNF276, HKR1, ZNF467, ZNF132,
ZNF75A, NFYA, MEIS1, ZKSCAN4,
ZNF184, ZSCAN22, PGBD1, ZFP90,
ZSCAN26, ZNF607, ZNF266, ZNF263,
CIITA, ZFP30, ZBTB40, ZNF497,
ZNF585A, ZNF165, ZBTB25, ZNF718,
ZFP82, PKNOX1, PRDM4, NOTCH4,
ZSCAN32, MZF1, ZSCAN16
3.30E-03
6 GOTERM_CC_DIRECT GO:0005634
nucleus
68 40.24 IER3, HKR1, FIGNL1, GAR1, COPS8,
ZKSCAN4, CCHCR1, ZNF184,
NLRC5, PKN3, ZFP90, PSMC3IP,
ANKRD11, CTDSP1, NCKIPSD,
TIGD6, ZNF641, OTX1, ZFP30, ZFP82,
ZNF718, HHEX, PRDM4, ZSCAN16,
SRCAP, NEK6, ZNF276, ZNF467,
ZNF132, SKIV2L, MAPKAPK3, NFK-
BIA, ZNF75A, NFYA, MEIS1, ATF1,
PLAGL1, NPAS2, PTK2, PGBD1,
ZSCAN22, ZSCAN26, TEF, HSPA5,
ZNF607, GAPDH, ZNF266, ZNF263,
HIST1H2BD, NFE2, SMG5, KLF11,
TRIM27, ZBTB40, RPS9, ZNF497,
ZNF585A, ZNF165, PWP1, PKNOX1,
NOTCH4, ZSCAN32, CENPV, MZF1,
WDR4, PARP2, PPP2R3C, CBS
1.50E-02
7 GOTERM_BP_DIRECT GO:0006351
transcrip-
tion, DNA-
templated
34 20.12 ZNF276, HKR1, ZNF132, ZNF467,
ZNF75A, ZKSCAN4, PLAGL1,
ZNF184, NPAS2, ZSCAN22, ZFP90,
ZSCAN26, ZNF607, ZNF266, ZNF263,
CIITA, ZNF641, NFE2, ZFP30,
TRIM27, ZBTB40, ZNF497, ZNF585A,
ZNF165, ZBTB25, PWP1, ZFP82,
HHEX, ZNF718, ZSCAN32, MZF1,
ZSCAN16, USP22, SRCAP
1.64E-02
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TABLE 4.4: Master regulators identified in the DGN dataset. 20 regulators that were
identified to regulate more than 3 trans target genes in DGN. Genes are ordered by
the number of target genes.
Regulator Chrom Start End No. of targets
1 SRCAP chr16 30709914 30756517 88
2 PLAGL1 chr6 144261437 144385735 21
3 EXOC1 chr4 56719816 56771244 20
4 ZKSCAN4 chr6 28212490 28227011 9
5 ANKRD11 chr16 89334029 89556969 9
6 PGBD1 chr6 28249314 28270326 8
7 ZSCAN16 chr6 28092387 28097856 8
8 GAR1 chr4 110736666 110745893 5
9 ZNF165 chr6 28048482 28057340 5
10 KIAA0391 chr14 35591527 35786682 5
11 LYSMD2 chr15 52015261 52043650 5
12 PKNOX1 chr21 44394643 44453688 5
13 SMG5 chr1 156219015 156252620 4
14 TMEM79 chr1 156252704 156262234 4
15 NEK6 chr9 127019885 127114719 4
16 PKN3 chr9 131464802 131483199 4
17 NFKBIA chr14 35870716 35873960 4
18 NLRC5 chr16 57023459 57117436 4
19 PEX12 chr17 33901814 33905656 4
20 CBS chr21 44473301 44496472 4
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TABLE 4.5: SRCAP targets that are associated with cell type proportions. 19 genes
overlap with genes significantly associated with cell type proportion in GWAS cata-
log [Welter et al. (2013)]. Table is in alphabetical orders of gene names.
Genes Traits in GWAS catalog
1 ANKRD11 Lymphocyte counts
2 ARID1A Granulocyte percentage of myeloid white cells
3 ASAP1 Mean platelet volume, Platelet count
4 ATP11A Reticulocyte fraction of red cells, Mean corpuscular volume, Red cell
distribution width
5 BAZ2A Mean platelet volume
6 CLEC16A Eosinophil percentage of white cells,Eosinophil counts,Sum eosinophil
basophil counts,Eosinophil percentage of granulocytes, Lymphocyte
counts, Neutrophil percentage of granulocytes
7 EP400 Red cell distribution width
8 HECTD4 Sum neutrophil eosinophil counts,Sum basophil neutrophil counts,
Granulocyte count, Myeloid white cell count, White blood cell
count,Neutrophil count
9 HIVEP3 Eosinophil percentage of white cells,Eosinophil counts,Sum eosinophil
basophil counts,Eosinophil percentage of granulocytes, Neutrophil
percentage of granulocytes
10 KDM2A Mean corpuscular volume
11 KDM6B Eosinophil percentage of white cells,Eosinophil counts,Sum eosinophil
basophil counts,Eosinophil percentage of granulocytes, Granulocyte
percentage of myeloid white cells
12 MYO9B Reticulocyte fraction of red cells, Mean corpuscular volume, Mean
platelet volume, Reticulocyte count, Red cell distribution width, High
light scatter reticulocyte count, High light scatter reticulocyte percent-
age of red cells, Plateletcrit, Platelet count
13 PPRC1 Mean corpuscular hemoglobin
14 RERE Eosinophil percentage of white cells,Eosinophil counts,Eosinophil per-
centage of granulocytes,Lymphocyte counts, White blood cell count,
Neutrophil count, Neutrophil percentage of granulocytes
15 STAT3 Mean corpuscular volume
16 TLN1 Platelet distribution width
17 TNS3 Sum neutrophil eosinophil counts,Sum basophil neutrophil counts,
Granulocyte count, Myeloid white cell count,High light scatter retic-
ulocyte count, High light scatter reticulocyte percentage of red cells,
Neutrophil count
18 WNK1 Eosinophil percentage of white cells,Eosinophil counts
19 YLPM1 Platelet count
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Chapter 5
An integrative genetic examination of
metabolic pathways highlights strong
pleiotropy and identifies variability
across time and context †
5.1 Abstract
The concentration of metabolites in an individual’s serum reflects the state of diverse core biological pro-
cesses ranging from fuel consumption to information signaling. Genetic studies of metabolites have identi-
fied thousands of individual mutation-metabolite pairs many of which are associated downstream metabolic
and obesogenic disorders. However, these studies have relied on univariate analyses, reducing power and
limiting context specific understanding. Here we aim at providing an integrated perspective of the ge-
netic basis of metabolites leveraging the Finnish Metabolic Syndrome In Men (METSIM) cohort, a unique
genetic resource which contains metabolic measurements across distinct time points as well as detailed
statin usage. We increase effective sample size by an average of two-fold by applying the Covariates for
Multi-phenotype Studies (CMS) analysis method, identifying 588 significant SNP-metabolite associations,
†A manuscript related to this chapter is available on bioRχiv . doi: https://doi.org/10.1101/461848. Apolline
Gallois*, Joel Mefford*, Arthur Ko, Amaury Vaysse, Markku Laakso, Noah Zaitlen, Päivi Pajukanta, Hugues Aschard.
A comprehensive study of metabolite genetics reveals strong pleiotropy and heterogeneity across time and context.
123
including 248 novel associations. We further show that many of these SNPs are master metabolic regula-
tors, balancing the relative proportion of dozens of metabolite levels. We then identify the first associations
to changes in metabolic levels across time as well as evidence of genetic interaction with statin use. Finally,
we show an overall decrease in genetic control of metabolic processes with age.
5.2 Introduction
The human metabolome includes over 100,000 small molecules, ranging from peptides and lipids, to drugs
and pollutants [Wishart et al. (2007)]. Because metabolites affect or are affected by a diverse set of biological
processes, lifestyle and environmental exposures, and disease states [Assfalg et al. (2008)], they are routinely
used a biomarkers [Rauschert et al. (2014)]. Thanks to recent technological advances, diverse components
of the metabolome are being measured in large human cohorts, offering new opportunities to improve our
understanding of the molecular mechanisms underlying metabolism and corresponding human traits and
diseases [Kastenmüller et al. (2015)]. For example, previous work has highlighted the role of metabolites in
diseases such as Type 2 diabetes [Stumvoll et al. (2005); Suhre et al. (2010)], cardiovascular disease [Sasso
et al. (2004)], and obesity [Rauschert et al. (2014); Newgard et al. (2009)]. Here we focus on the identification
of genetic variants with pervasive effects on the metabolome, and those with effects dependent on statin
treatment and age, two established modifiers of metabolite profiles [Würtz et al. (2016)] and disease risk.
Our study also introduces several analytical novelties. First, unlike previous genetic analyses of metabolites
[Gieger et al. (2008); Tukiainen et al. (2011); Inouye et al. (2012); Shin et al. (2014); Draisma et al. (2015);
Kettunen et al. (2016); Teslovich et al. (2010); Rhee et al. (2013)], we leverage the high correlation structure
between metabolites to increase the power via the CMS method [Aschard et al. (2017)]. Second, we used
analytical and graphical tools to produce an integrated view of the genetic-metabolite network. Third, we
use bivariate heritability and interaction analyses to examine changes in genetic regulation of metabolites
as a function of aging and exposure to statins.
5.3 Results
We first performed genome-wide association studies (GWAS) of 158 serum metabolites measured with
nuclear magnetic resonance (NMR) in 6,263 unrelated individuals from the METSIM [Laakso et al. (2017)]
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cohort. These measurements consisted of 98 lipoproteins (42 VLDL, 7 IDL, 21 LDL and 28 HDL), 9 amino
acids, 16 fatty acids, and 35 other molecules. Metabolites showed strong pairwise correlation, especially
within the aforementioned groups (Figure 5.1). GWAS was performed using standard linear regression
(STD), but also using the CMS approach [Aschard et al. (2017)], a powerful method we recently developed
for the analysis of multivariate datasets. For both methods we tested association between each SNP and
metabolite while adjusting for potential confounding factors including age and medical treatments (statins,
beta blockers, diuretics and fibrates). We used a significance threshold of 1.28x10−9, derived as the standard
GWAS threshold (5x10−8) divided by the effective number of tests (Online Methods).
FIGURE 5.1: Metabolite pairwise correlations. Illustration of the 158 analyzed
metabolites pairwise correlation. (a) Correlation matrix of metabolites. Negative
values are in blue and positive values are in red. (b) Histogram of pairwise correla-
tion between metabolites.
We obtained a total of 3,289 significant SNP-metabolite associations identified by either STD or CMS.
We grouped significant SNP within independent linkage disequilibrium blocks [Berisa and Pickrell (2016)]
of 1.6 Mb in average (10 Kb to 26 Mb) and obtained 588 locus-metabolite associations involving a total
of 54 loci. Figure 5.2a shows that these associations are spread over the 158 metabolites: we found 399
associations with lipoproteins (189 with VLDL, 38 with IDL, 88 with LDL and 84 with HDL), 17 with amino
acids, 50 with fatty acids, and 122 with other molecules. Among these associations, 9 were significant with
STD only (1.53%), 261 with both STD and CMS (44.39%) and 318 (54.08%) with CMS only. Overall, CMS
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FIGURE 5.2: Distribution of Locus - metabolite associations. Distribution of the 588
significant associations (P < 1.28x10−9) identified in the 158 metabolites GWAS in
the METSIM cohort. (a) Loci in dark blue were significant for standard linear regres-
sion adjusted by confounding factors. Loci in red were significant for linear regres-
sion adjusted with confounding factors and covariates selected by CMS. Loci in light
blue were significant for both models. (b) Same plot including only the 248 new as-
sociations, not identified in previous metabolites GWAS (P > 1.28 x 10-9 in previous
studies [Shin et al. (2014); Kettunen et al. (2016); Teslovich et al. (2010); Rhee et al.
(2013)])
led to a 118% increase in identified signals (Figures 5.3-5.4). Among the 588 locus-metabolite associations
identified, 248 signals (involving 34 loci) were not identified at genome-wide significant level by previous
large-scale metabolite studies. For each new association, we further mapped the top SNPs per locus to their
nearest gene in a window of 100 Kb. Table 1 presents the aggregated results. As illustrated in Figure 5.2b,
new associations exist for 110 of the 158 metabolites. Among the 248 signals, 3 were significant with STD
only (1.21%), 176 with both STD and CMS (70.97%) and 69 (27.82%) with CMS only.
We next performed in silico replication for all new association signals using data from four previous
metabolites GWASs [Shin et al. (2014); Kettunen et al. (2016); Teslovich et al. (2010); Rhee et al. (2013)]. Note
that the metabolites analyzed differ widely across the replication datasets, and there was only a partial
overlap with the METSIM’s metabolites. In practice, the bulk of the replication analysis was performed
using data from Kettunen et al [Kettunen et al. (2016)] (N=24,925), while the other studies were informative
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FIGURE 5.3: Proportions of the variance in leucine levels explained by SNP, con-
founding factors and covariates. CMS effect on leucine residual variance in the case
of association with SNP rs1260326. Each subplot represents leucine variance. (a) In
standard model, SNP and confounding factors explain a small fraction of leucine
variance. Residual variance is 96%. (b) Adding preselected covariates in the model.
Residual variance is 9%. (c) Exclusion of covariates likely associated with the SNP
by CMS. (d) Final model with CMS-selected covariates. Residual variance is 34%.
only for a very limited set of metabolites. Furthermore, we focused replication only in the subset of over-
lapping metabolites. Out of the 248 new SNP-metabolites pairs, 102 were available for in-silico replication
(41.1%). Among those, 73 (71.6%) were replicated at a nominal threshold of 5%. Finally, when comparing
the top SNPs from every loci associated with at least one metabolite (N=70, see next paragraph) with pre-
vious GWAS on coronary heart disease (CHD) [Teslovich et al. (2010)], body mass index (BMI) [Rhee et al.
(2013)] and type 2 diabetes (T2D) [Aschard et al. (2017)], we observed substantial enrichment for nominally
significant association. Given a false discovery rate (FDR) at 10%, we observed 30 significant genes for
CHD, 5 for BMI and 4 for T2D indicating that a fraction of these variants are also likely involved in the
genetics of these common diseases.
We observed substantial polygenicity and pleiotropy. Using the aforementioned SNP-gene assignment,
147 metabolites were associated with at least one gene, and a total of 70 genes associated with at least
one metabolite. Metabolites were associated with 1 to 9 genes, with an average of 4 genes. On the other
hand, genes showed high level of pleiotropy with an average of 8.4 metabolites associated with each gene.
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FIGURE 5.4: Variance explained by covariates in each SNP – metabolite pair. The
more the outcome variance is explained by the covariates, the more the power
increases. (a) Outcome variance explained by covariates selected by CMS in 158
metabolites GWAS. (b) Equivalent sample size resulting from the outcome variance
explained by covariates in 158 metabolites GWAS.
Although, 13 genes (LIPC, APOA5, CETP, PCSK9, LDLR, GCKR, APOC1, LPL, GALNT2, CELSR2, TRIB1,
and DOCK7) capture over 75% (N=457) of all associations (Figure 5.5). These extensive pleiotropic effects
are illustrated in Figure 5.6, which includes all associations plotted in a Cytoscape [Shannon et al. (2003)]
network. The network highlights several known master regulatory effects of genes. For example, CETP
encodes a protein that transports cholesterol esters and triglycerides between HDL metabolites and VLDL
metabolites. Our network clearly displays the opposite effect of variants in CETP on HDL and VLDL. Our
results also contribute explaining the complex effect of PSK9. Besides its established association with LDL
and VLDL, our analyses confirm association with HDL [Shapiro et al. (2018)]. Overall, the gene displaying
the strongest pleiotropic effect was LIPC with 75 associated metabolites, of which 34 were new associations
(11 of them were available for replication, and 8 were replicated at a 5% alpha threshold).
To illustrate how multivariate results can help identify likely causal variants, we then applied the
FINEMAP [Benner et al. (2016)] algorithm to the 75 metabolites associated with the latter LIPC region.
Our analysis identified 3 distinct association signals (Figure 5.7 ) with consistently high probabilities of
causal effect on triglyceride in HDL and LDL from 7 SNPs. We cross-referenced top variants of these three
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FIGURE 5.5: Distribution of associations per gene. Bar plots represent the number
of metabolites associated for each of 70 genes. Contribution of the seven metabolite
groups is showed by different colors. Genes are ordered by their respective total
number of association. The red line shows the cumulative percentage of the total
number of gene-metabolite association reported in our study (right axis).
signals with GWAS of common human diseases [MacArthur et al. (2016)], and explored them with Hap-
loReg [Ward and Kellis (2011)] to find functional annotations. The first signal is composed only of SNP
rs10468017, which was previously strongly associated with age-related macular degeneration [Neale et al.
(2010); Yu et al. (2011)], but also with cardiovascular diseases [Middelberg et al. (2011)] and metabolic syn-
drome [Kraja et al. (2011)]. It lives in a region harbouring H3K4me1/H3K4me3 and H3K27ac/H3K9ac
marks of promoter and enhancer in Adipose Derived Mesenchymal Stem Cell Cultured Cells. The high
number of rs10468017-metabolite associations in our study, and previous analyses [Kathiresan et al. (2009)]
suggests an overall effect of rs10468017 on LIPC expression. The second signal includes 4 SNPs in com-
plete linkage disequilibrium that were previously associated advanced age-related macular degeneration
[Fritsche et al. (2016)]. It colocalize with histone marks of promoter and enhancer in liver. These SNPs are
also in a region bounds by 4 transcription factors: FOXA1 (rs1077834); FOXA1 and FOXA2 (rs1800588);
and RXRA and USF1 (rs2070895). Among those transcription factors, USF1 have been associated with
low-density lipoprotein cholesterol levels and triglycerides [Holzapfel et al. (2008); Coon et al. (2005)], and
hyperlipidemia [Di Taranto et al. (2015); Lee et al. (2006)]. Furthermore, USF1 has been implicated in the
expression of hepatic lipase [Van Deursen et al. (2009)], making rs2070895 the strongest candidate for po-
tential functional effects through differential regulation of LIPC. Finally, the last signal included 2 SNPs,
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among which rs113298164 clearly harboured the highest number of relevant bio-features. It is a rare mis-
sense mutation in a region having promoter histone marks in hESC Derived CD184+ Endoderm Cultured
Cells. The SNP is also detected by GERP [Davydov et al. (2010)] as part of a sequences that is constrained
across mammalian genomes, and induce a T405M mutation in LIPC protein and is reference as involved in
hepatic lipase deficiency [Ruel et al. (2003)].
An important component of the METSIM cohort is the collection of statin use amongst participants.
To examine changes in genetic regulation of metabolites when taking statins, we performed an interaction
test between SNPs and statin for each of the 588 locus-metabolite associations. While no interaction test
passed a Bonferroni correction for multiple testing (i.e., p < 8.5 x 10-5 ), 83 out of the 588 locus-metabolite
association showed nominally significant interactions (p-value < 0.05). Based on the q-value distribution
[Storey and Tibshirani (2003)], there were 35 significant interactions at a 10% FDR, showing that at least
some of the identified SNP-metabolite effects depends on statin use status. Many of these 35 interactions
involve the same two genes, TRIB1 (associated with VLDL particles) and APOC1 (mostly associated with
LDL and IDL particles), while other genes (FADS1, FADS2, MARCH3, MIR3925, MIR4634, and ITGAM)
show interaction with a single metabolite. Interestingly, APOC1, is associated with statin-mediated lipid
response [Berisa and Pickrell (2016)], and previous work suggests that FADS1 and FADS2 might modulate
response to simvastatin [Shannon et al. (2003)]. We also checked statin interaction in follow-up data, and
found limited interaction values, except for APOC1 region, in which 90% of interaction signals found in
baseline data are replicated.
Another unique aspect of the METSIM cohort is a second measurement of the same metabolites, using
the same technology, approximately five years after the baseline (Online methods) for 3,351 unrelated in-
dividuals. We used these data to screen for genetic variants associated with an intra-individual change
in metabolites level across time. In practice, we applied the same strategy as for our primary analy-
sis but using the difference between follow-up and baseline data divided by age difference as outcome
∆ f b =
( f − b)
[age] f − [age]b , while adjusting for the same confounding factors as baseline and covariates selected
by CMS in baseline measurements. There were 30 SNP-metabolites pairs reaching the standard 5× 10−8
p-value threshold with either STD or CMS, corresponding to 8 locus-metabolite associations. To the best of
our knowledge, these are the first reported SNPs associated with changes in metabolic activity during ag-
ing. These associations involved 7 metabolites: S_HDL_TG, VLDL_C, DHA, DHA/FA, LA/FA, Faw3/FA,
FAw6/FA, and 6 genes: PDZRN4, LGMN, FADS1, FADS2, TNIK, LIPC. Four of these associations were
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genome-wide significant in the marginal association at baseline (P < 5 x 10-8). The four new signals were
observed for S-HDL-TG, VLDL-C, LA-FA and Faw6-FA. We also performed age interaction test on the linear
regression between ∆ f b and significant SNPs (Online methods). However, this approach has substantially
lower power and unsurprisingly, none of the age interaction p-values was significant.
To examine global changes of genetic regulation of metabolites across time we also estimated heritabil-
ity for each phenotype at each timepoint as well as the genetic and environmental correlations of the same
phenotype between timepoints using bivariate linear mixed models [Bulik-Sullivan et al. (2015b,a)]. Fig-
ure 5.8 give heritability values for each metabolite, in both baseline and follow-up data. To avoid any bias
in heritability estimation, we computed it on samples present in both baseline and follow-up studies and
excluded those who were present in baseline study only. The average heritability decreased from 24.9% at
baseline to 18.8% at follow up, with only 30.8% (p-value < 2× 10−9) having higher heritability at follow-
up. The sample size was not large enough to estimate genetic correlation with low standard error, but
the average estimate of 0.92, and the strong correlation of fixed effect sizes between time points, suggests
that increasing environmental variance as opposed to decreased genetic variance underlie the reduction in
heritability.
There are several shortcomings of this work. The study can be improved by adding the related indi-
viduals in the model, further increasing power. However, CMS cannot currently handle related individuals
in reasonable computational time. The study can also be extended with imputed SNPs to improve fine-
mapping estimates. TWAS estimates [Gusev et al. (2016)] were not available for many of the core metabolic
genes, but could become feasible as larger RNA-seq data sets across more tissues are produced. Finally, di-
rect perturbations of individual genes in cell lines or model organisms could help resolve the causal genes
in the associated loci.
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FIGURE 5.6: Network representation of locus-metabolite associations. Network rep-
resentation of the 588 locus-metabolite associations identified in the 158 metabolites
GWAS in METSIM. Each node represents either a gene (blue diamonds, 70) or a
metabolite (orange circles, 147). Each edge is an association between one gene and
one metabolite. Node size is directly proportional to the number of nodes associ-
ated with it. Red edges correspond to opposite effect of a gene on a metabolite,
compared to the other metabolites associated with the same gene. Metabolites col-
ors (orange shades) represents correlation strength between a given metabolite and
all other metabolites. Genes colors (blue shades) represent strength of correlation
between a given gene and associated metabolites, quantified as the average of R-
squared across all corresponding metabolites. [most of the genes are not imputable
by TWAS and so we relied on closest gene, which is not necessarily the correct gene
in all cases].
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FIGURE 5.7: LIPC genic region fine mapping. Panel (a) indicates the posterior proba-
bility assessing the evidence that the SNP is causal for each of the 75 phenotypes and
the local recombination rate. Panel (b) contains genes from the UCSC hg19 annota-
tion. Panel (c) is a R2 based LD heatmap computed using PLINK1.9 on the METSIM
data. The gradient of red is proportional to the R2. For clarity, we represented the
LD only for SNPs with a posterior probability >0.01 for at least 1 phenotype.
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FIGURE 5.8: Heritability of metabolites in baseline and follow-up data. Heritability
of 154 studied metabolites, computed on individuals present in both baseline and
follow-up data. We first computed LD scores on these samples and then used the
scores to compute heritability on summary statistics. Light colors stand for heri-
tability in baseline data and dark colors stand for follow-up data.
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5.4 METHODS
5.4.1 METSIM cohort
The METSIM cohort [Laakso et al. (2017)] is composed of 10,197 Finnish men from 45 to 73 years old and
aimed at investigating non-genetic and genetic factors associated with Type 2 Diabetes and cardiovascular
diseases. Participants were recruited and examined between 2005 and 2010 in Kuopio town in Eastern Fin-
land. The study was approved by the ethics committee of the University of Kuopio and Kuopio University
Hospital, and it was in accordance with the Helsinki Declaration. For each sample, 228 serum metabolites
(lipids, lipoproteins, amino acids, fatty acids and other low molecular weight metabolites) measurements
were made with nuclear magnetic resonance (NMR) at baseline. A follow-up study was conducted about
5 years after the baseline study. 6,496 participants (64%) were reexamined with the same protocol and
metabolites were measured a second time using the same technology. In our study, we considered 158
variables, including 150 raw measurements and 8 ratios. Other available variables, which were mostly
percentages, were not included in the study. Besides metabolic measurements, several variables were also
available including drug treatment and large group of other phenotypes. All samples were genotyped for
665,478 SNPs using the Illumina OmniExpress chip. Genotype data already went through standard quality
control, filtering individuals with missing rate below 5%, and SNPs with missing rate below 5% or with P
< 10−5 in Hardy-Weinberg test.
5.4.2 Data pre-processing
In order to remove outliers without reducing sample size, we first applied inverse normal rank-transformation
on every analyzed metabolite. This was done using the rntransform() function in R package GenABEL
[Aulchenko et al. (2007)]. Because of potential confounding effect of statins use on metabolites, we ex-
cluded all statins users (1,722 individuals) when analyzing LDL, IDL, Apolipoprotein B and cholesterol.
We also excluded fibrates users (25 individuals) when analyzing VLDL, IDL, triglycerides and chylomicron
for similar reason. Finally, we removed all individuals with a genetic relationship coefficient larger than
0.05 and used only unrelated individuals. After filtering, there remained 6,263 samples available for anal-
ysis. For SNP data, we filtered variants with a minor allele frequency (MAF) lower than 1%. 609,262 SNPs
remained after filtering.
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5.4.3 Genome-wide association screening
We used two different models in the analysis. First, we performed a standard linear regression (STD)
between each metabolite (Y) and each SNP (G), adjusted for established confounding factors (C): age and
medical treatments (statins, diuretics, fibrate and beta blockers): Y ∼ βGG + βCC.
Then, we used the CMS algorithm to select additional covariates for each SNP-metabolite pair tested.
Consider a metabolite Yk, which we refer further as the primary outcome. The CMS approach select po-
tential covariates from the set of available metabolites Yl 6=k. In brief, the algorithm is divided in four steps.
The first step is the computation of marginal effects through standard linear regressions between variables
taken two by two: (i) Yk ∼ G where G is the genetic variant tested, (ii) Yl 6=k ∼ G where l includes a subset
of candidate covariates (see next paragraph) and (iii) Yk ∼ Yl 6=k. The second step consists in filtering co-
variates based on a multivariate test between G and all Yl 6=k. In practice, it uses a Multivariate analysis of
variance (MANOVA), which is applied iteratively, removing one by one covariates potentially associated
to the genetic variant tested, until G does not display association with Yl 6=k in the MANOVA. The third
step is the filtering of covariates based on Yl 6=k ∼ G association conditional on Yk ∼ G association. It is
a stepwise procedure that removes progressively covariates that are potentially associated with G. The
last step consists in a linear regression between predictor and outcome, adjusted for the selected covariates
(YL) : Yk ∼ βGG + βCC + βLYL.
To address some of the limitations of CMS, we also applied for each outcome Yk a pre-filtering of candi-
date covariates Yl 6=k before applying CMS. First, to avoid bias due to very high correlation between covari-
ates and the outcome, we excluded all Yl 6=k explaining more than 70% of the outcome variance. Second, to
reduce the risk of false positive due to the inclusion of covariates that are hierarchical parent of the outcome
under study, we excluded from the set of initial covariates all secondary outcome that were in the same bi-
ological group (LDL, HDL, ...) as the primary outcome. Third, to reduce the computational burden, we
reduced the number of candidate metabolites used as input of CMS to 30 through on Akaike information
criteria. As shown in Figure 5.9, it allows substantial reduction in computation time, while focusing on
candidate covariates that altogether still explain a substantial proportion of the primary outcome variance.
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FIGURE 5.9: Expected CMS computation time relative to the number of covariates.
Simulation of 500 phenotypes with a normal distribution. We run CMS on the first
phenotype – the outcome – varying the number of covariates from 1 to 200. We
measure computation time of CMS on each model. This plot shows that complexity
is in O(N) when N is the number of covariates.
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5.4.4 Post-GWAS processing
The threshold used to determine significant loci was calculated by dividing the standard genome wide
significant threshold of 5 x 10-8 by the number of effective tests accounting for all variants tested and all
metabolites. To estimate the number of effective tests, we first did a principal component analysis of our 158
metabolites. Then, we calculated the number of principal components that explained 99% of the total vari-
ance. We obtained 39 effective tests. The significance threshold was then 1.28× 10−9. Because of the great
number of signals, we chose to summarize our results by loci, corresponding to approximately independent
LD blocks. In practice, we sliced the genome in 1703 independent regions based on a recombination map
recently described by Berisa et al [Berisa and Pickrell (2016)]. These regions are 10 Kb to 26 Mb long, with
an average size of 1.6 Mb. For each region, we kept the SNP with the best p-value obtained by either STD
or CMS. We then used the UCSC database to assign the closest gene to each SNP, with a maximum distance
of 100 Kb.
GWAS of delta between baseline and follow-up across metabolites We used data from baseline and
follow-up studies to perform GWAS of the difference between the two time points, divided by the age
difference. We called that variable ∆ f b: ∆ f b =
( f − b)
[age] f − [age]b With f and b follow-up and baseline mea-
surements respectively. As for baseline data analysis, we used STD and CMS approaches, with covariates
pre-selection based on Akaike information criteria. Confounding factors used for the baseline analysis were
also included as covariate in all delta analysis. We did not adjust for baseline value.
5.4.5 Interaction analyses
We performed two follow-up interaction analyses for subset of SNP-metabolite associations identified in
the GWAS. First, we assessed SNP-by-age interaction effect in both baseline and follow-up analyses for
the subset of SNP showing significant effects on delta in metabolite levels between baseline and follow-up
(∆ f b). In practice, we applied a standard linear regression between the corresponding outcome and genetic
variant, adjusting for the same potential confounding factors as in the primary GWAS analysis, and adding
the interaction term βintG ∗ age: Y ∼ βGG + βcC + βageage + βintG ∗ age.
Second, we assess potential SNP-by-statin interaction for the 588 locus identified in the primary GWAS
analysis. In that specific analysis, we included all statin users (which were removed in the primary analysis
for some metabolites, as explained before) and performed linear regression between each metabolite and
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the best SNP in the associated loci (minimum p-value). The regression was adjusted by confounding factors
and included the interaction term βintG ∗ statin: Y ∼ βGG + βcC + βstatinstatin + βintG ∗ statin.
5.4.6 Heritability
We first took a set of 3,342 individuals corresponding to the intersection between baseline and follow-up
data. The baseline and follow up phenotypes were combined, normalized, and separated into baseline and
follow up series, so the normalized phenotypes at baseline and follow up were directly comparable (i.e.
equal normalized phenotypes at baseline and follow up correspond to equal raw phenotypes). We used
GCTA’s bivariate REML [Lee et al. (2012)] and included 10 genetic PCs, age, and age2 as fixed effects. The
effect sizes of the aformentioned fixed effects were strongly correlated at each time point (rho>0.6) and there
were minimal differences in variance explained (<5%). Heritability estimates at the two time points were
plotted using circlize R package [Gu et al. (2014)].
5.4.7 CMS overview
Consider testing the association between a genotype G and a phenotype Y1. When there exists another mea-
sured variable Y2 correlated with the outcome Y1 because both variables depend on the same unmeasured
risk factor (say U), then Y2 can be considered a proxy for that risk factor U. As a proxy, Y2 can potentially
be used as a covariate when regressing Y1 on G. Adjusting Y1 for Y2 can substantially reduce the resid-
ual variance of Y1, increasing power to detect G-Y1 association. However, as we discussed in previous
work1, when Y2 depends on the predictor G, using it as a covariate faces a multicollinearity issue, further
leading to both false positive and false negative results depending on the underlying causal structure of
the data. The core of the CMS method is a principled approach to selecting a set of covariates Yk 6= 1 that
are correlated with the phenotype, but not with the genotype tested, thereby reducing phenotypic variance
independent of the genotype and concomitantly increasing power. Our previous work showed that a naïve
solution consisting in filtering out covariates based on a p-value threshold from the association test between
each covariate and the predictor (e.g. testing whether G-Y2 association p-value is < 0.05) results in an over-
all type I error inflation. Instead, we develop a heuristic that uses conditional mean and variance of the
parameters in question. In brief, consider δ and β , the marginal estimated regression coefficients between
G and Y2, and between G and Y1 (not adjusted for Y2), respectively, and let be the estimated correlation
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between Y1 and Y2. The central advance of CMS is the implementation of an inclusion threshold based on
E(δ β ) and varδ β ) under a complete null model δ=β=0).
5.4.8 Covariate pre-selection method
To address the high computational burden of CMS, we applied some additional pre-filtering to Ylnek be-
fore applying CMS. Indeed, CMS computation time increases with the number of covariates (N) with a
complexity of O(N2) ( Figure 5.9). Thus, instead of using about 150 candidate covariates as CMS input
for each outcome tested, we focused only on the subset explaining the largest (but not too large, see next
section) amount of the outcome variance. We considered two approaches: (1) a naïve one, only based on
the marginal correlation between each covariates and the outcome tested, and (2) an alternative one using
existing model selection methods -i.e. Akaike information criterion (AIC) and Bayesian information crite-
rion (BIC)- in order to avoid selecting sets of highly correlated covariates to avoid redundancy. The two
strategies are described in Supplementary Figure 5.10. Overall, exploratory analyses in the METSIM data
showed that a total number of covariates N=30 was enough in most cases to capture the vast majority of
the primary outcome variance ( Figure 5.11). As expected, the naïve approach requires a larger number of
covariates than model selection-based approaches to explain the same amount of total variance. There was
no observable qualitative difference between AIC and BIC analyses, we therefore only present results from
the AIC analyses.
Besides pre-selecting covariates for computational reason, we also applied some additional filtering to
maximize robustness. Indeed, the CMS principle paper [Aschard et al. (2017)] showed a potential increased
risk of false positive when including covariates with very high correlation with the primary outcome. To
address this potential issue, we used an arbitrary correlation threshold of T=0.7 (reflecting the amount of
outcome variance explained) above which candidate covariates were automatically filtered out. Further-
more, previous work also showed potential robustness issues when covariates are either parent or linear
combination of the outcome tested. To address this issue, we excluded from the set of initial covariates all
secondary outcomes that were in the same biological group as the primary outcome. For example, for the
GWAS of total lipids in large VLDL (L_VLDL_L), we excluded all other VLDL related variables from the
list of candidates’ covariates.
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FIGURE 5.10: Covariate preselection procedure. Presentation of the two methods
tested to preselect covariates before applying CMS. (a) Naïve approach where we
compute outcome variance explained by each variable. We sort the variables accord-
ing to this criterion and select the N first as covariates. (b) Approach using Akaike
Information Criteria (AIC). We first add the variable that explains the highest out-
come variance. Then we compute AIC for each possible model and iteratively add
covariates, stopping when we have N of them.
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FIGURE 5.11: Outcome variance explained by preselected covariates. We applied
the procedure described in Figure 5.10 in METSIM data, to leucine. Plots show out-
come explained variance depending on the number of covariates incorporated in the
model, for method 1 (in red) or 2 (in blue). We applied the thresholds 0.1 (a), 0.3 (b),
0.5 (c), 0.7 (d), 0.9 (e), 1 (f) on outcome variance explained by each covariate added
in the model. Dashed grey line shows that most of the outcome variance can be
explained by approximately 30 covariates.
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5.4.9 Definition of regions using LD blocks
In our analysis, we summarized results per locus, using linkage disequilibrium (LD) blocks computed by
Berisa et al [Berisa and Pickrell (2016)]. In brief, they computed blocks using European data from 1000
Genomes phase 1 dataset. The mean block size was set at 10,000 SNPs. They first computed covariance
matrix for all pair of SNPs, and then derived a matrix of squared Pearson product moment (where each
coefficient is obtained dividing covariance Ci,j by the product of Ci,i and Cj,j). They converted this last
matrix to a vector by summing antidiagonals, then they applied a low-pass filter to filter out high-frequency
fluctuation in the signal. Eventually, they performed local search around minima to define LD blocks. Here
we used blocks pre-computed using the 1000 Genomes Europeans individual data as a reference panel for
ease of comparison with other studies which include other European ancestry. There were a total of 1703
blocks, with a minimum and maximum length of 10Kb and 26Mb, respectively, and an average size of
1.6 Mb. However, to ensure the map of blocks for Finns and other European population was comparable,
were re-computed LD blocks using genotype data from 1000 Genomes Finnish participants. We found only
minimal variation with less than 3% of our associations being impacted.
5.4.10 Mapping of genes with top associated variants
Parsing of the results and assignment to genes was performed through a multi-steps procedure. First, we
selected all SNPs-metabolites associations with STD or CMS p-value under the genome-wide significance
threshold after correction for multiple testing (P < 1.28 x 10-9). This results in 3289 SNP-metabolite associ-
ations. Second, we used the UCSC database to assign a gene to each SNP. For SNPs, we used table snp150
with columns name, chrom, chromStart and chromEnd, corresponding to rs number, chromosome and po-
sition. For Genes, we used table refFlat with columns geneName, chrom, txStart and txEnd corresponding
to gene name, chromosome and transcription start and end. If the SNP position was in to one or more
genes transcription areas, we kept these genes in the output; otherwise, we selected the closest gene in a
window of 100Kb. Third, we grouped these results by locus, keeping the SNP with the minimum p-value
(either in STD or CMS approach) in each locus-metabolite associations. This results in 588 locus-metabolite
associations. Finally, to determine which associations were new, we filtered locus-metabolite associations
with p-values above our significance threshold in replication studies. Figure 5.2, shows the assignment to
each locus of 588 significant associations including 248 new associations. In Figure 5.6, we present 70 genes
and the 147 metabolites involved in locus-metabolite associations.
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5.4.11 Replication
We used four reference metabolite GWAS to replicate our results. These studies were those of, Teslovich et
al [Teslovich et al. (2010)], Rhee et al [Rhee et al. (2013)], Shin et al [Shin et al. (2014)], and Kettunen et al
[Kettunen et al. (2016)]. These studies analyzed respectively 4, 217, 486 and 123 metabolites with an overlap
of respectively 4, 15, 16 and 114 with METSIM metabolites. These GWAS were performed using standard
linear regressions adjusted for known confounding factors such as age, sex, and principal components of
the genotypes. The power of the replication analysis at a 5% p-value threshold was very high with an
average of 98.6% in the Kettunen et al study.
We performed two types of replication with these reference studies. First, we checked replication
per SNP in the 3289 SNP-metabolite associations, and replicated 71.51% of SNP-metabolite associations
at a nominal threshold of 5%. These replications were checked with results from the Kettunen et al and
Teslovich et al studies, from which we had access to complete summary statistics. Then, we checked
replication per locus of the 588 locus-metabolite associations. We used the best p-values per locus from
four reference studies, which replicated 75.68% of locus-metabolite associations and 42.34% of new locus-
metabolite associations at a nominal threshold of 5%. We also analyzed follow-up data, measured in a
subgroup of the individuals about five years after the first measurements, and replicated 77.82% of new
associations at a nominal threshold of 5%.
5.4.12 Association with diseases
We compared our gene-metabolites association results with previous GWAS on coronary heart disease
(CHD) [Teslovich et al. (2010)], body mass index (BMI) [Rhee et al. (2013)] and type 2 diabetes (T2D) [As-
chard et al. (2017)]. We considered here the 70 genes associated with at least one metabolite (Figure 5.6).
We observed substantial enrichment for nominal significance, with 25, 7, and 11 of these genes showing
p-value below the 5% significance threshold for CHD, BMI and T2D, respectively. Among those, CELSR2,
PSRC1 and LDLR were genome-wide significant (P = 9.01 x 10-19, P = 5.20 x 10-17 and P = 1.42 x 10-13
respectively) with CHD, while CELF1 and MTCH2 were genome wide significant (P = 2.24 x 10-13 and P =
1.41 x 10-13) with BMI. Conversely, no association showed genome-wide significance with T2D. To quan-
tify further the observed enrichment for association with these phenotypes, we derived the q-values for all
SNPs per disease [Storey and Tibshirani (2003)]. Given a false discovery rate (FDR) at 10%, we observed 30
significant genes for CHD, 5 for BMI and 4 for T2D.
144
5.4.13 Genome-wide association study of ∆ f b
We checked replication in Kettunen et al [Kettunen et al. (2016)] data. Among the associations, only one
is replicated in: the one between DHA and rs2727270. The other were not replicated in previous studies
(P = 0.471 for S_HDL_TG in the Kettunen study and data were not available for VLDL_C, LA_FA and
FAW6_FA). We also checked if results are replicated in baseline analysis, and found that 4 associations are
replicated in baseline and 4 are new. Note that we didn’t use baseline value as adjustment in delta analysis.
If we add it, we replicate 97% of associations at a nominal threshold of 5% and 50% at a genome wide
significant threshold of 5 x 10-8.
5.4.14 LIPC fine mapping
An individual locus might harbor hundreds of trait-associated variants. To prioritize potentially causal
variants, we explored the identified locus using FINEMAP software [Benner et al. (2016)]. FINEMAP uti-
lizes shotgun stochastic search algorithm to identify the most likely causal variants within a trait-associated
locus. FINEMAP software requires SNP association statistics for a locus and a variant correlation matrix
as an input. We defined a locus by taking the region spanned by the SNPs associated with any metabolite
and expanding it by 750Kb on each side. This resulted in a large region (chr15:57,935,995-59,498,577). We
increased the SNP density of this region by imputing new SNPs using minimac and the 1000 Genome phase
1 v3 panel. After imputation our region contained 5,100 SNPs with MAF>0.01. We computed the variant
correlation matrix using the METSIM subjects. We then applied FINEMAP with default settings for each of
the 75 metabolites associated with the LIPC region separately. To select the main causal SNPs, we summed
the posterior probability for each SNPs across the 75 phenotypes to form a single probability score. We de-
clared the SNPs value of this score above 10 as best causal candidate SNP. We next explored the functional
annotation of theses SNPs. We first search for previous association of those SNPs in the GWAS catalog
[Welter et al. (2013)] and Pubmed search. We then used HaploReg v4.111 to check if the potentially causal
SNPs are (i) in promoter or enhancer regions (according to the H3K4me1/H3K4me3 and H3K27ac/H3K9ac
peaks), (ii) in transcription factors binding sites, (iii) missense variants.
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